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Abstract
Prostate cancer (PC) is characterised by dependence upon androgen
receptor (AR) as its driving oncogene. When organ-confined, radical
treatment can be curative, however there is no cure for advanced,
castration-resistant prostate cancer (CRPC). There is therefore a need
to better understand the biology of PC, and how influencing AR can
modify disease progression.
Estrogen is essential for prostate carcinogenesis with evidence from
epidemiological, in vitro, human tissue and animal studies. Most sug-
gests that estrogen receptor beta (ERβ) is tumour-suppressive, but
trials of ERβ-selective agents have not improved clinical outcomes.
ERβ has also been implicated as an oncogene, therefore its role re-
mains unclear. Additional evidence suggests interplay between ERβ
and AR, the mechanisms of which are uncertain. The study hypoth-
esis ‘ERβ is an important modulator of prostate carcinogenesis’ was
developed to establish whether targeting ERβ could affect PC pro-
gression.
Much of the confusion around ERβ stems from use of inadequately
validated antibodies and cell line models. The first phase of this work
was to test ERβ antibodies using an ERβ-inducible cell system. Eight
ERβ antibodies were assessed by multiple techniques, showing that
commonly used antibodies are either non-specific or only specific in
one modality. Two reliable antibodies were identified.
Next, cell lines previously used to study ERβ were assessed using
validated antibodies and independent approaches. No ERβ expression
was detected; an important finding that casts doubt on previously
published ERβ biology. Subsequently, a PC cell line with inducible
ERβ expression (LNCaP-ERβ) was developed and validated to enable
controlled experiments on the effects of ERβ on proliferation, gene
expression and ERβ/AR genomic cross-talk.
Phase three of this work focused on ERβ biology in PC and its rela-
tionship to AR. Interrogation of clinical datasets showed that greater
ERβ expression associated with favourable prognosis. Gene expres-
sion data from men treated with androgen deprivation therapy re-
vealed that AR represses ERβ. This was confirmed in vitro. The
LNCaP-ERβ cell line was treated with androgen and/or ERβ-selective
estrogen. Activated ERβ in the presence of androgen-stimulated AR
inhibited cell proliferation and down-regulated androgen-dependent
genes. Genome-wide mapping of ERβ binding sites reveals that ERβ
antagonises AR through competition for shared DNA binding sites.
In conclusion, ERβ expression is down-regulated by AR during ma-
lignant transformation of prostate epithelium. We reveal an antag-
onistic relationship between ERβ and AR whereby sustaining or re-
placing ERβ may inhibit tumour growth through down-regulation of
AR-target genes. In future, an ERβ-selective compound may be used
to slow or abrogate PC progression.
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Chapter 1
Introduction
1.1 Clinical aspects of Prostate Cancer
1.1.1 Epidemiology
Prostate cancer is the commonest, non-cutaneous cancer in men, affecting 21%
of men in Europe. It is the second most common cause of male cancer-related
death, accounting for 15% of deaths in developed countries [Heidenreich et al.,
2011; Mottet et al., 2011]. In the UK, recent estimates suggest an annual incidence
of 111 cases per 100,000 people, with an age-standardised mortality rate of 23 per
100,000 [Ferlay et al., 2013]. It is primarily a disease of elderly men, with a mean
age in those affected of 72-74 years. Approximately 85% of new prostate cancer
diagnoses are made in men over 65 years of age [Gro¨nberg, 2003]. Historical post
mortem studies have shown that the incidence of indolent, or sub-clinical disease
is much greater than this, with 50% of 50-year-old men and up to 80% of 80-
year-old men having histological evidence of prostate cancer [Sakr et al., 1996].
The incidence of prostate cancer in the UK has steadily risen over the past few
decades; partly as a consequence of ad hoc serum prostate specific antigen (PSA)
testing and improved diagnostics, but also as a result of a genuine increase in
disease incidence [Center et al., 2012; Mayor, 2012; Potosky et al., 1995]. Despite
its increasing incidence, mortality from prostate cancer in the UK has been in
decline for the past 10 to 15 years [Center et al., 2012].
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1.1.2 Risk factors
There are a number of well-established risk factors for the development of prostate
cancer [Heidenreich et al., 2011]. It is recognised that men with a first-degree
relative with prostate cancer have a two-fold increase in risk over the general
population. If more than 2 first-degree relatives are affected, the risk increases by
up to eleven-fold [Gro¨nberg et al., 1996; Steinberg et al., 1990]. Approximately
9% of men have true hereditary prostate cancer, defined as three or more affected
family members, or at least two who have developed disease before the age of
53 years [Carter et al., 1992]. Prostate cancer incidence has been shown to have
greater concordance between monozygotic than heterozygotic twins, indicating a
strong influence of genetic factors [Ahlbom et al., 1997; Gro¨nberg et al., 1994].
Some studies have shown familial association between the incidence of prostate
cancer and female breast cancer [Bratt, 2000]. Some of this may be explained
by the increase in risk of both these cancers associated with germ-line mutations
of BRCA1 and BRCA2 genes. The risk of prostate cancer for carriers of muta-
tions in either of these genes is increased three-fold as compared with the general
population [Easton et al., 1997; Ford et al., 1994; Thorlacius et al., 1998]. Fur-
thermore, BRCA1 and BRCA2 mutations are associated with development of
more aggressive prostate cancer, with increased likelihood of lymph node spread
and distal metastases [Castro et al., 2013]. Mutations of DNA mismatch repair
genes, associated with Lynch syndrome have also been shown to increase the risk
of developing prostate cancer by three-fold over the general population [Ryan
et al., 2014] and are a risk factor for the development of aggressive, metastatic
disease [Pritchard et al., 2016].
The risk of prostate cancer is up to 80% greater in men with a history of inflam-
mation or infection of the prostate (prostatitis) [Dennis et al., 2002; Jiang et al.,
2013]. This may simply reflect the consequences of increased medical investi-
gation in this patient cohort, however, inflammation is thought to have a direct
impact on prostate cancer development and progression [Celhay et al., 2010; Gru-
bisha and DeFranco, 2013]. The potential mechanisms of this effect are discussed
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further in section 1.5.1. The other principle risk factors for prostate cancer are
age, ethnicity, diet and obesity. These are discussed in section 1.3.1.
1.1.3 Disease presentation
As a result of the prostate’s location deep within the pelvis combined with the fact
that prostate cancer tends to arise on the outer, posterior aspect of the prostate
(the peripheral zone) [Heidenreich et al., 2011; McNeal, 1988], many men with
localised prostate cancer do not have any signs or symptoms attributable to the
disease. Occasionally, localised disease in the centre of the prostate (transition
zone) may give rise to lower urinary tract symptoms that cause difficulty with
passing urine (Figure 1.1). New onset of erectile dysfunction has also been shown
to be an important symptom of early prostate cancer [Hamilton et al., 2006].
Instead, most localised prostate cancer is detected as a consequence of men un-
dergoing PSA testing, or in men who have prostate tissue removed surgically to
relieve urinary symptoms where cancer is then detected incidentally [Center et al.,
2012]. In the later stages of the disease, men may present with bone pain arising
from metastatic disease or unexplained weight loss [El-Amm and Aragon-Ching,
2016; Hamilton et al., 2006].
Zon l&a atom &
AFS!
TZ!
PZ!
CZ!Ur!
ED!
Figure 1.1: The zonal anatomy of the prostate gland. Schematic diagram
of an axial section through the mid-prostate, based on McNeal’s description of
histological zones [McNeal, 1988]. Prostate cancer usually arises in the periph-
eral zone (PZ) and does not impinge upon the urethra (Ur) to cause urinary
symptoms. Benign enlargement of the prostate however, typically arises from
the transition zone (TZ) to impair urinary function. AFS, anterior fibromuscular
stroma; CZ, central zone; ED, ejaculatory duct.
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1.1.4 Risk stratification in prostate cancer
The disparity between the incidence of prostate cancer, and mortality from prostate
cancer highlights that a large proportion of prostate cancer is clinically indolent
(i.e. men die with the disease, rather than from it). Conversely, in its most
aggressive form, untreated prostate cancer has a mortality rate approaching 80%
[Bill-Axelson et al., 2014]. Currently in the UK, risk stratification in prostate can-
cer is based on the D’Amico system, which includes serum PSA, histological grade
of cancer (Gleason grade) and clinical stage of the disease (using the Tumour,
Nodes, Metastases (TNM) system) as determined by digital rectal examination
and cross-sectional imaging such as Computed Tomography (CT) or Magnetic
Resonance Imaging (MRI) scan (Table 1.1) [D’Amico et al., 1998; Graham et al.,
2014; Heidenreich et al., 2014].
The Gleason score is an assessment of the degree of de-differentiation of prostate
tissue as determined by the histological architecture of the tissue and a number of
cytological features [Gleason, 1966]. The original description graded cancer from
1 - 5, however as Gleason 1 and 2 are no longer regarded as malignant, this was
revised to a grading from 3 - 5 [Epstein et al., 2005]. Grade 3 prostate cancer
is well differentiated, whereas grade 5 is poorly differentiated. The Gleason sum
score is generated from adding the two most predominant areas of histology, or
the predominant area plus the highest grade minority area to give a sum score of
between 6 and 10.
Using the D’Amico stratification, men are grouped into low, intermediate or high
risk disease at the time of diagnosis. The longest currently available follow up
data of untreated prostate cancer has demonstrated that cancer specific survival
(CSS) for low risk disease is 86%, whereas for high risk disease it is 64% at 18
years follow up [Bill-Axelson et al., 2014].
1.1.5 Treatment of localised prostate cancer
There are multiple established treatments for prostate cancer. The principle
determinants of which treatments are suitable are the D’Amico risk profile and
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Level of 
Risk!
PSA !
(ng\ml)!
Gleason 
sum score!
Clinical 
Stage!
Low! <10! and! <7! and! cT1c!
Intermediate! 10-20! or! 7! or! cT2b-2c!
High! >20! or! 8-10! or! ≥cT3a!
Clinical T staging – Primary tumour!
Tx! Primary tumour cannot be assessed!
T0! No evidence of primary tumour!
T1! Clinically inapparent tumour not palpable or 
visible by imaging!
T1a! Incidental finding in ≤5% resected tissue!
T1b! Incidental finding in >5% resected tissue!
T1c! Tumour identified by needle biopsy!
T2! Tumour confined to the prostate!
T2a! Tumour involves up to one half of one lobe!
T2b! Tumour involves more than half of one lobe!
T2c! Tumour involves both lobes!
T3! Tumour extends through prostatic capsule!
T3a! Extracapsular extension!
T3b! Tumour invades seminal vesicles!
T4! Tumour is fixed or invades adjacent 
structures other than seminal vesicles!
A!
B!
Table 1.1: Clinical risk stratification in localised prostate cancer is based
on the clinical tumour stage as determined by the TNM classification (A) in
conjunction with the serum PSA level and Gleason score. These are combined
into the D’Amico classification (B), which stratifies men into low, intermediate
or high risk disease. These are the parameters currently recommended by the
European Urological Association (EAU) [Heidenreich et al., 2014].
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the general medical health (often known as performance status) of the individual
patient (Table 1.2). In UK practice, the patient’s own preferences are also an
important factor. A detailed discussion of the clinical management of prostate
cancer is beyond the scope of this thesis, however a brief summary is presented
below with the aim of establishing the clinical context for the work presented in
this study.
Low! Intermediate! High!
Watchful 
Waiting! option! option! option!
Active 
Surveillance! preferred! option!
not 
recommended!
Brachytherapy! option! option! with EBRT!
Radical 
Prostatectomy! option! preferred! preferred!
Radical 
Radiotherapy! option! preferred! preferred!
Table 1.2: Summary of treatment options for localised prostate can-
cer, as determined by D’Amico risk stratification and patient performance sta-
tus. EBRT; external beam radiotherapy. Summarised from NICE Guidance
(www.nice.org.uk/guidance/CG175).
Watchful waiting
It is well-established that in order for a man to expect to benefit from radical (i.e.
curative) treatment of prostate cancer, he must have a life expectancy of at least
10 years from the time of diagnosis [Bill-Axelson et al., 2014]. For those men who
do not have a life expectancy of 10 years (as a consequence of advanced age or
medical comorbidities) and are asymptomatic at the time of disease presentation,
a ‘watchful waiting’ approach may be used. Men receive no treatment unless they
develop symptoms related to prostate cancer progression such as lower urinary
tract symptoms or pain. If symptoms develop, then they are treated palliatively,
with the aim of symptom control, rather than cancer cure [Heidenreich et al.,
2014].
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Active surveillance
Active surveillance aims to address the problems of over-diagnosis and over-
treatment of prostate cancer, by accounting for the fact that a proportion of histo-
logically diagnosed prostate cancer is clinically indolent, and will not progress to
manifest in clinical symptoms in the course of the patient’s lifetime [Heidenreich
et al., 2014]. Men with low, or selected men with intermediate risk disease, who
are suitable for radical therapy, do not receive immediate treatment, but instead
enter a program of careful monitoring with repeated serum PSA measurements
and prostate biopsies. In this way, if their disease does not progress then the
patients do not incur the risks associated with unnecessary treatment, but if pro-
gression does occur, then it can be detected and treated radically in a timely
manner. Clinical outcomes of active surveillance programs are very favourable,
with 5-year cancer specific survival rates in low risk disease of 97-100% [Dall’Era
et al., 2008; Klotz et al., 2010; Soloway et al., 2010; Tosoian et al., 2011; van As
et al., 2008; van den Bergh et al., 2009].
Brachytherapy
Brachytherapy is a form of localised radiotherapy, which in prostate cancer is
delivered by two methods. Low dose rate brachytherapy involves permanent im-
plantation of radioactive seeds (Iodine125) into the prostate, whereas in high dose
rate brachytherapy Iridium192 wires are placed into the prostate transperineally
for several hours to deliver a predetermined dose of radiotherapy. Brachytherapy
is used in low and intermediate risk disease, and combined with external beam
radiotherapy (EBRT) in high risk disease. It is contraindicated in men with large
prostates or lower urinary tract symptoms due to the risk of urinary retention
following tissue implantation. Five-year progression-free survival is 80-85% and
50% for low and intermediate risk disease respectively [Ragde et al., 2000].
Radical prostatectomy
Radical prostatectomy (RP) is the surgical removal of the entire prostate gland
and seminal vesicles, from the external urethral sphincter at the level of the per-
ineal membrane, to the bladder neck. The founding principles for the operation in
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its current form were established following landmark work by Walsh and Donker
[Walsh, 1980; Walsh and Donker, 1982]. The procedure may be performed by
open surgical, laparoscopic and robot-assisted laparoscopic approaches [Heiden-
reich et al., 2014]. Randomised trial data has shown that RP reduces the risk
of death from prostate cancer (compared with no treatment) by 50%, and the
greatest benefit is seen in younger men with intermediate risk disease [Bill-Axelson
et al., 2014]. Recently published data has shown that increasing numbers of men
with high risk disease are undergoing RP with oncological outcomes equivalent
to those achieved previously for low and intermediate risk disease, demonstrating
ongoing improvement in surgical technique and increasing surgeon confidence in
operating on high risk men [Gnanapragasam et al., 2016].
Radical radiotherapy
Radical radiotherapy (RRT), also known as External Beam Radiotherapy (EBRT)
to differentiate it from brachytherapy can be used in men suitable for radical
treatment, with low, intermediate or high risk disease. The current gold standard
is Intensity Modulated Radiotherapy (IMRT), which uses 3D anatomical imaging
to map the radiation beam to the prostate in real time [Heidenreich et al., 2014].
A typical course of IMRT for localised prostate cancer delivers a radiation dose
of at least 74 Gy. Combining RRT with androgen deprivation therapy (ADT)
(section 1.1.6) significantly improves oncological outcomes [Widmark et al., 2009].
1.1.6 Treatment of advanced prostate cancer
Androgen deprivation therapy
Men presenting with prostate cancer unsuitable for radical treatment either due
to poor performance status or because the disease has spread from the prostate
into surrounding structures (locally advanced) or to distant sites (metastasis)
will typically receive ADT as first-line treatment. ADT was developed as a di-
rect result of the landmark discovery by Huggins and Hodges that prostate can-
cer is an androgen-regulated and androgen-driven disease [Huggins, 1942, 1943;
Huggins and Clark, 1940] (section 1.2.1). The mainstay of ADT is leutinising
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hormone-releasing hormone (LHRH) analogues, which suppress testicular an-
drogen production by positive-feedback inhibition of the hypothalamo-pituitary-
gonadal (HPG) axis [Huggins and Hodges, 1972]. LHRH analogues may be used
in combination with androgen receptor (AR) antagonists such as Bicalutamide
to achieve complete androgen blockade [Heidenreich et al., 2014]. ADT is also
used to treat men with biochemical relapse (BCR - defined as two consecutive
increases in serum PSA ≥0.2 ng/ml [Heidenreich et al., 2014]) or metastatic re-
currence following radical therapy.
Treatment of castrate-resistant prostate cancer
Unfortunately, despite the fact that most men initially respond to ADT, in-
evitably the tumours become resistant to this treatment leading to BCR and ulti-
mately clinical progression, at which point the disease is termed castrate-resistant
prostate cancer CRPC [Scher et al., 2004] (section 1.2.1). CRPC carries a poor
prognosis, with median survival of 18 months from diagnosis [Wu et al., 2007].
First-line treatment of CRPC is with docetaxel chemotherapy, which inhibits mi-
tosis by blocking microtubule assembly. Fifty-three percent of patients see a 50%
reduction in serum PSA, and overall survival is improved by approximately 2.5
months [Shelley et al., 2006]. For men who develop docetaxel resistance, newer
AR-targeting agents such as abiraterone and enzalutamide are available and have
been shown to improve prostate cancer survival [de Bono et al., 2011; Scher et al.,
2012], however, they are not curative [Lamb et al., 2013].
1.1.7 A clinical rationale for biological research in prostate
cancer
There is an ongoing and pressing need to further our understanding of the un-
derlying biology that drives the initiation and progression of prostate cancer, and
how its natural history might be modified in the early stages of this process in or-
der to improve clinical outcomes. This is highlighted by two key clinical sequelae
of prostate cancer: i) BCR occurs in 20-50% of patients despite radical therapy
[Paller and Antonarakis, 2013] and ii) all AR-targeted therapies (ADT, Enzalu-
tamide, Abiraterone) drive a selection pressure, which results in prostate cancer
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eventually developing resistance to these treatments [Claessens et al., 2014; Gi-
acinti et al., 2014; Scher et al., 2004]. It has become apparent that alternative
strategies to treating prostate cancer are required that do not focus directly on
the AR. Recent work on metabolic pathways [Jurmeister et al., 2014; Kaushik
et al., 2016; Pertega-Gomes et al., 2015] and immune pathways [Carosella et al.,
2015] that influence AR function are such examples. The aim of this approach
is to find ways of modulating the influence of AR in prostate cancer initiation
and progression so that the selection pressure of direct AR-targeting therapies is
slowed or avoided [Mills, 2014].
To that end, understanding the biology and targeting the effects of estrogen in
prostate cancer are attractive propositions as estrogen has been shown to have an
essential role in prostate cancer development and progression, and drugs aimed at
estrogen-dependent targets are already in clinical use for the treatment of breast
cancer. Historically, the first approach to hormone treatment of prostate cancer
used systemic estrogen therapy in the form of diethylstilbestrol (DES) [Huggins
and Hodges, 1972]. This suppressed androgen production indirectly via negative
feedback inhibition of the HPG axis. Although still used as a second- or third-
line hormonal treatment, DES has fallen out of widespread clinical usage because
of the unacceptably high rate of cardiovascular side effects [Morales and Pujari,
1975]. More recently however, it has been found that parenteral administration
of estrogens using a transdermal patch avoids first-pass liver metabolism and is
not associated with the cardiovascular toxicity of enterally administered estro-
gens [Langley et al., 2013]. Whilst this important finding addresses the issue
of estrogen-induced cardiovascular toxicity, any estrogen-derived prostate cancer
treatment must account for the potentially differing roles of the two estrogen
receptors in order to be beneficial.
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1.2 Steroid hormone receptors in prostate can-
cer
The sex steroid hormone receptors AR, estrogen receptor alpha (ERα) and es-
trogen receptor beta (ERβ) are Type I nuclear hormone receptors and members
of the nuclear hormone receptor superfamily. They are characterised by com-
mon structural elements, composed of four functional domains. The N-terminal
domain (NTD) followed by the DNA-binding domain (DBD), the C-terminal
ligand-binding domain (LBD) and the hinge domain, which connects the DBD to
the LBD and is important for the process of nuclear localisation (Figure 1.2). In
the absence of ligand, these receptors (with the exception of ERα) are typically
located in the cell cytoplasm bound to a chaperone complex. Upon binding of
ligand to the LBD, these receptors are translocated to the cell nucleus to bind to
DNA and activate transcription of target genes [Mangelsdorf et al., 1995].
1.2.1 The androgen receptor
One of the earliest observations suggesting a role for androgens in regulation of
the prostate gland came from John Hunter in 1786 [Hunter, 1786]. He found
that the prostates of male animals such as roe deer were substantially greater in
size and more mucinous during the rutting season than those of animals observed
in winter. Subsequently, the landmark research of Huggins and Hodges demon-
strated conclusively that the prostate increased or decreased in size following
administration of testosterone or surgical castration respectively [Huggins, 1942,
1943; Huggins and Clark, 1940]. They went on to show that administration of
systemic estrogens suppressed androgen production via the HPG axis to suppress
prostate cancer growth [Huggins and Hodges, 1972], forming the basis for ADT.
The AR gene is located on the X-chromosome between Xq11 and Xq12 [Brown
et al., 1989; Migeon et al., 1981], and contains a protein coding region of eight
exons. The AR protein consists of 919 amino acids and has a molecular weight of
110 kDa [Gelmann, 2002] (Figure 1.3). Unliganded AR is located in the cell
cytoplasm, bound to the chaperone complex made up many proteins includ-
11
1. Introduction
AR#Lonergan#2011#(Jess),#Lorente#2015,#Tan#2015#
ERa#and#ERb#Hewi<#and#Korach#2002#
1 537! 625! 669! 919!
N! C!
AF-1! AF-2!
AR protein! NTD (A/B)! DBD (C)! Hinge !(D)! LBD (E)!
305! 556! 595!
Hinge !
(D)! LBD (E)!
AF-2!
(F)! C!
1 183! 266!
NTD (A/B)! DBD (C)!
AF-1!
N!ERα protein!
258! 503! 530!
Hinge !
(D)! LBD (E)!
AF-2!
(F)! C!
1 142! 226!
NTD (A/B)! DBD (C)!
AF-1!
N!ERβ protein!
Figure 1.2: Structure of nuclear steroid hormone receptors. As with
other type-I nuclear receptors, AR, ERα and ERβ are composed of domains A-
E, which contain the N-terminal domain (NTD), DNA-binding domain (DBD),
hinge domain and ligand binding domain (LBD). The LBD consists of 12 alpha-
helices, which allow for ligand docking. The role of the F-domain in ERα/β is
less well-defined. The location of activation function (AF) 1 and 2 domains is
shown. Numbers below each schematic indicate the amino acid position of each
domain (Figure adapted from Hewitt and Korach, 2002; Lorente et al., 2015; Tan
et al., 2015).
ing HSP90, FKBP5 and FKBP4. Upon ligand activation with the potent an-
drogen 5α-dihydrotestosterone (DHT), AR decouples from the chaperone com-
plex, translocates into the cell nucleus and undergoes dimerization. The DBD
then recognises and binds to androgen response elements (ARE) on DNA, which
are typically located in promoter and enhancer regions of AR-regulated genes
[Claessens et al., 1996; Schoenmakers et al., 2000; Verrijdt et al., 2000].
AR is a key factor that plays an essential role in all stages of prostate cancer de-
velopment and progression [Pomerantz et al., 2015; Scher et al., 2004], although
much less is known about the role of AR in the initiation of prostate carcinogenesis
[Zhou et al., 2015]. AR is required for the normal in utero development and sub-
sequent homeostasis of the prostate, where it maintains differentiation of luminal
epithelial cells. In order for prostate cancer to develop, it has been proposed that
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AR! ERβ!ERα!
Chromosome! 14q23.2!6q25.1!Xq12!
Size (kDa)! 59!110! 66!
Benign 
expression!
Stroma!Luminal !
epithelium!
Basal epithelium!
Ligand! DHT! E2! 3β-adiol/E2!
DNA binding! ARE!
ERE (~50% overlap)!
97% DBD homology!
Figure 1.3: Key characteristics of steroid hormone receptors in prostate
cancer, showing the gene loci, protein size and typical expression in benign
prostate tissue. Binding of the receptor with its principle ligand results in translo-
cation to the cell nucleus, DNA binding at ARE or ERE and transcription of
target genes. E2, estradiol; ERE, estrogen response element; ARE, androgen
response element; ERα, estrogen receptor alpha; ERβ, estrogen receptor beta.
the role of AR must therefore ‘switch’ from a homeostatic to an oncogenic one
[Zhou et al., 2015]. The mechanism of this switch is as yet undefined, though it has
been proposed that multiple processes such as post-translational modifications to
AR [Coffey and Robson, 2012; Gioeli and Paschal, 2012], aberrant expression of
AR co-factors in response to DNA damage and oxidative stress [Mills, 2014] or
chronic exposure to low serum testosterone levels as occurs with advancing age,
all result in upregulation of AR expression [Zhou et al., 2013]. Recent work has
shown that two co-transcription factors FOXA1 and HOXB13 act to reprogram
AR genome-wide binding (the cistrome) from a benign to a cancer-associated AR
cistrome. This altered binding profile then drives the transformation of epithelial
cells from a benign to malignant phenotype [Pomerantz et al., 2015].
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The majority of prostate tumours will initially respond to ADT as evidenced by
tumour shrinkage and decrease in serum PSA. Inevitably, however after a pe-
riod of time prostate cancer develops resistance to ADT to become CRPC [Scher
et al., 2004]. Although resistant to hormonal manipulation, CRPC is still char-
acterised and driven by AR signalling. Mechanisms accounting for this include
amplification or mutation of the AR gene, stabilisation of AR protein, altered
expression of AR coregulators, generation of constitutively active AR splice vari-
ants and increased synthesis of intra-tumoural androgens [Bubendorf et al., 1999;
Cai and Balk, 2011; Chmelar et al., 2007; Dehm et al., 2008; Holzbeierlein et al.,
2004; Hu et al., 2012; Ishizaki et al., 2013]. Thus, whilst CRPC is characterised by
resistance to manipulation of androgens, it remains androgen receptor dependent.
1.2.2 The estrogen receptors
Both ERα and ERβ are expressed in prostate tissue. It is generally thought that
they have opposing roles with respect to prostate cancer with ERα being pre-
dominantly oncogenic, promoting cell proliferation and survival and ERβ being
predominantly protective, anti-proliferative and pro-apoptotic (reviewed in [Nel-
son et al., 2014]). ERα and ERβ share substantial sequence homology, with 97%
of the DBDs and 60% of the LBDs being identical between the two receptors
[Hewitt and Korach, 2002]. This allows both ERα and ERβ to recognise and
bind to estrogen response elements (ERE) on DNA with equal affinity [Kuiper
et al., 1996; Le et al., 2013].
Estrogen receptor beta
ERβ was first identified in the rat prostate [Kuiper et al., 1996]. Human ERβ
is a 59 kDa protein encoded by eight exons of the ESR2 gene, located on chro-
mosome 14 (Figure 1.3) [Enmark et al., 1997]. The principle ligand of ERβ is
5α-androstane-3β,17β-diol (3β-adiol), which is formed from metabolism of DHT
by prostatic 3β hydroxysteroid dehydrogenase [Oliveira et al., 2007; Steckelbroeck
et al., 2004; Weihua et al., 2002a,b]. Intraprostatic production of 3β-adiol is re-
ported to be high in benign prostate tissue [Piccolella et al., 2014] and 3β-adiol
14
1. Introduction
has been shown in vitro to inhibit prostate cancer cell migration by ERβ-mediated
induction of E-cadherin expression [Guerini et al., 2005].
ERβ has been shown to bind to DNA as both a ERβ/β homodimer, and ERα/β
heterodimer [Pettersson et al., 2000]. In this heterodimer configuration, ERβ is
thought to act as a dominant negative regulator of ERα, acting to modulate tran-
scriptional responses to estrogens in a tissue-dependent manner [Bottner et al.,
2014; Pettersson et al., 2000]. ERβ is expressed in a wide range of reproductive
and non-reproductive tissues including the central nervous system, cardiovascu-
lar system, gastrointestinal tract, urogenital tract (male and female) and skeleton
[Bottner et al., 2014; Enmark et al., 1997]. The physiological role of ERβ in each
of these tissues has not been fully determined, but it has been implicated in glu-
cose and insulin homeostasis, and may also modulate immunologically-mediated
inflammatory pathways [Foryst-Ludwig et al., 2008; Harris et al., 2003].
Estrogen receptor beta isoforms
At least five isoforms of ERβ have been identified [Leung et al., 2006b]. Wild type
(wt) ERβ is composed of eight exons, the first six of which are common to the
five isoforms. The functional domains A-D (which includes the DBD) are located
in these conserved exons, but the LBD differs between the isoforms (Figure 1.4).
Expression of ERβ3 is limited to the testis [Moore et al., 1998] and in ovarian
carcinoma, levels of ERβ5 mRNA are increased as compared with benign tissue
[Suzuki et al., 2008].
ERβ2, ERβ4 and ERβ5 have all been shown to be expressed in prostate tis-
sue, particularly ERβ2, which has been implicated as an oncogene in high grade
and late-stage disease [Chen et al., 2009]. In prostate cancer, increased ERβ2
and ERβ5 expression has been shown to correlate with poor prognosis, BCR
and decreased time to metastasis following radical prostatectomy [Dey et al.,
2012; Leung et al., 2010]. ERβ2 is the principle isoform seen in prostate can-
cer; it is thought to act as a dominant negative regulator of wtERβ by forming
wtERβ/ERβ2 heterodimers. As ERβ2 lacks a functional LBD, this prevents
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ligand activation of wtERβ and disables its tumour-suppressive effect [Cotrim
et al., 2013; Leung et al., 2006b]. Furthermore, ERβ2 has been shown to regulate
genes involved in epithelial-mesenchymal transition (EMT) such as TWIST1 and
RUNX2, which may increase the metastatic potential of tumour cells [Dey et al.,
2012; Leung et al., 2010].
469! 530!
490!
417!
472!
530!
wtERβ!
ERβ2!
ERβ3!
ERβ4!
ERβ5!
!
Exon! 2! 3!1! 4! 6! 7! 8!5!
121! 178! 216! 317! 364! 408!
121! 178! 216! 317! 364! 408!
121! 178! 216! 317! 364! 408!
121! 178! 216! 317! 364! 408!
121! 178! 216! 317! 364! 408!
469!
Amino acid number:!
DBD! LBD!
Figure 1.4: ERβ isoform structure. Wild type (wt) ERβ is composed of 8
exons. Exons 1 - 6 are shared between the isoforms, but the LBDs differ. (Figure
adapted from Nelson et al., 2014).
Estrogen receptor alpha
The gene coding ERα (ESR1 ) is located on chromosome 6 (Figure 1.3). It is a
66 kDa protein, which is structurally similar to other nuclear receptors except for
an extra F-domain at the carboxy terminal of the protein [Montano et al., 1995]
(Figure 1.2). ERα has been well-characterised and is known to be a principle
driver of female breast cancer, in a manner analogous to the AR in prostate
cancer [Curtis et al., 2012]. It is less well-known however, that ERα also has a
role in the development of prostate cancer.
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In utero studies of the developing rodent prostate have shown that ERα expres-
sion precedes that of ERβ, and excessive estrogenisation of the prostate mediated
by ERα results in squamous metaplasia, inflammation and epithelial dysplasia.
This ‘imprinting’ later manifests as increased risk of prostate cancer development
[Arai et al., 1978; McPherson et al., 2008; Prins and Birch, 1997; Prins and Ko-
rach, 2008; Prins et al., 2006, 2007]. In benign prostate tissue, ERα is expressed in
the prostatic stroma, but not in the epithelial compartment [Tilley et al., 1985;
Wernert et al., 1988]. In cancer however, there is evidence of epithelial ERα
expression in high-grade prostatic intraepithelial neoplasia (PIN), intermediate-
and high-grade tumours and in CRPC [Bonkhoff and Berges, 2009; Celhay et al.,
2010; Nelles et al., 2011]. Although not fully understood it has been shown that
increased risk of CRPC progression correlates with increased expression of ERα
and aromatase, and polymorphisms of aromatase [Celhay et al., 2010; Sissung
et al., 2011]. The role of ERα with respect to inflammatory pathways in prostate
tissue will be discussed in section 1.5.1.
1.3 The role of estrogen in prostate cancer
1.3.1 Epidemiological evidence
Age and racial factors
As highlighted by the epidemiology of prostate cancer, the primary risk factor
for the disease is increasing age [Heidenreich et al., 2011]. It has been observed
that the peak age of onset of prostate cancer coincides with the age at which
serum testosterone levels begin to decline, whilst serum estrogen levels remain
relatively constant [Vermeulen et al., 2002]. This has led to the hypothesis that
it is the ratio of estrogen to testosterone (and other circulating androgens) that
determines the risk of prostate cancer, rather than the absolute levels of either
hormone in isolation [Bosland, 2013; Ellem and Risbridger, 2007]. Indeed, nu-
merous studies have failed to demonstrate a correlation between absolute levels
of serum androgens or estrogens and prostate cancer risk [Bosland, 2013; Ross
et al., 1992; Yao et al., 2011].
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This understanding of circulating hormone levels and prostate cancer risk is of
further importance when examining the relationship between race and prostate
cancer risk. It is well established that Caucasian men have a lower risk of devel-
oping prostate cancer than men of African descent, and that for Japanese men,
the lifetime risk of developing prostate cancer is lower still [de Jong et al., 1991;
Ellem and Risbridger, 2007; Ross et al., 1992]. Whilst there have been no sig-
nificant differences in levels of circulating androgens between these three ethnic
groups [Ross et al., 1992], levels of serum estrogens have been reported to be
greater in black men of African descent than Caucasians [Abd Elmageed et al.,
2013; Rohrmann et al., 2007], giving additional credence to the estrogen:androgen
ratio hypothesis. Additionally, racial differences in ERβ tissue expression as de-
termined by IHC have demonstrated greater frequency of ERβ staining in black
men of African descent than Caucasian men, which in turn correlated with poorer
clinical outcome [Abd Elmageed et al., 2013]. It has been proposed that the in-
creased risk of prostate cancer in black men may be partly explained by greater in
utero estrogen exposure secondary to higher levels of maternal estrogens in black
women [Henderson et al., 1988; Nelles et al., 2011; Powell and Meyskens, 2001],
resulting in the previously discussed embryological ‘imprinting’ [Arai et al., 1978;
McPherson et al., 2008; Prins and Birch, 1997; Prins and Korach, 2008; Prins
et al., 2006, 2007].
Dietary factors and obesity
Estrogen-related dietary factors are also thought to be important in modulating
prostate cancer risk [Hori et al., 2011]. Japanese men have a very low incidence
of prostate cancer [de Jong et al., 1991], and it is thought that the traditional
Japanese diet, which is very rich in phytoestrogens may be protective against
prostate cancer. Phytoestrogens and other dietary estrogens such as lignans,
flavonoids and lipoflavonoid are thought to have up to 30-fold greater affinity
for ERβ than ERα [Ellem and Risbridger, 2007; Kuiper et al., 1998; Thelen
et al., 2014]. In prostate cancer cell lines, phytoestrogens have been shown to up
regulate ERβ activity, which in turn results in decreased expression of AR [Stet-
tner et al., 2007; Thelen et al., 2005, 2007] and induction of G1-cell cycle block
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[Shen et al., 2000]. RNA-sequencing studies conducted in an ERβ-overexpressing
MCF-7 breast cancer cell line have shown that the phytoestrogens genistein and
S-equol direct ERβ to upregulate genes associated with apoptosis, antiprolifera-
tion and DNA-damage response. This is in contrast to estradiol treatment, which
promoted proliferation, inflammatory pathways and increased cell motility, thus
demonstrating distinctive, ERβ-mediated patterns of gene regulation in response
to phytoestrogens [Gong et al., 2014].
Studies in rat models of prostate cancer have demonstrated induction of prostate
epithelial cell apoptosis by phytoestrogens [Attia and Ederveen, 2012] and a large
epidemiological study has demonstrated reduced prostate cancer incidence in
those with a diet rich in phytoestrogens [Hedelin et al., 2006]. It is notewor-
thy that first- and second-generation immigrants from low-risk countries (such as
Japan) to high-risk countries (USA) have a greater risk of developing prostate
cancer than age-matched controls in the native country, suggesting that environ-
mental factors such as diet can have a significant influence over an individual’s
level of risk [Cook et al., 1999].
Obesity is a risk factor for prostate cancer, and is particularly associated with
the development of aggressive prostate cancer [Allott et al., 2013; De Nunzio
et al., 2013; Vidal et al., 2014]. White adipose tissue, which is predominant in
obesity, is a source of estrogen synthesis [Cui et al., 2013]. It expresses significant
quantities of aromatase, which is responsible for the conversion of androgens to
estrogens [Polari et al., 2015; Wang et al., 2013]. Furthermore, there is a positive
correlation between serum estradiol levels and quantity of visceral adipose tissue
as measured by MRI [Gautier et al., 2013]. It may be therefore, that the increased
risk of prostate cancer associated with obesity is attributable to increased levels of
circulating estrogens (with a greater affinity for ERα than ERβ) and disturbance
of the previously mentioned estrogen:androgen ratio [Rahman et al., 2016].
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1.3.2 Evidence from animal studies
Compelling evidence of the importance of estrogen in prostate carcinogenesis was
demonstrated in a series of animal studies, which showed that androgen, estro-
gen, aromatase and functional ERα are all required for prostate carcinogenesis
to occur [Ricke et al., 2008]. Aromatase is expressed in stromal cells of benign
prostate [Risbridger et al., 2007], however its expression is upregulated in malig-
nant epithelial cells resulting in increased intraprostatic production of estrogens
[Celhay et al., 2010; Ellem et al., 2004]. Expression of aromatase with ERα is
an independent predictor of decreased time to BCR in men treated with ADT
[Celhay et al., 2010].
To demonstrate the necessity of estrogen in prostate carcinogenesis, Ricke et
al. administered androgen alone, or androgen and estrogen to aromatase knock-
out (ArKO) mice [Ricke et al., 2008]. Only the mice receiving both hormones
developed prostatic intraepithelial neoplasia (PIN - a premalignant histological
phenotype known to be a risk factor for the development of invasive prostate
cancer [Merrimen et al., 2009; Nelson et al., 2003]). This lead the authors to
conclude that intraprostatic, aromatase-mediated production of estrogens was an
important factor in early prostate carcinogenesis (Figure 1.5A). The differential
effects of ERβ and ERα were then determined by administering androgen and
estrogen to either ERβ knockout (bERKO) or ERα (aERKO) mice (Figure 1.5B).
No difference was seen between wild type and bERKO mice, whereas the aERKO
mice did not develop PIN, suggesting that ERα is responsible for mediating the
harmful, oncogenic effects of estrogen within the prostate gland [Ricke et al.,
2008].
Similar studies conducted in rats confirmed these findings [Attia and Ederveen,
2012]. In this study it was shown that testosterone alone was insufficient for PIN
to develop; it was only with the addition of a selective ERα agonist (ERα-45) that
PIN developed. Furthermore, the addition of an ERβ-selective agonist (ERβ-26)
prevented the development of this premaligant phenotype. Taken together, these
studies demonstrate firstly, that estrogen is required for prostate cancer to develop
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Figure 1.5: Animal studies showing effects of estrogen and estrogen re-
ceptors on prostate carcinogenesis. Summary of studies conducted by Ricke
et al. 2008, demonstrating the necessity of aromatase (A), androgen, estrogen
and ERα (B) in prostate carcinogenesis. This process is suppressed by functional
ERβ. ARKO; aromatase knock-out, aERKO; ERα knock-out, bERKO; ERβ
knock-out, PIN; prostatic intraepithelial neoplasia. (Figure adapted from Nelson
et al., 2014).
and secondly, that ERα mediates the harmful effects of estrogen in the prostate,
whereas ERβ is protective against estrogen-mediated carcinogenesis.
1.3.3 Evidence from preclinical studies of therapeutic com-
pounds
The estrogen receptors represent attractive therapeutic targets as a number of
approved drugs are already in widespread use for the treatment of hormone-
dependent breast cancer [Lumachi et al., 2011]. The selective estrogen receptor
modulator (SERM) raloxifene has been shown in vitro to induce apoptosis in
androgen-sensitive and androgen-independent prostate cancer cell lines through
activation of ERβ, suppression of ERα and induction of caspase-8 and -9 apop-
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totic pathways [Kim et al., 2002a,b; Rossi et al., 2011]. A further study showed
that raloxifene, tamoxifen (another SERM) and genistein (an ERβ-selective phy-
toestrogen) reduced growth and proliferation in AR-negative prostate cancer cell
lines PC3 and DU145 [Piccolella et al., 2014]. There are however conflicting data
in the literature on the in vitro effects of genistein, as it has also been reported
to promote the development of metastatic disease in an ERβ-dependent manner
in mice bearing xenograft tumours [Nakamura et al., 2013]. The ERα antagonist
fulvestrant has also been shown to inhibit the growth of prostate cancer cell lines
in vitro [Lau et al., 2000; Leung et al., 2006a].
Studies conducted in ArKO mice have shown that administration of ERβ-selective
agonists induces cystic atrophy in basal cells of prostatic epithelium [McPherson
et al., 2010]. These cells express high levels of ERβ, but not AR and are there-
fore unaffected by conventional ADT [Ruizeveld de Winter et al., 1991]. Thus,
once ADT is withdrawn, the prostatic epithelium can be regenerated from this
basal cell population. Administration of the ERβ agonist perturbs this process
resulting in cellular apoptosis mediated by tumour necrosis factor α (TNFα) in
an androgen-independent manner [Hussain et al., 2012; McPherson et al., 2010].
1.3.4 Evidence from drug trials
Despite encouraging preclinical in vitro data, as yet there is no clinical trial ev-
idence to support the use of SERMs in prostate cancer. In a promising phase
IIb clinical trial of 154 men with biopsy-proven PIN, toremifene (ERα-selective
antagonist) was shown to reduce the incidence of invasive carcinoma at 12 months
by 48% versus placebo, thus preventing 6.8% of cancers per 100 men per year
[Price et al., 2006]. Unfortunately however, a much larger study using toremifene
in 1590 men with PIN, with 3 year follow up did not show any statistically sig-
nificant benefit over placebo [Taneja et al., 2013]. Similarly, fulvestrant [Chadha
et al., 2008] and tamoxifen [Bergan et al., 1999] have been shown to be ineffective
in the treatment of CRPC.
The reasons underlying the discrepancy between the in vitro data and the out-
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comes of clinical trials are not presently clear. However, it seems likely that
limitations of prostate cancer cell lines used in preclinical studies may be at least
partly to blame. None of the prostate cancer cell lines endogenously and simul-
taneously express ERα, ERβ and AR. Therefore they are not representative of
prostate tissue (section 1.4) and can not recapitulate the complex interactions
between these three receptors, and other stromal-epithelial interactions relevant
to cancer known to occur in vivo [Grubisha and DeFranco, 2013; Hanahan and
Weinberg, 2011; Madak-Erdogan et al., 2013; Rizza et al., 2014; Robinson et al.,
2011; Thelen et al., 2005, 2007; Yang et al., 2012].
1.4 Expression of estrogen receptors in prostate
tissue
The reported expression profiles of ERβ and ERα in benign and malignant
prostate tissue have strongly contributed to the current paradigm that ERβ is
tumour-suppressive and ERα is tumour-promoting in prostate cancer. In benign
prostatic tissue, ERα expression is confined to the stromal tissue [Tilley et al.,
1985; Wernert et al., 1988]. With the development of cancer however, ERα ex-
pression is down-regulated in the stromal cells, and upregulated in malignant
epithelial cells [Bonkhoff and Berges, 2009; Celhay et al., 2010; Nelles et al.,
2011]. It has been suggested that stromal ERα expressed within cancer associ-
ated fibroblasts may even suppress prostate cancer invasion through modulation
of macrophage activity [Yeh et al., 2016]. Conversely, stromal ERα expression
and elevated aromatase levels have been shown to be independent predictors of
shorter time to relapse in CRPC [Celhay et al., 2010], and ERα expression com-
bined with aromatase with the R264C polymorphism have also been linked to
decreased progression-free survival in CRPC [Sissung et al., 2011]. A recent study
showed that administration of the LHRH antagonist degarelix to men undergoing
radical prostatectomy for localised prostate cancer resulted in increased epithe-
lial ERα expression and upregulation of ERα-associated genes, suggesting that
ERα expression in prostate tissue may be repressed by AR [Shaw et al., 2016].
Taken together, these data suggest that ERα may have differing roles depending
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on specific tissue compartment-dependent contexts, but that when expressed in
malignant epithelial cells it may continue to drive prostate cancer progression in
castrate conditions.
ERβ is highly expressed in the basal and secretory compartments of benign pro-
static epithelium [Horvath et al., 2001]. In malignant prostatic epithelium, how-
ever, expression of ERβ is absent [Bonkhoff et al., 1999; Horvath et al., 2001].
It has been reported that ERβ expression negatively correlates with increasing
Gleason grade of prostate cancer [Asgari and Morakabati, 2011; Attia and Ed-
erveen, 2012; Dey et al., 2014; Leav et al., 2001] and that its expression is low in
high grade PIN [Risbridger et al., 2007], reflecting its premalignant phenotype.
Decreased ERβ expression has been shown to result in epithelial de-differentiation
and growth of high-grade, aggressive tumours [Mak et al., 2013]. All these data
support the notion that ERβ is a tumour-suppressor, the expression of which is
lost in the process of malignant transformation of epithelial cells. However, in a
study of 159 radical prostatectomy specimens, Horvath et al. showed that whilst
75% of tumours in their cohort did not express ERβ, those tumours in which ERβ
expression was maintained were associated with decreased relapse-free survival ir-
respective of tumour grade [Horvath et al., 2001]. In contrast, other studies have
demonstrated high ERβ expression in bone and lymph node metastases [Bouchal
et al., 2011; Zhu et al., 2004] or that the combination of ERβ expression and AR
phosphorylation in hormone na¨ıve (untreated) prostate cancer correlates with
poor clinical outcome [Zellweger et al., 2013]. Zellweger et al. also reported that
increased ERβ expression was associated with higher Gleason grade cancer and
greater proliferative activity [Zellweger et al., 2013]. These data present a rather
more complex, and perhaps confused picture of what the role of ERβ may be in
prostate cancer.
There are a number of potential biological explanations for these apparently con-
flicting data regarding ERβ tissue expression profiles in prostate cancer. It may
be due to varying levels of promoter methylation throughout the carcinogenic
process resulting in reversible, stage- and tissue-specific changes in ERβ expres-
sion, altering its transcriptional role [Cotrim et al., 2013; Risbridger et al., 2007].
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It has also been proposed that maintained ERβ expression in cancer cells may
convey a selective advantage to subclones of prostate cancer cells, helping them to
metastasise, resulting in continued ERβ expression in metastatic deposits [Zhu
et al., 2004]. A further explanation may lie with ERβ isoforms, particularly
ERβ2, which is reported to be more highly expressed in high-grade and metastatic
prostate cancer [Dey et al., 2012]. As previously discussed (Section 1.2.2) ERβ2
is thought to negatively regulate the tumour-suppressive role of wtERβ through
heterodimerisation and prevention of ligand binding [Cotrim et al., 2013; Leung
et al., 2006b] and ERβ2 has been implicated specifically in the process of cancer
metastasis through upregulation of EMT genes such as TWIST1 and RUNX2
[Chen et al., 2009; Dey et al., 2012; Leung et al., 2010]. If the antibodies used for
IHC in these studies recognise the protein region common to both wtERβ and
specific isoforms then this too may be an explanation for some of the apparently
contradictory IHC data described.
It may be however, that the underlying source of these controversies is a tech-
nical, rather than a biological one. It is widely known in the field that there
is marked variability in the specificity and sensitivity of commercially available
ERβ antibodies, which may give rise to inconsistencies in the findings reported
between IHC-based studies [Choi et al., 2001; Hartman et al., 2012; Skliris et al.,
2002; Weitsman et al., 2006; Wu et al., 2012]. This critically important question
is the focus of studies presented in Chapter 3 of this thesis.
1.5 Biology of ERβ in cancer
1.5.1 Estrogens, inflammation and EMT in prostate can-
cer
Inflammation of the prostate is a recognised risk factor for the development of
prostate cancer and cancer in general [Dennis et al., 2002; Hanahan and Wein-
berg, 2011; Jiang et al., 2013]. Several mechanisms, centring on ER function and
linking to EMT-related pathways have been implicated in the development and
progression of prostate cancer. EMT is a marker of oncological progression, which
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enables cancer cells to invade surrounding tissues and subsequently metastasise
to distant sites [Hanahan and Weinberg, 2011]. ERβ is a negative regulator of
inflammatory processes [Harris et al., 2003], and in prostate tissue its expression
has been shown to correlate with E-cadherin levels [Mak et al., 2010]. Loss of E-
cadherin expression is a well-established marker of EMT, and as ERβ expression
declines during malignant transformation, E-cadherin levels also decline. In addi-
tion, ERβ transcriptional activity is sensitive to inflammation-related oxidation
by hydrogen peroxide (H2O2) and other reactive oxidation species. This leads to
reduced DNA-binding by ERβ resulting in decreased E-cadherin expression [Gru-
bisha et al., 2012]. This results in loss of cell adhesion, increased cell motility
and increased propensity for metastastic dissemination of the disease [Grubisha
and DeFranco, 2013]. Reactive oxygen species such as H2O2 are generated by the
pro-inflammatory enzyme cyclo-oxygenase 2 (COX2), which is over-expressed in
prostate cancer [Kirschenbaum et al., 2001; Richardsen et al., 2010]. This estab-
lishes a pro-inflammatory positive feedback loop (Figure 1.6).
A second pro-inflammatory positive feedback loop, centring on ERα function
is also thought to have a role in prostate cancer progression [Ellem and Ris-
bridger, 2007] (Figure 1.6). Expression of aromatase is increased in prostate
cancer, which results in raised levels of intraprostatic estrogens that then act via
ERα to promote tissue inflammation via local generation of nitric oxide (NO)
[Celhay et al., 2010; Ellem and Risbridger, 2007; Nelles et al., 2011; Pinzone
et al., 2004; Risbridger et al., 2007]. Pro-inflammatory mediators such as TNFα
and prostaglandin E2 in turn upregulate CYP19 expression, which increases aro-
matase activity [Subbaramaiah et al., 2011]. This inflammatory process has been
confirmed in mouse models through observation of neutrophil and leucocyte mi-
gration from the stroma to the epithelial compartment [Bianco et al., 2002, 2006].
1.5.2 Genomic mechanisms of ERβ
Regulation of ERβ expression
Transcription from the ESR2 gene is controlled by two gene promoters, 0N and
0K [Lee et al., 2013; Suzuki et al., 2008]. The 0N promoter is regulated epi-
26
1. Introduction
!Aromatase!
!E2!
!ERα!
!NO!
!Inflammation!
PC Progression!
COX-2!
!H2O2!
"ERβ!
!HIF-1α!
"E-cadherin!
!Twist1!
ERβ! ERα!
EMT program!
Tissue inflammation!
Tissue inflammation!
Loss of direct 
repressive function!
!WBC migration!
!Epithelial proliferation!
Figure 1.6: Estrogen-mediated influence of inflammation in prostate can-
cer. In response to tissue inflammation, decreased ERβ expression results in up-
regulation of the EMT program to promote metastasis. Inflammation also leads
to increased aromatase expression and infiltration of inflammatory cells. (WBC,
white blood cell; E2, estradiol; NO, nitric oxide; H2O2, hydrogen peroxide; COX2,
cyclo-oxygenase 2). (Figure adapted from Nelson et al., 2014).
genetically by a CpG island contained within it [Zhu et al., 2004]. Wild type
ERβ is transcribed predominantly from the 0N promoter, which has the greater
transcriptional activity of the two [Lee et al., 2013; Suzuki et al., 2008]. Several
studies have shown that decreased expression of ERβ in cancer is the conse-
quence of DNA-methylation of the 0N promoter [Lee et al., 2013; Rody et al.,
2005; Zhao et al., 2003]. In contrast, ERβ isoforms, ERβ2 and ERβ5 are pre-
dominantly transcribed from the 0K promoter, which is not hypermethylated,
resulting in maintained transcription of ERβ2 and ERβ5 mRNA in cancer [Lee
et al., 2013; Suzuki et al., 2008]. It is hypothesised that this is the mechanism by
which ERβ2 expression increases in high grade and metastatic prostate cancer
[Lee et al., 2013].
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The 0N promoter is also thought to be regulated by the transcriptional repressor
BMI-1, which is a key component of the polycomb repressive complex [Jacobs
et al., 1999]. BMI-1 binds within the 0N, but not the 0K promoter regions of
the ESR2 gene [Mak et al., 2015a]. Expression of BMI-1 is increased follow-
ing loss of PTEN, one of the most common genetic lesions occurring in prostate
cancer. Indeed, the frequency of PTEN loss increases with Gleason grade and
is associated with increasingly aggressive disease [Cairns et al., 1997]. Further-
more, PTEN loss results in inhibition of the apoptotic functions of FOXO3a, a
forkhead protein, which is upregulated in ERβ-mediated cellular apoptosis via
the intrinsic pathway [Dey et al., 2014]. Following BMI-1 induced repression of
ERβ expression, HIF1α and VEGF expression are upregulated, which in turn
establishes a positive feedback loop to sustain BMI-1 expression [Goel et al.,
2012; Mak et al., 2015a]. Taken together, these findings provide insight into some
of the early events in prostate carcinogenesis and an important relationship be-
tween PTEN deletion and silencing of ERβ expression with resultant loss of its
tumour-suppressive effect [Mak et al., 2015a] (Figure 1.7).
ERβ-DNA binding
ERβ and ERα both bind to EREs on DNA to activate dependent gene transcrip-
tion [Kuiper et al., 1996; Le et al., 2013]. The two receptors share 97% sequence
homology in the DBD and 60% in the LBD, with the result that there is substan-
tial overlap in their genome-wide DNA binding profiles [Madak-Erdogan et al.,
2013]. The binding affinity of each ER to the ERE can be affected by changes in
the nucleotide sequence, which results in differential recruitment of co-activators,
protein conformation and transcriptional activity. This highlights an important
mechanism by which the differential functions of ERβ and ERα are mediated at
a genomic level [Klinge et al., 2004].
At present, the genome-wide binding of endogenously expressed ERβ has not been
determined from any experimental model, so current understanding is based on
studies using exogenous or tagged ERβ in cell line models [Le et al., 2013; Madak-
Erdogan et al., 2013; Zhao et al., 2010]. Using the breast cancer cell line MCF-
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Figure 1.7: Silencing wtERβ activates multiple carcinogenic mecha-
nisms. PTEN deletion results in disregulation of ERβ’s tumour suppressive
function by i) Silencing wtERβ expression from 0N promoter whilst maintaining
ERβ2 and ERβ5 expression. ERβ2 heterodimerises to inhibit wtERβ function;
ii) Loss of wtERβ results in upregulation of VEGF signalling to promote car-
cinogenesis, establishing a positive feedback loop via BMI-1; iii) Loss of wtERβ
disables caspase-9-mediated apoptosis to promote carcinogenesis. (Figure based
on Dey et al., 2014; Lee et al., 2013; Leung et al., 2006b; Mak et al., 2015a;
Suzuki et al., 2008).
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7 with force-expressed ERβ (MCF-7 ERα/β), force-expressed ERβ with ERα
knockdown (MCF-7 ERβ) or wild type MCF-7 (MCF-7 ERα), Madak-Erdogan et
al. showed that the two receptors compete for DNA binding sites, and in doing so,
modify each other’s transcriptional effects. Specifically, when each of the recep-
tors was expressed alone, there was 40% overlap between ERα and ERβ binding
sites. However, when co-expressed (MCF-7 ERα/β cells) the number of binding
sites available to each receptor decreased by approximately 50% [Madak-Erdogan
et al., 2013]. Additionally, they showed that the proliferative effects of ERα tran-
scription were reduced by the co-expression of ERβ, demonstrating that ERβ can
modulate the oncogenic effects of ERα. ERβ has been shown to directly bind
to the ERα promoter region to repress ERα expression, providing a mechanistic
explanation for this particular observation [Bulun et al., 2012]. By integrating
cistromic and transcriptomic analyses, Madak-Erdogan et al. showed that ERβ’s
anti-proliferative effects were mediated through direct binding to apoptosis and
cell-cycle regulation genes, and modulation of metabolic pathways through cou-
pling with the coregulator NRIP1 (RIP140) [Madak-Erdogan et al., 2013]. These
data, along with similar work by others [Le et al., 2013] support the hypothe-
sis that ERβ is predominantly tumour-suppressive. However, as these studies
were conducted in derivatives of breast cancer cell lines, it is important that the
hypothesis is further tested in appropriate prostate cancer models.
Genomic crosstalk between ERβ and AR
It is becoming increasingly apparent in the nuclear receptor field that individual
receptors do not function in isolation, but rather they influence and modulate each
other’s actions through a number of mechanisms. This phenomenon is known as
‘crosstalk’ and is an area of significant research interest and translational rele-
vance. One such example is recent work showing that the glucocorticoid receptor
(GR) is expressed in CRPC, and can bypass complete androgen blockade to re-
store expression of a selection of AR target genes and thus continue to drive
prostate cancer progression [Arora et al., 2013]. This has important clinical rel-
evance, as corticosteroids are often used to treat patients with advanced CRPC
[Heidenreich et al., 2014]. The findings described by Arora et al. suggest that
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corticosteroid use may in fact accelerate cancer progression in these patients.
Several studies have demonstrated evidence of interaction between ERβ and AR
in breast and prostate cancer models, but there are currently no studies reporting
genome-wide ERβ/AR crosstalk at the level of chromatin binding in any cell or
tissue context.
Upregulation of ERβ in response to phytoestrogens in vitro resulted in decreased
expression of AR and PSA (an AR target gene) in a prostate cancer cell line model
[Thelen et al., 2007]. Another in vitro study showed that ligand-activated ERβ
repressed AR-dependent cell proliferation [Weng et al., 2013]. These two stud-
ies suggest that ERβ negatively regulates AR activity. AR-driven inflammatory
pathways in prostate cancer have been shown to inhibit ERβ’s tumour-suppressive
effect through oxidation by reactive oxygen species (Figure 1.6) [Grubisha and
DeFranco, 2013]. It has been suggested that cross-reactivity of ligands may also
influence receptor crosstalk. For example, 3β-adiol, the natural ligand for ERβ
and the predominant intra-prostatic estrogen [Oliveira et al., 2007; Piccolella
et al., 2014] has been shown in vitro to activate mutant AR typically found in
CRPC, suggesting that 3β-adiol could continue to drive prostate cancer in the
testosterone-deplete conditions of maximal androgen blockade [Mizokami et al.,
2004]. It has also been suggested that DHT will directly stimulate ERβ resulting
in its recruitment to EREs [Teng et al., 2014], however, given that 3β-adiol is a
metabolite of DHT this finding may require cautious interpretation. Interestingly,
this same study by Teng et al. demonstrated dihydroepiandrosterone- (DHEA -
the steroid precursor of androgens and estrogens [Labrie et al., 2005]) and estra-
diol (E2)-induced recruitment of ERβ to AREs [Teng et al., 2014], suggesting
a mechanism by which ERβ directly regulates AR function. As this work was
conducted in a liver cell line model, it may be that the findings are not generalis-
able across differing cell or tissue contexts. Indeed a study conducted in a breast
cancer cell line showed that AR, upregulated by a non-metabolisable synthetic
androgen ligand binds to an ARE within the ERβ promoter region to increase
ERβ expression and inhibit breast cancer cell growth [Rizza et al., 2014].
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It is difficult to distill one single, coherent mechanistic model of the relationship
between ERβ and AR from the above-mentioned studies, and in particular to
work out whether ERβ regulates AR or vice versa. This may reflect the differing
cell- and tissue-specific contexts in which each study has been conducted. Partic-
ularly in the context of prostate cancer, where little is known about the genomic
actions of ERβ and its potential effect on AR function at a chromatin level, this
is an important area for further investigation.
1.5.3 ERβ as an oncogene
The majority of the evidence discussed thus far holds to the paradigm that in
breast and prostate cancer, wtERβ is a tumour suppressor and negative regulator
of processes that lead to carcinogenesis (ERβ isoforms excepted; see section 1.2.2).
However, there are several studies published in the literature that contradict this
notion and implicate wtERβ as an oncogene.
Yang et al. proposed a model of wtERβ-mediated, non-androgenic AR sig-
nalling, which suggested that E2 stimulated ERβ could continue to drive AR-
dependent gene transcription in castrate conditions and thus maintain prostate
cancer growth [Yang et al., 2012]. In hormone replete conditions, DHT activates
AR, which then binds to AREs to stimulate AR-dependent transcription. How-
ever, in the absence of DHT, they propose that E2-stimulated wtERβ binds to the
AR co-factor and proto-oncogene PELP1 (proline-, glutamic acid- and leucine-
rich protein 1), to form a complex that then binds to AR with PELP1 acting
as a bridge between the two nuclear receptors. This complex is then recruited
to an ARE, to maintain AR-dependent gene transcription, now under estrogen
regulation and thus providing a mechanism for ongoing progression of CRPC.
In a study using IHC of hormone-na¨ıve (HN) and castrate-resistant prostate can-
cer tissue, Zellweger et al. reported high expression of wtERβ in CRPC [Zellweger
et al., 2013]. Furthermore, expression of wtERβ in HN tumours was significantly
associated with adverse prognosis, particularly when co-expressed with phosphy-
lated AR. In light of their findings, the authors propose that the role of wtERβ
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may switch from tumour-suppressor, to tumour-promoting as tumourigenesis pro-
gresses. Recently, Lombardi et al. found that ligand-activated wtERβ was pro-
proliferative in the AR-negative, castrate-resistant PC-3 prostate cancer cell line
through upregulation of β-catenin induced Cyclin D2 expression [Lombardi et al.,
2016].
1.6 Hypothesis and aims
In summary, the literature discussed thus far highlights several key points; firstly,
estrogen is essential for the development of prostate cancer and estrogen exposure
is an important epidemiological risk factor for prostate cancer; secondly, most
evidence suggests that wtERβ is a tumour-suppressor and acts as a gate-keeper
to a number of carcinogenic processes, however there are ongoing controversies
regarding the role of wtERβ at various stages of prostate cancer progression;
thirdly, there is evidence of relationship and interplay between ERβ and AR, but
this has not been thoroughly explored at the genomic level, particularly in the
context of prostate cancer.
Based on the hypothesis that ERβ is an important modulator of prostate
carcinogenesis, the principle aim of this work is to investigate and further un-
derstand the influence of ERβ on AR-driven carcinogenesis in prostate cancer.
To address this, the following studies have been undertaken and are presented in
this thesis:
1. Validation of ERβ antibodies.
A panel of commonly used ERβ antibodies were assessed for ERβ specificity
and validated using multiple, independent experimental approaches. This
is to establish reliable reagents to be used for subsequent validation and
mechanistic experiments.
2. Establishing an experimental model for the study of ERβ.
Prostate and breast cancer cell lines commonly used in previously pub-
lished studies for the study of ERβ were assessed for ERβ expression us-
ing the newly validated antibodies and additional, antibody-independent
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approaches. As no ERβ expression was detected in these cell lines, an
androgen-sensitive prostate cancer cell line model with stably transfected,
inducible ERβ expression was developed and validated for use in in vitro
mechanistic studies of ERβ function. Differential expression of ERβ in
benign versus cancerous prostate tissue was confirmed using validated an-
tibody.
3. Genomic crosstalk between ERβ and AR in prostate cancer.
To investigate the relationship between ERβ and AR, published clinical
datasets were interrogated, revealing that increased ERβ expression is as-
sociated with improved BCR-free survival in men with prostate cancer.
Inhibition of AR signalling in vitro by silencing RNA and in vivo by ADT
increases ERβ expression, indicating that ERβ expression is repressed by
AR. Using the androgen-sensitive prostate cancer cell line with inducible
ERβ expression, we found that ligand-activated ERβ inhibits prolifera-
tion and down-regulates androgen-dependent genes. We identified DNA-
binding sites shared by ERβ and AR, suggesting that this antagonism oc-
curs through competition for binding sites. These data reveal the genomic
mechanisms by which ERβ modulates AR-driven carcinogenesis for the first
time. In future, an ERβ-selective compound may be used to slow prostate
cancer progression.
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Materials and methods
2.1 Cell Culture Techniques
2.1.1 Cell lines and culture media
The cancer cell line MDA-MB-231-ERβ with doxycycline-inducible ERβ expres-
sion (gift from Dr. J. Hawse, Mayo Clinic, Minnesota, USA) was cultured in
Dulbeccos Modified Eagle Medium with F12 supplement (DMEM/F12) with 10%
heat-inactivated tetracycline-free foetal bovine serum (FBS), 2mM L-glutamine,
50 U/ml penicillin, 50 µg/ml streptomycin, 5 µg/ml blasticidin S (to select for
the tetracycline repressor) and 500 µg/ml zeocin (to select for the ERβ expression
vector).
Prostate cell lines LNCaP (androgen sensitive), C4-2, C4-2b, PC3, DU145, 22Rv1
(androgen resistant) and PNT1a (benign) were obtained from ATCC and grown
in RPMI-1640 with 10% heat-inactivated FBS, 2mM L-glutamine, 50 U/ml peni-
cillin and 50 µg/ml streptomycin. Breast cell line MCF-7 was obtained from
ATCC and grown in DMEM supplemented with 10% heat-inactivated FBS, 2mM
L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin.
LNCaP-ERβ cell line was cultured in RPMI-1640 with 10% heat-inactivated
tetracycline-free FBS, 2mM L-glutamine, 50 U/ml penicillin, 50 µg/ml strepto-
mycin, 2.5 µg/ml blasticidin S (to maintain selection of the tetracycline repressor)
and 250 µg/ml zeocin (to maintain selection of the ERβ expression vector).
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2.1.2 Cell Culture
All cell lines were incubated at 37◦C with 5% CO2 and cultured to 80 to 90%
confluence. Cells were washed with warmed, sterile phosphate buffer saline (PBS)
(137 mM NaCl, 2.7mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4), trypsininsed
with 0.05% trypsin-EDTA, neutralised with media and then centrifuged for 3
minutes at 1,300 rpm (Heraeus Megafuge, Thermo Fisher Scientific, Leicester-
shire, UK). The cell pellets were then resuspended in media and replated at a
dilution of 1:2 to 1:10 depending on initial confluency and cell line growth rate.
To prepare frozen stocks of cell lines, 1x106 cells were resuspended in 1ml of 10%
dimethyl sulphide (DMSO) and 90% FBS per aliquot. Cells were frozen to -80◦C.
Frozen cells were revived by rapid thawing to 37◦C followed by resuspension in
appropriate media after centrifugation. All cells lines were confirmed to be free
of mycoplasma infection by RNA capture ELISA. STR genotyping was used to
confirm the identity of all cell lines used.
To induce ERβ expression in MDA-MB-231-ERβ and LNCaP-ERβ cells, doxycy-
cline was added at doses of either 0.1 µg/ml or 0.5 µg/ml for 24 hours depending
on specific experimental requirements.
Conditioned media for LNCaP-Tet-R and LNCaP-ERβ cells was prepared by
adding media to parental LNCaP cells for 48 hours. Media was collected and
filtered through a Stericup R© 0.22µm pore filter (Millipore UK, Watford, UK),
then stored at 4◦C.
2.1.3 Creation of the LNCaP-ERβ cell line
The LNCaP-ERβ cell line was generated using the T-RexTM system (Invitrogen)
following a previously described protocol [Monroe et al., 2003]. This approach
uses two vectors, the pcDNA6/TR c©, which is a regulatory plasmid express-
ing the tetracycline-repressor (Tet-R) and the pcDNA4/TO c©. This contains a
CMV promotor driving the expression of ERβ under the control of Tet-operator
sequences (pcDNA4/TO c©-ERβ vector gifted by Dr. J. Hawse, Mayo Clinic,
Minnesota, USA). Treating cells with doxycycline releases the Tet-R from the
Tet-operator sequence resulting in expression of ERβ.
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Preparation of plasmids
pcDNA6/TR c©, pcDNA4/TO c©-Luc and pcDNA4/TO c©-ERβ plasmids were
bulked up using Subcloning efficiencyTM DH5αTM competent E. coli bacterial
cells. For each plasmid, 2 ng of plasmid DNA was added to 50 µl of cells and
incubated on ice for 30 minutes. Cells were heat-shocked for 20 seconds at 42◦C
and returned to ice for 2 minutes. To each tube, 950 µl of prewarmed LB me-
dia was added and the tubes incubated at 37◦C and rotated at 225 rpm for 1
hour. Twenty microlitres of each transformation was then spread on pre-warmed
amplicillin-selective plates, and the plates then incubated overnight at 37◦C.
Transfection of Tet-R plasmid into LNCaP cells
The pcDNA6/TR c© was linearised via Fsp1 restriction digest. Plasmid DNA
was purified by phenol chloroform cleanup. Fourteen micrograms of plasmid
DNA was transfected into genotyped LNCaP cells at a density of 90% confluence
using Lipofectamine R© 3000 (Thermofisher Scientific, Leicestershire, UK). Cells
were incubated overnight at 37◦C with 5% CO2. Twenty-four hours later, the
culture media was replaced. Forty-eight hours after transfection, the cells were
split to a 1:20 dilution to enable growth of single-cell colonies on a 10 cm2 dish.
Following further overnight incubation, Blasticidin S 5 µg/ml was added to select
for cells that had successfully integrated the tetracycline repressor. Fresh culture
media and blasticidin was added every 48 hours until discrete colonies of cells
were apparent on the petri dish.
Selection of LNCaP-Tet-R clones
With the aid of 4x magnification under a light microscope, individual colonies of
cells were trypsinised (5µl trypsin), taken from the 10 cm2 plate and seeded into
96-well plates. Approximately 80 clones of LNCaP-Tet-R cells were sampled in
this manner and cultured in 50% fresh culture media and 50% conditioned media
up to 6-well plates.
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Luciferase screen of LNCaP-Tet-R clones
Twenty clones were successfully raised to 6-well plates. Cells were counted
with the Vi-CELLTM (Beckman Coulter Life Sciences, Indianapolis, USA) and
10,000 cells from each clone seeded into 96-well plates in sextuplicate. Follow-
ing 48 hours of incubation at 37◦C in 5% CO2 the colonies were transfected with
pcDNA4/TO c© plasmid containing a cloned luciferase gene using Lipofectamine R©
3000. Following overnight incubation at 37◦C in 5% CO2 fresh media was added.
Doxycycline 0.1 µg/ml was added to 3 wells of each clone for 24 hours to induce
luciferase expression. Steady Glo R© (Promega, Southampton, UK) was added
to each well and the resulting fluorescence measured using the PHERAstar R©
(Thermo Fisher Scientific, Leicestershire, UK).
Zeocin dose response assay in LNCaP-Tet-R cells
As the pcDNA4/TO c©-ERβ plasmid contains a Zeocin-resistance gene, a dose re-
sponse assay was conducted to determine the optimal dose of zeocin, which would
kill cells that had failed to integrate the pcDNA4/TO c©-ERβ vector. LNCaP-
Tet-R cells were seeded into 6-well plates (3x105 cells per well) and treated with
zeocin at the following doses: 0 µg/ml; 250 µg/ml; 500 µg/ml; 750 µg/ml; 1000
µg/ml; 1250 µg/ml. Fresh media and antibiotic was added every 48 hours and
cells examined with microscopy for cell death on day 6. On the basis of this exper-
iment, 1 mg/ml zeocin was subsequently used for selection of the pcDNA4/TO c©-
ERβ plasmid.
Transfection of ERβ plasmid into LNCaP-Tet-R cells
The pcDNA4/TO c©-ERβ plasmid was transfected into the LNCaP-Tet-R clone
exhibiting firstly; greatest induction of luciferase signal and secondly; the lowest
signal from the ‘doxycycline-off’ condition. Using Lipofectamine R© 2000, 2 µg
of pcDNA4/TO c©-ERβ plasmid was transfected into LNCaP-Tet-R cells at 90%
confluence. Following 6 hour incubation at 37◦C in 5% CO2 fresh media was
added. The following day, blasticidin 5 µg/ml and zeocin 1 mg/ml were added
to the media. Fresh media and antibiotics were added every 48 hours for 6 days.
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Cells were then maintained in in tetracycline-free media with 2.5 µg/ml blasticidin
and 250 µg/ml zeocin as described in section 2.1.1.
2.1.4 Hormone deprivation followed by ligand treatment
Cells were plated at 50% confluence in growth media as described (section 2.1.1).
The following day, cells were washed with PBS and media replaced with phenol
red-free RPMI 1640 supplemented with 5% charcoal/dextran-treated, tetracycline-
screened FBS (Thermo Fisher Scientific, Paisley UK), 2mM L-glutamine, 50 U/ml
penicillin and 50 µg/ml streptomycin. Cells were maintained in steroid-depleted
conditions for 3 days, with fresh media replaced every 48 hours. Hormone treat-
ments consisted of vehicle control (ethanol), synthetic androgen R1881 (1nM)
(Sigma-Aldrich Company Ltd. Dorset, UK) and 5α androstane 3β, 17β-diol (3β-
adiol) 10 nM (LGC Standards, Teddington, UK).
2.1.5 Cell proliferation assay
Cell proliferation in LNCaP-ERβ+ and LNCaP-ERβ- cells, treated with vehicle,
1 nM R1881, 10 nM 3β-adiol or both R1881 and 3β-adiol was assessed using the
IncuCyteTM (Welwyn Garden City, UK). Three biological replicates, each of 4
technical triplicate experiments were set up in 48-well plates with 15,000 cells
seeded per well. Cells were hormone-deprived as described (section 2.1.4) for 3
days prior to hormone treatment. Cell confluence in each well was measured daily
for 7 days.
2.1.6 Silencing RNA to AR
Genotyped and mycoplasma negative LNCaP cells at 90% confluence were treated
with silencing RNA (siRNA) to AR (Dharmacon On Target plus Smartpool, L-
003400-00, Lot 131115, ThermoScientific, Leicestershire, UK) or non targeting
pool (siNT - D-001810-10-20, Lot 1557666). Transfection was carried out using
Lipofectamine R© 2000 with 50 nM siRNA. Cells were incubated with siRNA for
6 hours at 37◦C in 5% CO2. Cells were then washed with PBS and fresh growth
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media added. Media was refreshed 15 hours later, and the cells harvested in PBS
with protease inhibitor after a further 24 hours incubation 37◦C in 5% CO2.
2.2 Quantification of mRNA expression
2.2.1 Preparation of mRNA
Cell lines were harvested for collection of mRNA using the RNEasy R© Mini Kit
(Qiagen, California USA) according to the manufacturer’s instructions. On-
column DNase digestion was performed with 20 units of RNase-free DNaseI
(Roche Diagnostics GmbH, Mannheim, Germany) for 15 minutes at room tem-
perature to remove contaminating genomic DNA.
2.2.2 cDNA synthesis
RNA was quantified by measuring the absorbance at 260 nm and 280 nm with
the NanoDrop R© 8000 (Thermo Scientific, Delaware USA). Samples containing
250 ng random primers (Promega, Madison, WI, USA), 1 µg RNA, 1 µl 10mM
dNTP mix and water to a total volume of 13 µl were prepared and heated to
65◦C for 5 minutes, followed by 1 minute incubation on ice. To each sample 4 µl
5X First-strand buffer, 1 µl 0.1M DTT, 1 µl RNaseOUT and 1 µl SuperScript III
reverse transcriptase (RT) (Thermo Fisher Scientific, Leicestershire, UK) were
added and incubated at 25◦C for 5 minutes then 50◦C for 60 minutes followed by
inactivation of the reaction by heating at 70◦C for 15 minutes. Synthesised cDNA
was diluted 1:5 using nuclease-free water and stored at -20◦C for subsequent use.
2.2.3 Quantitative RT-PCR (RT-qPCR)
Each RT-qPCR reaction contained 7.5 µl Power SYBR R© Green PCR Master Mix
(Applied Biosystems, California USA), 0.5 µl of 10 µM primer mix, 2 µl of a 1:5
dilution of cDNA and nuclease-free water to a final volume of 15 µl. Reactions
were performed with the Stratagene R© Mx3005P RealTime machine in triplicate.
Hot-start Taq polymerase was heat-activated at 95◦C for 10 minutes followed by
40 cycles of 15 seconds at 95◦C and 30 seconds at 60◦C. Fluorescence was read
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in each cycle and a melting curve constructed as the temperature was increased
from 65◦C to 95◦C with continuous fluorescence readings. UBC was used as a
control gene to normalise between the samples and relative expression determined
using the delta-delta Ct method [Livak and Schmittgen, 2001].
2.2.4 RT-qPCR Primer design
Primers for mRNA RT-qPCR were designed based on published genomic se-
quences (available from USCS genome browser at http://genome.ucsc.edu/) us-
ing the Primer3 software package [Koressaar and Remm, 2007; Untergasser et al.,
2012] available at http://bioinfo.ut.ee/primer3-0.4.0/primer3/. Primer sequences
are shown in table 2.1.
Forward! Reverse!
ERβ" 5' AAAACCGGCGCAAGAGCTG 3' " 3' TGCTCGTCGGCACTTCTCTG 5’ "
AR" 5’ CTCACCAGCTCCTGGACTC 3’" 3’ CAGGCAGAAGACATCTGAAAG 3’"
UBC" 5’ ATTTGGGTCGCGGTTCTTG 3’" 5’TGCCTTGACATTCTCGATGGT 3’"
Table 2.1: Sequences of primers used in RT-qPCR
2.2.5 RNA Sequencing
Total RNA was extracted using the method described. Libraries for Illumina
sequencing were prepared using TruSeq Stranded mRNA HT kit (Cat. RS-122-
2103, Illumina, Chesterford UK). Prior to library preparation samples were quan-
tified using fluorescence based method and RNA quality was assessed using RNA
6000 Nano Kit (Cat. 5067-1511, Agilent Technologies LDA UK Limited, Cheshire
UK) on Bioanalyzer2100 (Agilent Technologies LDA UK Limited, Cheshire UK).
500 ng of total RNA was used for library preparation with RNA Integrity Num-
bers (RINs) varying from 5.7 to 10. Samples were processed following manu-
facturer’s HS (High-Sample) instructions (part no. 15031048 Rev. E, Illumina,
Chesterford UK) with 12 PCR cycles used to enrich RNA fragments. A subset
of 12 final libraries was analysed using DNA 1000 Kit (Cat. 5067-1504, Agilent
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Technologies LDA UK Limited, Cheshire UK) and average library length deter-
mined as 300 bp. All libraries were quantified using RT-qPCR. Serial dilutions
were made in singlicate and 100,000x dilution used for quantification by KAPA
Library Quantification Kit Illumina ROX Low (cat. KK4873, KAPA Biosystems,
London UK). Libraries were normalised to 30 nM and pooled in equal volumes
to create a balanced pool. The pool of libraries was quantified after serial di-
lutions in triplicate and 10,000x and 100,000x dilutions used for quantification.
The pool was used for clustering on HiSeq4000 sequencing flow cell following the
manufacturer’s instructions at 200 pM concentration with 1% spike-in of PhiX
control (Cat. FC-110-3001, Illumina, Chesterford UK). A total of three lanes of
sequencing was performed using HiSeq4000 50 bp single-end run type for dual-
indexed libraries. Demultiplexing was performed using bcl2fastq2 v.2.17 software
(Illumina, Chesterford UK), allowing 0 mismatches.
Single-end 50-bp reads generated on the Illumina HiSeq sequencer were aligned
to the human genome version GRCh38.p5 using TopHat v2.1.0
(www.ncbi.nlm.nih.gov/pubmed/19289445). Read counts were obtained using
HTSeq-count v1.5.0-p1
(www-huber.embl.de/users/anders/HTSeq/doc/overview.html). Read counts were
then normalized and tested for differential gene expression using the DESeq work-
flow v1.18.0 (https://www.ncbi.nlm.nih.gov/pubmed/20979621). Multiple test-
ing correction was applied using the Benjamini-Hochberg method. Genes were
selected as differentially expressed with a false discovery rate (FDR) <0.01.
Preparation of libraries for RNA-seq performed by the CRUK CI Genomics Core
Facility, data analysis conducted by the CRUK CI Bioinformatics Core Facility.
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2.3 Targeted protein analysis and Proteomics
Techniques
2.3.1 Antibodies
The following antibodies were used for Western blotting and Rapid Immunopre-
cipitation Mass-spectrometry of Endogenous protein (RIME) [Mohammed et al.,
2013]: ERβ1 PPG5/10 (MAI-81281) (Thermo Scientific Pierce, Rockford IL
USA), Novocastra-ER-beta (EMR02-NCL-ER-BETA) (Leica Biosystems, New-
castle, UK), ERβ-antibody H150 (Sc8974) (Santa Cruz Biotechnology, Dallas
TX, USA), GeneTex ERβ 70182 (Irvine, CA, USA), ERβ 06-629 (Merck Milli-
pore, Watford, UK), Abcam 288 [14C8] (Cambridge, UK), AR (sc816) (Santa
Cruz Biotechnology, Dallas TX, USA), FOXA1 (ab5089) (Abcam Cambridge,
UK), E2F1 C20 (sc193), Mouse IgG (sc2025) (Santa Cruz Biotechnology, Dallas,
Texas USA), Rabbit anti-beta actin (ab8227) (Abcam, Cambridge, UK), mouse
anti-beta actin [AC-15] (ab6276) (Abcam Cambridge, UK).
Two non-commercially available mouse monoclonal antibodies, ERβ CWK-F12
(gift from Dr. B. Katzenellenbogen, University of Illinois, USA)[Choi et al., 2001]
and ERβ MC10 (gift from Dr. J. Hawse, Mayo Clinic, Minnesota, USA)[Wu et al.,
2012] were used. Details of the ERβ antibodies included in the validation study
are summarised in table 2.2 and the locations of antibody binding on the ERβ
protein shown in figure 2.1.
2.3.2 Protein extraction for Western blotting
Cell lines were harvested for nuclear protein extraction using the Ne-Per R© nuclear
extraction kit (Thermo Scientific Pierce, Rockford IL USA) according to the
manufacturer’s instructions. Extracted protein was quantified using the Direct
Detect R© system (Merrick Millipore, Massachusetts USA).
2.3.3 Western blotting
Nuclear protein extracts were prepared with 4X protein sample loading buffer
(LI-COR Biosciences, USA), 10X NuPage sample reducing agent (Thermo Fisher
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Antibody! Immunogen! Host 
species!
Class! Binding region! Application!
NCL-ER-BETA! Recombinant protein. Wt 
ERβ. C terminus!
Mouse! Monoclonal! C terminus! IHC, WB!
PPG5/10! Synthetic peptide C 
terminus of wt ERβ !
Mouse! Monoclonal! C terminus! IF, IHC, WB!
GeneTex 70182! Amino acids 1-153 of 
human ERβ expressed in 
E.coli!
Mouse! Monoclonal! N terminus! IP, WB, ChIP!
Millipore 06-629! Amino acids 46-63 of 
human ERβ!
Rabbit! Polyclonal! NTD! WB, IHC!
Santa cruz 
sc8974!
Amino acids 1-150 of 
human ERβ!
Rabbit! Polyclonal! N terminus! WB, ChIP, IF, 
ELISA!
Abcam 288 
[14C8]!
Recombinant fusion 
protein. Amino acids 1-153 
of human ERβ in E.coli!
Mouse! Monoclonal! N terminus! WB, Flow cyt, 
IHC, ICC, ChIP!
CWK-F12! Recombinant protein. 
Amino acids 256-505 of 
human wt ERβ!
Mouse ! Monoclonal! C-terminus! WB, IP, IHC!
MC10! Fusion protein. Amino 
acids 1-140 of human ERβ!
 in E.coli!
Mouse! Monoclonal! N terminus! IHC, IP, WB, IF!
Table 2. Details of ERβ antibodies validated. Application details are as recommended by the 
manufacturer. IHC, immunohistochemistry; WB, western blot; IF, immunofluorescence; ChIP, 
chromatin immunoprecipitation; ELISA, enzyme-linked immunosorbent assay; Flow cyt, flow 
cytometry; ICC, immunocytochemistry; IP, immunoprecipitation; Wt, wild type; NTD, N 
terminal domain; LBD, ligand binding domain.!
!
Table 2.2: etails of ERβ antibodies included in validation study, ac-
cording to manufacturers’ published datasheets.
Scientific, Leicestershire, UK) and water, and 15 µg protein per lane loaded into
Bolt 4-12% Bis-Tris gels (Thermofisher Scientific, Leicestershire, UK). Gels were
run with MOPS running buffer for 30 minutes at 60V followed by 30 minutes at
120V.
Western transfer was performed using the iBlot system (Invitrogen, Paisley, UK)
according to the manufacturer’s instructions. Membranes were blocked with
Odyssey R© blocking buffer (LI-COR Biosciences, USA) for 1 hour at room tem-
perature. Primary antibodies were added at the following dilutions in Odyssey R©
blocking buffer/PBS/0.1% tween and incubated overnight at 4◦C: Novocastra
1:100, PPG5/10 1:100, CWK-F12 1:200, MC10 1:300, Sc8974 1:200, GeneTex
70182 1:200, Millipore 06-629 1:500 and Abcam 288 [14C8] 1:500, AR (sc816)
1:500, FOXA1 (ab5089) 1:1000. The following were used as loading controls ac-
cording to the species of the primary antibody undergoing assessment: rabbit
anti-beta actin 1:5000, mouse anti-beta actin 1:1000.
The membranes were washed 3 times each for 5 minutes with PBS/0.1% tween
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C!
258! 503! 530!
Hinge !
(D)!
1! 142! 226!
N! (F)!LBD (E)!DBD (C)!NTD (A/B)!
MC10! Novocastra!
PPG5/10!
CWK-F12!
Abcam 288 [14C8]/
Genetex 70182!
sc 8974!
Millipore 06-629!
wtERβ!
Amino acid:!
Supplementary Figure 1!
Figure 2.1: Binding sites of ERβ antibodies included in validation study,
according to manufacturers’ published datasheets.
and incubated with secondary antibodies in Odyssey R© blocking buffer/PBS/0.1%
tween for 1 hour at room temperature: Goat anti-mouse (green) 1:5000, Goat
anti-rabbit (red) 1:20000. Membranes were imaged to visualise the bands using
the Li-Cor Odyssey R© fluorescent imaging system (LI-COR Biosciences, USA) at
169 µm wavelength, medium quality, intensity rating 5 as per provided instruc-
tions.
2.3.4 Rapid Immunoprecipitation Mass-spectrometry of
Endogenous proteins (RIME)
RIME experiments were conducted as previously described [Mohammed et al.,
2013]. Briefly, cells were grown in 15 cm2 plates in appropriate culture media.
For antibody validation experiments in the MDA-MB-231-ERβ cell line, 4 x 107
cells were used for each experimental condition. For all other RIME experiments,
8 x 107 cells were used per condition.
Cells were crosslinked with media containing 1% EM grade formaldehyde (TEBU
biosciences) for 8 minutes and the formaldehyde then quenched with 0.1M glycine.
Cells were washed, harvested and pelleted in cold PBS. The nuclear fraction was
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enriched by resuspending the cell pellet in 10 ml of lysis buffer 1 (LB1) (50 mM
HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40
or Igepal CA-630, and 0.25% Triton X-100) for 10 minutes at 4◦C. Cells were
then pelleted and resuspended in LB2 (10 mM Tris-HCL [pH 8.0], 200 mM NaCl,
1 mM EDTA, and 0.5 mM EGTA) for 5 minutes at 4◦C. Cells were pelleted and
resuspended in 300 µl of LB3 (10 mM Tris-HCl [pH 8], 100 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.5% N-lauroylsarcosine) and
sonicated in a waterbath sonicator (Diagenode Bioruptor R©, Diagenode, Seraing,
Belgium) for 45 minutes. A 10 µl aliquot of sonicated chromatin was reverse
cross-linked at 95◦C for 10 minutes and run on a 2% E-Gel (Thermo Fisher
Scientific, Leicestershire, UK) to confirm sufficient sonication and that fragments
were 200-300 base pairs in length. 30 µl of 10% Triton-X was added and the
sonicated lysate centrifuged at 17,000G for 10 minutes to remove cell debris.
The supernatant was then incubated with 100 µl of magnetic beads (Protein
G Dynabeads R©, Dynal), which had been previously washed three times with
PBS containing 5 mg/ml BSA, incubated with the appropriate volume of an-
tibody overnight rotating at 4◦C overnight and then washed three times with
PBS containing 5 mg/ml BSA. The washed beads and sonicated samples were
incubated overnight at 4◦C. Beads were collected using a magnetic concentrator,
the supernatant removed and the beads washed 10 times in 1 ml ice-cold RIPA
buffer (50mM HEPES pH 7.6, 1mM EDTA, 0.7% Na deoxycholate, 1% NP-40,
0.5M LiCL) and twice in 100 mM ammonium hydrogen carbonate (AMBIC) so-
lution. Dry, frozen beads were submitted for tryptic digestion of bead-bound
protein, and peptides pulled down by immunoprecipitation (IP) identified by
mass-spectrometry (LTQ Velos-Orbitrap MS).
RIME data analysis
Raw MS data files were processed using Proteome Discoverer v.1.3 (Thermo Sci-
entific). Processed files were searched against the SwissProt human database
using the Mascot search engine version 2.3.0 with a FDR of <1%. For each
ChIP, the resulting list of purified peptides identified by MS was filtered against
the corresponding IgG negative control to remove non-specific proteins pulled
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down. Mean percentage peptide coverage, and mean number of unique peptides
identified in biological duplicate experiments were calculated.
2.3.5 Parallel Reaction Monitoring (PRM)
With Dr. A. Groen, Proteomics Core Facility, CRUK Cambridge Institute.
Nuclear pellets from cell lines were prepared using the Panomics nuclear extrac-
tion kit (Affymetrix, CA USA) as per the manufacturer’s provided instructions.
Nuclear pellets were lysed in 8M Urea, 0.1% SDS in 50 mM TEAB by waterbath
sonication for 2 x 5 minutes. After protein estimation 20 µg of protein was taken
for tryptic digestion. 50 mM of TEAB (pH = 8) was added up to a total volume
of 100 µl. Cysteines were reduced in 0.1 mM DTT for 1 hour at room temper-
ature and alkylated in 0.1 mM IAA for 30 minutes at room temperature in the
dark. Alkylation was quenched by adding 0.1 mM DTT for 15 minutes. Trypsin
(Promega trypsin (V5111)) was added in a 1:100 trypsin:protein ratio for 1 hour
at room temperature. Another batch of trypsin (1:100 ratio) was added to have
a final ratio of 1:50 for incubation overnight. Next day samples were acidified
to a final concentration of 1% formic acid and subsequently cleaned over C18
spin columns (Harvard apparatus C18 Micro SpinColumnTM). Finally after elu-
tion from the columns samples were lyophilised in a speedvac and resolubilised in
0.1% formic acid, 5% ACN to a final peptide concentration of 1 µg/µl. Samples
were subjected to liquid chromatography-electrospray ionization in an Orbitrap
nano-ESI Q-Exactive mass spectrometer (Thermo Scientific, Leicestershire, UK),
coupled to a nanoLC (Dionex Ultimate 3000 UHPLC). Samples were trapped on
a 100 µm 2 cm, C18, 5 µm, 100 trapping column (Acclaim PepMap 100) in µL-
pickup injection mode at 4 µL/min flow rate for 10 minutes. Samples were then
loaded on a Rapid Separation Liquid Chromatography, 75 µm 25 cm nanoViper
C18 3 µm 100 column (Acclaim, PepMap) retrofitted to an EASY-Spray source
with a flow rate of 300 nL/min (buffer A, HPLC H2O, 0.1% formic acid; buffer
B, 100% ACN, 0.1% formic acid; 60-min gradient; 0-5 min: 5% buffer B, 5-45
min: 5 to >56% buffer B, 45.1 to 50 min: 56% to >95% buffer B, 50.1 to 60
min, 5% buffer B). Peptides were transferred to the gaseous phase with positive
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ion electrospray ionization at 1.8 kV. Precursors were targeted in a 2Th selection
window around the m/z of interest. Precursors were fragmented in high-energy
collisional dissociation mode with normalised collision energy dependent on the
target peptide. The first mass analysis was performed at a 70,000 resolution, an
automatic gain control target of 3 x 106, and a maximum C-trap fill time of 200
milliseconds; MS/MS was performed at 35,000 resolution, an AGC target of 5 x
104, and a maximum C-trap fill time of 100 milliseconds. Spectra were analysed
using Skyline with manual validation.
2.4 Immunohistochemistry (IHC)
2.4.1 Preparation of MDA-MB-231-ERβ cell pellets
Formalin-fixed, paraffin-embedded MDA-MB-231-ERβ- and MDA-MB231-ERβ+
cell pellets were generated for IHC validation of the CWK-F12 ERβ antibody,
with ∼2 x 107 cells per pellet. ERβ expression was induced by addition of 0.5
µg/ml doxycycline for 24 hours. Antigen retrieval was achieved by incubating
in citrate-based retrieval solution for 20 minutes. Sections were stained using
CWK-F12 ERβ antibody, diluted 1:250 in standard Bond diluent using Leica’s
Polymer Refine Kit (Catalogue No: DS9800) on the automated Bond platform
(Leica Biosystems Newcastle Ltd, Newcastle UK). Images were captured using
Aperio R© software (Leica Biosystems Newcastle Lt, Newcastle UK).
2.4.2 Prostate tissue microarrays
The mini-prostate tissue microarray (TMA) was created from a random selec-
tion of prostate cancers, including a range of different tumour grades, and benign
prostatic tissue (10 cancer, 5 benign in total) (ethical approval: ProMPT study
MREC/01/4/061). The areas to be sampled from the formalin-fixed and paraffin
embedded tissue donor blocks were marked on the original corresponding haema-
toxylin and eosin-stained paraffin sections. Each donor block was assessed to
ensure that there was an adequate amount of tissue available for sampling, and
cores of tissue were punched from the selected area of the donor block using 5
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mm skin biopsy punches. Each core was then re-embedded into a new recipient
paraffin block and its position in the block recorded on a TMA map. Cores of
pig kidney were used as markers for orientation purposes.
The degarelix TMA has been previously published [Shaw et al., 2016]. It was
constructed using prostate tissue obtained by radical prostatectomy taken from 27
men with high-risk prostate cancer, treated preoperatively with 240 mg degarelix,
and 20 untreated control patients. ERβ expression from areas of cancer and
benign tissue in both treated and untreated patients were scored in a blinded
fashion by Dr. A.Y. Warren (Consultant Histopathologist, Cambridge University
Hospitals NHS Foundation Trust) using the Allred scoring system [Harvey et al.,
1999] (ethical approval: REC ref:11/H0311/2 and REC ref:01/4/061).
In both the mini-prostate and degarelix TMA, 3.5 µm sections were cut from
the recipient paraffin block, and mounted onto charged slides which, when dried,
were sealed with paraffin wax. The CWK-F12 ERβ antibody was optimised to
the clinical samples and diluted at 1:200 in antibody diluent consisting of 1%
donkey serum, 0.05% Tween20 in 300 mM TBS to reduce background stain-
ing. Antigen retrieval was achieved by incubating in Tris EDTA for 20 minutes
at 100◦C. Images were captured at 250x magnification using Image Pro-Insight
(Media Cybernetics. Rockville, MD. USA).
2.5 Chromatin Immunoprecipitation and high
throughput sequencing (ChIP-seq)
ChIP-seq was performed according to a previously published protocol [Schmidt
et al., 2009], with some alterations detailed below.
2.5.1 Crosslinking, lysis and sonication
Four 15 cm2 plates were used per condition. Cells were crosslinked in Solution
A (0.1 M NaCl, 1.0 mM EDTA, 0.5 mM EGTA, 50 mM HEPES) containing
1% formaldehyde for 10 minutes and the formaldehyde then quenched with 0.1M
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glycine. Cells were washed, harvested and pelleted in cold PBS. The nuclear
fraction was enriched by resuspending the cell pellet in 10 ml of LB1 for 10
minutes at 4◦C. Cells were then pelleted and resuspended in LB2 for 5 minutes
at 4◦C. Cells were pelleted and resuspended in 300 µl of LB3 and sonicated in the
Bioruptor R© for 30 minutes. A 10 µl aliquot of sonicated chromatin was reverse
cross-linked at 95◦C for 10 minutes and run on a 2% E-Gel (Thermo Fisher
Scientific, Leicestershire, UK) to confirm sufficient sonication and that fragments
were 200-300 base pairs in length. 30 µl of 10% Triton-X was added and the
sonicated lysate centrifuged at 20,000G for 10 minutes to remove cell debris.
2.5.2 Preparation of magnetic beads and immunoprecipi-
tation
Fifty microlitres of lysate was removed and stored at -20◦C to be used as input.
The remaining supernatant was then incubated with 100 µl of magnetic beads
(Protein G Dynabeads R©, Dynal), which had been previously washed three times
with PBS containing 5 mg/ml BSA, incubated with the appropriate volume of
antibody overnight rotating at 4◦C overnight and then washed three times with
PBS containing 5 mg/ml BSA. The washed beads and sonicated samples were
incubated overnight at 4◦C. Beads were collected using a magnetic concentrator,
the supernatant removed and the beads washed 6 times in 1 ml ice-cold RIPA
buffer. Beads were washed once in 1 ml TE. 200 µl of elution buffer (50 mM
TrisHCl, pH8, 10 mM EDTA, 1% SDS) was added and the beads vortexed. 150
µl elution buffer was added to the input sample. Both ChIP and input samples
were incubated in a water bath at 65◦C overnight to reverse cross-link DNA.
Following incubation and using a magnetic rack, the supernatant was transferred
to a fresh Eppendorf and 200 µl TE added. RNAse A (8 µl of 1 mg/ml) was
added and the samples incubated at 37◦C for 30 minutes. Proteinase K (4 µl
of 20 mg/ml) was added and the samples incubated at 55◦C for 1 hour. Phe-
nol:chloroform:isoamyl alcohol cleanup was performed using pre-spun Eppendorf
phase-lock columns. Following centrifugation for 5 minutes at 10,000 G the upper
layer was removed and added to 16 µl of 5M NaCl with 2 µl glycogen (20 µg/µl).
800 µl of 80% ethanol was added and samples left at -80◦C for 1 hour. Samples
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were centrifuged at 21,000 G for 20 minutes.
The supernatant was removed and the pellet washed in 70% ethanol, then left
to air dry at 37◦C for <10 minutes. Pellets of ChIP and input samples were
resuspended in 13 µl or 20 µl 10 mM Tris HCl pH 8.0 respectively and stored at
-20◦C.
2.5.3 Library preparation and Illumina Sequencing
DNA fragment length of input samples was measured using the Agilent 2100
Bioanalyzer system with Agilent DNA 1000 Kit (Agilent Technologies, Santa
Clara, CA, USA). The concentration of DNA in input samples was quantified
using the Quant-itTM dsDNA Assay Kit (broad range) and the PHERAstar R©
(Thermo Fisher Scientific, Leicestershire, UK). Input samples were diluted in 10
nM Tris HCl to a concentration of 0.5 ng/µl.
Library preparation was carried out using the ThruPLEX R© DNA-seq Kit (Cat.
no. R400407, Rubicon Genomics, Ann Arbor, MI, USA) according to the man-
ufacturer’s provided instructions. Twelve cycles were used in the amplification
step. Agencourt AMPure XP beads (Beckman Coulter Life Sciences, Indianapo-
lis, USA) were used to purify the DNA following the manufacturer’s provided
protocol. DNA fragment lengths of all samples (ChIPs and inputs) were assessed
using the Bioanalyzer and samples quantified using the Kapa Library Quantifi-
cation kit (Kapabiosystems, London, UK).
Libraries were pooled at equal concentration and submitted for one lane of se-
quencing on the HiSeq 2500 (Illumina Inc. San Diego, CA, USA) to check the
balance of indexes in the submitted pool. These data were then used to re-balance
the pool according to the relative representation of each index. The re-balanced
pool was then sequenced to generate a total of 2 x 107 reads per sample.
2.5.4 Analysis of ChIP-seq data
Performed by Dr. Igor Cherneukhin, Carroll group, CRUK Cambridge Institute
Sequenced reads were mapped to hg38 genome using bowtie2 2.2.6 [Langmead
and Salzberg, 2012]. Aligned reads with the mapping quality less than 5 were
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filtered out. The read alignments from four replicates were combined into sin-
gle library and peaks were called with MACS2 version 2.0.10.20131216 [Zhang
et al., 2008] using sequences from LNCaP-ERβ cells’ chromatin extracts as a
background input control. The peaks yielded with MACS2 q value ≤ 1 x 104
were selected for downstream analysis. Meme version 4.9.1 [Bailey et al., 2009]
was used to detect known and discover novel binding motifs amongst tag-enriched
sequences. For visualizing tag density and signal distribution heatmap the read
coverage in a window of +/- 2.5 or 5 kb region flanking the tag midpoint was
generated using the bin size of 1/100 of the window length. Differential binding
analysis (Diffbind) was performed as described previously (Stark, R., Brown, G.
D. 2011. DiffBind: differential binding analysis of ChIP-Seq peak data. Biocon-
ductor http://bioconductor.org/packages/release/bioc/html/DiffBind.html).
To integrate the ChIP-seq and RNA-seq datasets, ChIP-seq binding sites were
annotated using genomic features of the Human Genome Assembly (GCR-h38).
Genes whose coordinates were mapped in the proximity of +/- 50kb to ChIP-seq
peak summits were selected as potential target genes for regulation by the studied
factor. RNA-seq expression values of the potential target genes were extracted
and normalised using library size coefficiencies and standard deviation values.
Bioinformatics toolbox of Matlab framework (https://uk.mathworks.com) was
used as a source for hierarchical clustering functions and also heatmap visualisa-
tion.
2.6 Statistical analyses
2.6.1 Analysis of cell proliferation assay (Section 2.1.5)
To assess differences between treatment conditions in the IncuCyteTM experiment,
cell confluence was normalised to the starting confluence in each well. Technical
replicates were averaged to give a mean result per biological replicate. Biological
replicates were averaged to give a mean result per treatment condition. Final
percentage change in cell confluence at 7 days was compared between conditions
using unpaired t-tests performed in GraphPad Prism version 6 to determine sta-
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tistical significance. Error bars indicate standard deviation and a p value of <0.05
was considered statistically significant.
2.6.2 Analysis of mRNA expression data (Section 2.2.3)
mRNA expression data as determined by RT-qPCR were analysed using unpaired
t-tests in GraphPad Prism version 6. Differences were considered statistically
significant at a p value of <0.05. Data presented are mean of technical triplicate
experiments +/- standard deviation.
2.6.3 Analysis of ERβ expression in degarelix TMA (Sec-
tion 2.4.2)
Statistical analysis by Dr. Matthew Eldridge, CRUK Cambridge Institute.
Allred scores from the ERβ-stained degarelix TMA were compared using a Wilcoxon
rank sum test with continuity correction as previously described [Shaw et al.,
2016].
2.6.4 Interrogation of clinical datasets (Section 5.2.1)
The CamCap dataset [Ross-Adams et al., 2015] was interrogated using a pub-
lished, online software tool [Dunning et al., 2017]. This dataset was generated by
integration of copy number analysis and transcriptomics data from 482 tumour,
benign and germline samples obtained from 259 men with primary prostate can-
cer. The integrated data were then used to identify five prognostic groups with
distinct transcript expression profiles and genomic alterations (iClusters). Vari-
ability in gene expression across the iClusters was assessed by analysis of variance
(ANOVA).
Data from two published datasets [Rajan et al., 2014; Shaw et al., 2016] compar-
ing gene expression in prostate tissue pre- and post-treatment with ADT were
interrogated for ERβ mRNA expression (GSE48403 and GSE72920). Expression
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was analysed by unpaired t-tests in GraphPad Prism version 6, with statistical
significance set at <0.05.
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Chapter 3
Validation of Estrogen Receptor
Beta Antibodies
3.1 Introduction
3.1.1 Essential background information
The role of ERβ in both physiological and disease states remains uncertain [Bot-
tner et al., 2014; Haldosen et al., 2014; Nelson et al., 2014]. Despite a large body
of published literature regarding ERβ in prostate cancer, there is still controversy
as to whether its predominant role is tumour-suppressive [Attia and Ederveen,
2012; Chang and Prins, 1999; Ellem and Risbridger, 2007; Horvath et al., 2001;
McPherson et al., 2010; Muthusamy et al., 2011; Nakajima et al., 2011; Zhu et al.,
2004] or tumour promoting [Yang et al., 2012, 2015; Zellweger et al., 2013]. Much
of the evidence concerning the hypothesised role of ERβ arises from ERβ expres-
sion profiles in prostate tissue as determined by IHC [Asgari and Morakabati,
2011; Attia and Ederveen, 2012; Bouchal et al., 2011; Dey et al., 2014; Horvath
et al., 2001; Leav et al., 2001; Risbridger et al., 2007; Zellweger et al., 2013; Zhu
et al., 2004]. There are, however inconsistencies in the findings between these
studies, contributing to the uncertainty regarding the role of ERβ in cancer.
In prostate cancer, previous studies showed that ERβ is highly expressed in be-
nign luminal epithelial cells, with expression declining in cancer development.
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ERβ expression therefore inversely correlated with increasing Gleason grade of
cancer [Asgari and Morakabati, 2011; Attia and Ederveen, 2012; Dey et al., 2014;
Horvath et al., 2001; Leav et al., 2001; Risbridger et al., 2007]. However, it has also
been reported that ERβ expression is high in bone and lymph node metastases
[Bouchal et al., 2011; Zhu et al., 2004], and that high ERβ expression correlates
with poor clinical prognosis [Horvath et al., 2001; Zellweger et al., 2013]. One
potential biological explanation for this is the expression of ERβ isoforms, which
are fully conserved in exons 1 - 6, but have different C-terminal domains [Leung
et al., 2006a] (see section 1.2.2 for details). Different antibodies may have higher
affinity for either the conserved N-terminal region or the variant C-terminal end
of the protein. This may, therefore give different IHC results in prostate cancer,
where it has been reported that ERβ isoform 2 (ERβ2) expression increases with
advanced and castrate-resistant disease [Dey et al., 2012; Leung et al., 2010].
However, it is well documented in the literature that antibodies to ERβ are
problematic, with marked variation in specificity and sensitivity to ERβ [Choi
et al., 2001; Hartman et al., 2012; Skliris et al., 2002; Weitsman et al., 2006].
This results in discrepancy and controversy surrounding the expression profile
of ERβ in tissues and its molecular role as determined by antibody-dependent
functional studies. This is likely to have contributed to the conflicting conclusions
regarding ERβ.
A number of ERβ antibody validation studies have been previously published.
Choi et al. [Choi et al., 2001] generated three monoclonal ERβ antibodies and
assessed them by Western blotting using baculovirus-mediated expression of ERβ
protein. These antibodies were further assessed in rat ovary and epididymis by
IHC, where tissue-specific expression of ERβ was found to correlate with mRNA
expression [Hess et al., 1997; Rosenfeld et al., 1999]. Furthermore, Skliris et al.
evaluated seven ERβ antibodies by Western blotting and IHC of benign breast
tissue, including two antibodies (PPG5/10 and 14C8) assessed in the current
study. Lastly, Wu et al. [Wu et al., 2012] developed a monoclonal ERβ anti-
body MC10 (included in the present study) and tested it by Western blotting
in a U2OS cell line with inducible ERβ expression and by IHC in breast tissue.
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Despite these attempts to address the problems associated with ERβ antibodies,
many researchers have continued to work on ERβ biology using non-validated
antibodies, or antibodies that are only validated for one particular experimental
technique. It has been shown that not all antibodies are specific to their tar-
get across multiple experimental platforms [Baker, 2015; Bordeaux et al., 2010],
indicating that this is not a reasonable assumption to make.
A limitation of some previous antibody validation studies is that they rely on two
key assumptions; namely that when assessing an antibody by Western blotting in
a cell line model, the factor of interest is expressed and secondly, when assessing
an antibody’s specificity by IHC in tissue, the tissue expression of the factor has
been well characterised. In the case of ERβ these assumptions are problematic, as
its expression in commonly used cell line models [Al-Bader et al., 2011; Holbeck
et al., 2010; Nakajima et al., 2011; Shaaban et al., 2003; Skliris et al., 2002; Zhou
et al., 2012] and in tissues [Asgari and Morakabati, 2011; Attia and Ederveen,
2012; Bouchal et al., 2011; Dey et al., 2014; Gruvberger-Saal et al., 2007; Guo
et al., 2014a,b; Hieken et al., 2015; Horvath et al., 2001; Leav et al., 2001; Omoto
et al., 2002; Risbridger et al., 2007; Umekita et al., 2006; Zellweger et al., 2013;
Zhu et al., 2004] is not universally accepted. As such, previous assumptions
of ERβ expression in cell line models and cancer tissue might hinder genuine
validation of reagents.
3.1.2 Aims
The first priority of this study therefore was to test and validate a panel of ERβ
antibodies, in a manner that addresses the aforementioned assumptions. Com-
mercially available and non-commercially available antibodies obtained from col-
laborators [Choi et al., 2001; Wu et al., 2012] were assessed by multiple indepen-
dent techniques. In a cancer cell line model with stable, doxycycline-inducible
ERβ expression (MDA-MB-231-ERβ), antibodies were firstly assessed for pro-
tein detection by Western blotting. Secondly, antibodies were assessed by Rapid
Immunoprecipitation Mass spectrometry of Endogenous protein (RIME) [Mo-
hammed et al., 2013]. Thirdly, the CWK-F12 ERβ antibody validated using the
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above techniques was subsequently optimised for IHC and validated using the
inducible MDA-MB-231-ERβ cell line model as positive and negative controls.
ERβ antibody validation has not previously been explored in such a systematic
manner.
3.1.3 Key Findings
1. The MDA-MB-231-ERβ cell line serves as a valid model for ERβ antibody
validation, demonstrating strong induction of ERβ mRNA and protein ex-
pression with doxycycline treatment and no ERβ mRNA or protein expres-
sion in the absence of doxycycline.
2. Assessment of the eight ERβ antibodies by Western blotting demonstrated
high variability in antibody specificity with one of the most commonly pub-
lished antibodies (NCL-ER-BETA) yielding a false-positive result.
3. RIME analysis confirmed that the NCL-ER-BETA antibody is not specific
to ERβ. Other antibodies were shown to have variable levels of protein
coverage and specificity.
4. The results demonstrate that two of the antibodies evaluated (MC10 and
CWK-F12) are specific to ERβ across multiple experimental platforms.
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3.2 Results
3.2.1 Validation of the MDA-MB-231-ERβ cell line model
The MDA-MB-231-ERβ cell line was provided by the laboratory of Dr. J. Hawse
(Mayo Clinic, Minnesota USA) [Reese et al., 2014]. MDA-MB-231 is a ‘triple
negative’ breast cancer cell line model into which the Hawse laboratory stably
transfected doxycycline-inducible ERβ expression using the T-RexTMsystem (In-
vitrogen, Fisher Scientific UK, Loughborough, UK). Importantly, following trans-
fection of the tetracycline-repressor (TET-R) construct, clonal selection was used,
followed by assessment of the TET-R activity by transient transfection with a lu-
ciferase reporter. The advantage of this approach is that the uninduced ‘off’
condition is known to be robust, with minimal ‘leakiness’ of expression from the
promotor, thus providing an ideal model for antibody validation.
The workflow of the antibody validation process is described in figure 3.1. MDA-
MB-231-ERβ cells were treated for 24 hours with doxycycline to induce ERβ
expression. Expression of ERβ mRNA was confirmed by RT-qPCR and shown to
be dose-dependent (Figure 3.2). Treatment with 0.1 µg/ml doxycycline induced
approximately 70-fold expression of ERβ and 0.5 µg/ml doxycycline resulted in
approximately 120-fold induction of expression (p = 0.01 and p = 0.003 respec-
tively).
3.2.2 Assessment of ERβ antibodies by Western blotting
A panel of six of the most commonly used, commercially available ERβ antibodies
were selected for evaluation [Al-Bader et al., 2011; Asgari and Morakabati, 2011;
Bouchal et al., 2011; Celhay et al., 2010; Chen et al., 2009; Ciucci et al., 2014;
Ellem et al., 2014; Foryst-Ludwig et al., 2008; Grubisha et al., 2012; Han et al.,
2015; Hussain et al., 2012; Madak-Erdogan et al., 2013; Mak et al., 2013, 2015a;
McPherson et al., 2007, 2010; Nakajima et al., 2011; Oliveira et al., 2007; Rossi
et al., 2011; Shaaban et al., 2003; Umekita et al., 2006; Vivar et al., 2010; Yang
et al., 2012, 2015; Zellweger et al., 2013; Zhou et al., 2012], along with two non-
commercially available antibodies obtained from collaborators (MC10 from Dr.
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Figure 3.1: Experimental workflow of ERβ antibody validation.
Doxycycline-induced expression of ERβ was confirmed by RT-qPCR. Nuclear
lysate was collected for Western blotting of ERβ protein. MDA-MB-231-ERβ-
and MDA-MB-231-ERβ+ cells were crosslinked and immunoprecipitated with
antibody coupled with beads, and mass spectrometry (MS) performed to identify
pulled-down peptides.
John Hawse, Mayo Clinic, Minnesota USA [Wu et al., 2012] and CWK-F12 from
Prof. Benita Katzenellenbogen, University of Illinois, Illinois USA [Choi et al.,
2001]) (Table 3.1).
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Figure 3.2: Induction of ERβ expression in doxycycline-treated MDA-
MB-231-ERβ cells. MDA-MB-231-ERβ cells were treated with 0.1 µg/ml or
0.5 µg/ml doxycycline for 24 hours. Untreated MDA-MB-231-ERβ- cells provided
a negative control. Data are mean + S.D. of technical triplicate experiments.
Western blots of MDA-MB-231-ERβ+ and MDA-MB-231-ERβ- nuclear lysates
were performed using above mentioned antibodies (Figure 3.3). The PPG5/10
antibody detected a protein band of 77 kDa, but importantly there was no dif-
ference between ERβ+ or ERβ- conditions, suggesting that it recognises a non-
specific protein. Similarly, the NCL-ER-BETA antibody detected a band of ∼59
kDa, which is the correct size for ERβ, however there was no difference between
ERβ+ or ERβ- conditions, implying that this band was not ERβ. The GeneTex
70182 antibody detected a band of 59 kDa with differential signal between ERβ+
and ERβ- conditions, with an additional non-specific band present at around 65
kDa. The Millipore 06-629 antibody detected a band of 59 kDa in both ERβ+
and ERβ- conditions. This band was stronger however, in the ERβ+ condition,
suggesting that the antibody could be cross-reacting with another protein of 59
kDa in addition to detecting ERβ. Our RIME data suggests that this may be
cross-reactivity with LACTB (discussed in section 3.2.3). MC10, CWK-F12, Ab-
cam 288 [14C8] and sc8974 ERβ antibodies all detected protein bands of 59 kDa
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Table 3.1: Commonly used ERβ antibodies in published literature. Six
of the most commonly used, commercially available ERβ antibodies were chosen
for validation, listed here with papers relevant to breast and prostate cancer in
which they were published.
with differential signal between ERβ+ and ERβ- conditions, confirming their
specificity to ERβ by Western blotting.
3.2.3 Assessment of ERβ antibodies by RIME
The eight ERβ antibodies were then assessed by RIME. This uses chromatin
immunoprecipitation (ChIP) followed by mass spectrometry (MS) to identify en-
riched peptides [Mohammed et al., 2013]. MDA-MB-231-ERβ cells were treated
for 24 hours with 0.5 µg/ml doxycycline to induce maximal ERβ protein expres-
sion (Figure 3.2) and untreated MDA-MB-231-ERβ- cells served as a negative
control. In both conditions, RIME purification of E2F1 was included in paral-
lel as a positive control, since E2F1 is a ubiquitously expressed protein and the
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Figure 3.3: Validation of ERβ antibodies by Western blotting in MDA-
MB-231-ERβ+ and MDA-MB-231-ERβ- nuclear lysates. PPG5/10 an-
tibody did not detect a band of appropriate size to be ERβ. NCL-ER-BETA
detected bands of appropriate size to be ERβ with no difference between ERβ+
and ERβ- conditions. MC10, CWK-F12, Abcam 288 [14C8] and sc8974 antibod-
ies detected bands of ∼59 kDa, with differential signal between ERβ+ and ERβ-
conditions indicating specificity to ERβ. GeneTex 70182 detected ERβ, with
non-specific signal at 65 kDa. Millipore 06-629 appears to detect ERβ, although
there is a 59 kDa band in the ERβ- condition.
antibody has been validated as being specific to E2F1 (Figure 3.4A). An IgG anti-
body specific to the species of the ERβ antibody was used to identify non-specific
peptides pulled out by the IP. Any peptides pulled down in either replicate of
the IgG were subtracted from the list of peptides identified by the ERβ RIME to
generate a list of peptides specific to the ERβ IP for each antibody. Importantly,
ERβ was not identified in any of the IgG RIMEs, and furthermore ERβ was not
identified by any antibody in the ERβ- condition, confirming no expression of
ERβ in the uninduced MDA-MB-231-ERβ cells (Figure 3.4C). In MDA-MB-231-
ERβ+ cells, RIME revealed diverse peptide coverage by the different antibodies
(Figure 3.4B). The most striking finding was that the NCL-ER-BETA antibody
did not identify any ERβ peptides by RIME, confirming its lack of specificity for
ERβ.
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Figure : RIME demonstrates specificity of ERβ antibodies 
ERβ antibodies were assessed by RIME in MDA-MB 231-ERβ+/- cells.  
(A)  E2F1 antibody positive control  
(B)  ERβ antibody tests: Coverage indicates the percentage of the full protein pulled down by the 
antibody and identified by MS with false discovery rate of ≤1% (mean of 2 biological replicates); 
corresponding with green areas shown on the peptide map. NCL-ER-BETA failed to identify ERβ. 
(C)   Negative controls: None of the antibodies detected ERβ in MDA-MB 231 ERβ- cells. Mouse IgG 
antibodies did not detect ERβ. 
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Figure 3.4: Validation of ERβ antibodies by RIME reveals diverse pep-
tide coverage. (A) E2F1 positive control in ERβ+ or ERβ- conditions. (B)
ERβ antibody tests in MDA-MB-231-ERβ+ cells revealed diverse peptide cover-
age by each antibody. NCL-ER-BETA did not identify any ERβ peptides. (C)
Negative controls: All ERβ antibodies were tested in MDA-MB-231-ERβ- cells,
to confirm absence of ERβ expression. None of the IgG antibodies purified ERβ.
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A number of factors were considered to facilitate comparison of the ERβ an-
tibodies (Table 3.2). Firstly the coverage of the protein, which indicates the
percentage of the full-length protein identified by MS with a false discovery rate
of ≤1%. Secondly, the mean number of unique ERβ peptides (mean of two inde-
pendent biological replicates) was calculated for each ERβ antibody. Finally, to
provide an indication of the specificity of each antibody, all the proteins pulled
down by the IP and identified by MS were ranked according to the mean number
of unique peptides. We hypothesised that the higher the ranking of ERβ, the
greater the specificity of the antibody. Hence, if ERβ has the greatest number of
unique peptides relative to all other proteins identified in the RIME, it is ranked
1st.
Antibody! Coverage (%)! Mean no. Unique Peptides! No. Interacting proteins! ERβ Rank!
Abcam 288! 31.9! 14.5! 285! 20!
MC10! 28.2! 11.5! 75! 1!
GeneTex 70182! 26.1! 11.5! 11! 1!
PPG5/10! 25.0! 11.0! 12! 3!
CWK-F12! 17.7! 7! 64! 2!
Millipore 06-629! 16.5! 6.5! 14! 3!
Sc8974! 12.0! 4.5! 2! 1!
NCL-ER-BETA! 0! 0! 0! n/a!
Table 3.2: Comparison of ERβ antibody characteristics by RIME. Sum-
mary of the characteristics of each ERβ antibody assessed by RIME, showing
peptide coverage, mean number of unique ERβ peptides identified by MS, the
number of other interacting proteins also pulled down in the IP and the ERβ
ranking, used as an indicator of antibody specificity.
NCL-ER-BETA did not pull-down any ERβ peptides (Figure 3.4B), which is con-
sistent with the lack of specificity by Western blotting (Figure 3.3). The Millipore
06-629 antibody pulled down ERβ in the test condition, although coverage and
ranking were not as favourable as compared with some of the other antibodies.
Interestingly, LACTB, a 60 kDa protein was pulled down by Millipore 06-629 in
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both ERβ+ and ERβ- conditions, which may explain the ∼60 kDa band identi-
fied from Western blotting (data not shown). Whilst the PPG5/10 antibody did
not perform well by Western blot, by RIME it detected ERβ with 25% coverage,
with ERβ ranking 3rd in the list of identified peptides, suggesting differences in
the specificity of this antibody from one experimental method to another. Inter-
estingly, PPG5/10 was previously validated for IHC in a doxycycline-inducible
U2OS-ERβ cell line, developed using the same plasmids as the MDA-MB-231-
ERβ cell line used here [Wu et al., 2012]. The Abcam 288 [14C8] antibody is a
very commonly used ERβ antibody (Figure 3.1), which performed well by West-
ern blotting and had the best antibody coverage by RIME (31.9%). However
ERβ ranked 20th in the list of identified peptides when using Abcam 288 [14C8],
suggesting that this antibody might be pulling-down additional non-specific pro-
teins. The CWK-F12 antibody had 17.7% coverage, with ERβ ranking 2nd in the
list of purified peptides. The MC10 antibody had the second-greatest coverage
(28.2%) with ERβ ranking 1st in the list of identified peptides.
Identification of known ERβ interactors by RIME
When the ERβ-specific peptides identified by each antibody (excluding NCL-ER-
BETA) were overlapped, the only commonly identified protein was ERβ itself.
The two antibodies that shared the greatest degree of overlap in terms of specific
interacting peptides were MC10 and CWK-F12, with 32 common proteins iden-
tified (Figure 3.5). Two known ERβ-interacting proteins were identified in this
list, heat-shock protein 90 (HSP90) [Powell et al., 2010] and ATP-dependent RNA
helicase DDX54 (DDX54) [Rajendran et al., 2003], giving additional confidence
in the use of RIME for antibody validation. Altogether, the degree of overlap
with respect to the identified proteins between MC10 and CWK-F12 antibodies,
combined with the results from Western blotting, resulted in selection of these
antibodies for further experiments.
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Proteins pulled down by top five antibodies overlapped. Only one common protein 
(ERβ). Highest degree of overlap between, CWK-F12 and MC10 (32 proteins). This 
overlap in conjunction with coverage/ranking formed basis for selection of MC10 and 
F12 antibodies for further ChIP-based experiments. List of common proteins shown."
Accession!
!
Protein!
P08238! Heat shock protein HSP 90-beta (HS90B)!
P08621" U1 small nuclear ribonucleoprotein (RU17)"
P09429" High mobility group protein B1 (HMGB1)"
P13639" Elongation factor 2 (EF2)"
P14618" Pyruvate kinase isozymes M1/M2 (KPYM)"
P15880" 40S ribosomal protein S2 (RS2)"
P23396" 40S ribosomal protein S3 (RS3)"
P46777" 60S ribosomal protein L5 (RL5)"
P51991" Heterogeneous nuclear ribonucleoprotein A3 (ROA3)"
P62249" 40S ribosomal protein S16 (RS16)"
P62851" 40S ribosomal protein S25 (RS25)"
P62917" 60S ribosomal protein L8 (RL8)"
P62937" Peptidyl-prolyl cis-trans isomerase A (PPIA)"
P83731" 60S ribosomal protein L24 (RL24)"
P84103" Serine/arginine-rich splicing factor 3 (SRSF3)"
Q01130" Serine/arginine-rich splicing factor 2 (SRSF2)"
Q05519" Serine/arginine-rich splicing factor 11 (SRS11)"
Q08211" ATP-dependent RNA helicase A (DHX9)"
Q08945" FACT complex subunit SSRP1 (SSRP1)"
Q13263" Transcription intermediary factor 1-beta (TIF1B)"
Q13601"
KRR1 small subunit processome component homolog 
(KRR1)"
Q14978" Nucleolar and coiled-body phosphoprotein 1 (NOLC1)"
Q15397" Pumilio domain-containing protein KIAA0020 (K0020)"
Q8IY81" Putative rRNA methyltransferase 3 (RRMJ3)"
Q8TDD1! ATP-dependent RNA helicase DDX54 (DDX54)!
Q8WTT2" Nucleolar complex protein 3 homolog (NOC3L)"
Q92731! Estrogen receptor beta (ESR2)!
Q9NV31"
U3 small nucleolar ribonucleoprotein protein IMP3 
(IMP3)"
Q9NY93"
Probable ATP-dependent RNA helicase DDX56 
(DDX56)"
Q9Y383" Putative RNA-binding protein Luc7-like 2 (LC7L2)"
Q9Y3T9" Nucleolar complex protein 2 homolog (NOC2L)"
Q9Y5B9" FACT complex subunit SPT16 (SP16H)"
PPG5/10"
Figure 3.5: ERβ interactors identified by RIME. ERβ was the only common
protein identified by all antibodies (excluding NCL-ER-BETA). CWK-F12 and
MC10 had the greatest degree of overla with respect to co mon proteins iden-
tified. Two known ERβ interactors were identified; HSP90 and DDX54. Venn
diagram constructed using online tool from Bioinformatics & evolutionary ge-
nomics (www.bioinformatics.psb.ugent.be/webtools/Venn).
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3.2.4 Optimisation of MC10 and CWK-F12 ERβ antibod-
ies for Immunohistochemistry
With Dr. J. Miller, Histopathology Core Facility, CRUK Cambridge Institute.
In light of the data showing MC10 and CWK-F12 specificity for ERβ using
Western blotting (Figure 3.3) and RIME (Figure 3.4), these antibodies were
optimised for IHC using paraffin-embedded pellets of MDA-MB-231-ERβ+ and
MDA-MB-231-ERβ- cells (Figure 3.6). Sections from the MDA-MB-231-ERβ+
and MDA-MB-231-ERβ- cell pellets were stained with MC10 diluted at 1:100
in standard Bond diluent. Three antigen retrievals were tested; Sodium Citrate
for 20 minutes at 100◦C, Tris EDTA for 20 minutes at 100◦C and an enzyme
digestion for 10 minutes at 37◦C. For the latter, Leica’s Bond enzyme concen-
trate, which contains a proteolytic enzyme (17 mg/mL) and stabiliser, diluted at
1:167 was used. No primary controls were tested for each of the retrieval condi-
tions. As the enzyme retrieval was negative, heat induced epitope retrieval was
used. Of these, Tris EDTA-treated retrieval gave better differentiation between
signal versus background. The CWK-F12 antibody was tested with the same
conditions as for MC10 but using a 1:250 dilution of the primary antibody based
on previously published literature [Choi et al., 2001]. Good differentiation was
achieved with both heat-induced epitope retrievals and no signal was detected
with the enzyme pre-treatment. Once optimised, both antibodies showed strong
nuclear staining in the MDA-MB-231-ERβ+ cells, with no nuclear staining in
MDA-MB-231-ERβ- cells. In both ERβ+ and ERβ- conditions, the cytoplasmic
staining with CWK-F12 was minimal to mild, confirming its specificity to ERβ
in the IHC context. As the CWK-F12 antibody produced lower background and
stromal staining than the MC10 antibody, it was preferred for further ERβ IHC
studies.
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MDA$MB231$ERβ–- MDA$MB$231$ERβ+-
Figure : IHC validation of CWK-F12 ERβ antibody in MDA-MB-231-ERβ– or 
MDA-MB-231-ERβ+ cell pellets, showing strong nuclear staining in MDA-
MB-231-ERβ+ cells, thus confirming the specificity of CWK-F12 to ERβ. 
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Figure 3.6: Optimisation of CWK-F12 and MC10 ERβ antibodies in
MDA-MB-231-ERβ cell pellets. Both antibodies gave strong nuclear stain-
ing in MDA-MB-231-ERβ+ cells, which was absent from the MDA-MB-231-ERβ-
control, confirming the specificity of both antibodies to ERβ. Cytoplasmic back-
ground staining was lower with the CWK-F12 antibody than the MC10, therefore
it was used in further IHC analyses.
3.3 Summary
In view of the known issues with the specificity of commonly used ERβ antibodies
[Choi et al., 2001; Hartman et al., 2012; Skliris et al., 2002; Weitsman et al., 2006]
we designed a process for testing and validating ERβ antibodies in a manner that
did not rely upon a priori assumptions regarding the expression of ERβ in tissues
or cell line models.
The MDA-MB-231-ERβ cell line, with doxycycline-inducible ERβ expression was
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validated by RT-qPCR, with dose-dependent induction of ERβ mRNA levels. Six
commonly used, commercially available and two non-commercially available ERβ
antibodies were tested for specificity to ERβ protein by Western blot and RIME
using MDA-MB-231-ERβ- and MDA-MB-231-ERβ+ cells as negative and posi-
tive controls respectively. NCL-ER-BETA antibody was shown to yield protein
bands of the appropriate size to be ERβ, but no difference was present between
ERβ- and ERβ+ conditions, confirming that this antibody is not specific to ERβ.
PPG5/10 antibody did not yield protein bands of appropriate size to be ERβ,
demonstrating that this antibody is not useful for Western blotting of ERβ pro-
tein. GeneTex 70182 and Millipore 06-629 antibodies appeared to detect ERβ
protein, with differential signal between ERβ- and ERβ+ conditions, however
there were multiple other non-specific bands detected, which may confuse inter-
pretation of data generated with these antibodies. MC10, CWK-F12, Abcam
288 [14C8] and sc8974 antibodies detected a protein band of appropriate size for
ERβ, with differential signal between ERβ- and ERβ+ conditions, confirming
their specificity to ERβ by Western blotting.
RIME confirmed that the NCL-ER-BETA antibody is not specific to ERβ, as
no ERβ peptides were purified by this antibody. As this antibody is very com-
monly used in the published literature [Ellem et al., 2014; Hussain et al., 2012;
McPherson et al., 2007, 2010; Oliveira et al., 2007; Umekita et al., 2006; Yang
et al., 2015; Zellweger et al., 2013] it is likely to be the source of much of the
controversy regarding the role and tissue expression profile of ERβ. All other an-
tibodies, including PPG5/10 purified ERβ with varying affinity and specificity, as
demonstrated by the mean number of unique ERβ peptides purified and the ERβ
ranking of each antibody. Known ERβ-interacting proteins were identified in the
RIME data, validating the findings. CWK-F12 and MC10 antibodies shared the
greatest degree of overlap in terms of interacting proteins, and were therefore se-
lected for use in subsequent experiments. The CWK-F12 antibody was optimised
and validated for IHC use in MDA-MB-231-ERβ- and MDA-MB-231-ERβ+ cell
pellets.
Using a robust and systematic methodology, this data has clearly demonstrated
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wide-ranging variability of ERβ antibodies to detect ERβ protein, and has now
identified reliable antibodies to be used in future applications.
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Chapter 4
Establishing an experimental
model for the study of Estrogen
Receptor Beta
4.1 Introduction
4.1.1 Essential background information
Preclinical models are an essential component of biomedical research as they per-
mit extensive study of the characteristics and molecular mechanisms of a disease
system without the need for utilising precious primary human material. Cell
lines form a substantial part of the available preclinical models currently in use
[Masters, 2000]. The first cancer cell line model was developed in 1953 from an
epidermoid carcinoma of the cervix and was used in the development of the po-
lio vaccine [Scherer et al., 1953]. The first prostate cancer cell line, DU145 was
developed in 1978 [Stone et al., 1978], followed by PC3 in 1979 [Kaighn et al.,
1979]. Both DU145 and PC3 were developed from metastatic deposits, both are
androgen receptor (AR) negative and do not respond to androgen stimulation
or inhibition. The LNCaP cell line was isolated from a lymph node metasta-
sis and became the first AR positive, androgen-sensitive cell line to be derived
[Horoszewicz et al., 1980]. It has since become the ‘workhorse’ of prostate cancer
research focusing on early stage disease, with a large number of studies published
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annually using LNCaP cells as an experimental model system.
There is a substantial body of literature on the function and mechanisms of action
of ERβ in prostate and breast cancer, derived from studies conducted in these and
other immortalised cancer cell lines [Abd Elmageed et al., 2013; Al-Bader et al.,
2011; Bouchal et al., 2011; Chen et al., 2009; Colciago et al., 2014; Dey et al.,
2012, 2014; Dondi et al., 2010; Ellem et al., 2014; Fuqua et al., 1999; Hinsche
et al., 2015; Holbeck et al., 2010; Kim et al., 2002a,b; Lau et al., 2000; Mak et al.,
2013; Nakajima et al., 2011; Shaaban et al., 2003; Skliris et al., 2002; Veldscholte
et al., 1990; Weng et al., 2013; Yang et al., 2012, 2015; Zhou et al., 2012]. There
are, however discrepancies between the reported expression profiles of ERβ in
individual cell lines [Holbeck et al., 2010; Nakajima et al., 2011] and furthermore,
some authors have reported directly opposing roles for ERβ in studies conducted
in the same prostate cancer cell line (LNCaP) [Kim et al., 2002b; Yang et al.,
2012]. In the breast cancer context, the MCF-7 cell line has been reported to
express endogenous ERβ [Al-Bader et al., 2011; Fuqua et al., 1999; Hinsche et al.,
2015; Shaaban et al., 2003; Skliris et al., 2002]. However, it is interesting to note
that mechanistic studies to determine the role of ERβ, conducted in wild-type
MCF-7 cells are lacking.
Many previous studies of ERβ in prostate cancer have been conducted using the
PC3 cell line [Dondi et al., 2010; Holbeck et al., 2010; Nakajima et al., 2011;
Piccolella et al., 2014]. This was initially isolated from a bone metastasis of
a poorly differentiated prostate adenocarcinoma [Kaighn et al., 1979] and is a
commonly used model of advanced or castrate-resistant prostate cancer. With
regard to nuclear steroid hormone receptors, PC3 is thought to express ERα
and ERβ but not AR (determined by Western blotting and RT-qPCR) [Holbeck
et al., 2010; Nakajima et al., 2011]. This has led many to regard PC3 as a
model of neuroendocrine differentiated prostate cancer [Gururajan et al., 2015;
Tai et al., 2011], a rare subtype of prostate cancer that rarely occurs de novo,
but which may arise as a result of selection pressure in response to ADT in
advanced disease [Beltran et al., 2012]. The lack of AR expression is a limitation
of this cell line model, as even in its advanced, castrate-resistant stage, prostate
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cancer tissue continues to be driven by AR and is characterised by altered AR
signalling. This may be as a result of AR amplification [Bubendorf et al., 1999],
mutation, stabilisation of the AR protein [Holzbeierlein et al., 2004] or generation
of constitutively active splice variant isoforms [Dehm et al., 2008; Hu et al., 2012].
Consequently, PC3 bears little resemblance to either early or late stage clinical
disease and is, in any case, not useful for examining the question of nuclear
receptor crosstalk between ERβ and AR, which is thought to be an important
phenomenon in cancer [Grubisha and DeFranco, 2013; Rizza et al., 2014; Yang
et al., 2012] and will be the focus of the studies presented in Chapter 5 of this
thesis.
4.1.2 Aims
Many of the previously published studies of ERβ in prostate and breast can-
cer have relied upon antibody-dependent techniques to determine the molecular
mechanisms of ERβ in cancer cell lines. In light of our findings regarding antibody
specificity (Chapter 3), it was necessary to undertake a fresh characterisation of
a panel of commonly used prostate cancer cell lines using the validated ERβ an-
tibodies, with the aim of selecting an appropriate experimental model to study
ERβ. When it became clear that none of the standard models expressed ERβ, a
stable, doxycycline-inducible LNCaP-ERβ cell line was developed with the aim
of investigating the role of ERβ in prostate cancer development and progression.
4.1.3 Key Findings
1. A panel of prostate cell line models commonly used to study ERβ were
found to lack ERβ protein expression. With the exception of PC3, none of
the cell line models expressed any detectable ERβ mRNA.
2. Further assessment of the most commonly studied cell line models in the
ERβ literature by RIME and PRM confirmed absence of ERβ expression.
3. The breast cancer cell line MCF-7 does not express ERβ mRNA or protein
using multiple experimental approaches.
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4. Expression of ERβ in prostate tissue was confirmed, demonstrating vari-
able ERβ expression in different grades of prostate cancer tissue and thus
reaffirming the rationale for investigating ERβ as a putatively important
factor.
5. The stable, doxycycline-inducible LNCaP-ERβ cell line was developed and
ERβ expression confirmed by multiple experimental approaches.
6. A number of proteins known to interact with ERβ and other nuclear steroid
hormones were identified by RIME, providing a preliminary insight into the
ERβ protein interactome in this cell line model.
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4.2 Results
4.2.1 Assessment of prostate cell lines for ERβ expression
A panel of genotyped prostate cell lines commonly used to study ERβ biology,
including the benign cell line PNT1a [Mak et al., 2013, 2015a,b], was assessed
for expression of ERβ mRNA and protein. Protein lysate and RNA from MDA-
MB-231-ERβ+ and MDA-MB-231-ERβ- cells were used as positive and negative
controls respectively. Using the validated CWK-F12 ERβ antibody, none of the
cell lines expressed any ERβ protein detectable by Western blotting (Figure 4.1A).
With the exception of PC3, which was shown to express a low level of ERβ mRNA,
none of the prostate cell lines expressed ERβ mRNA (Figure 4.1B).
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Figure 4.1: Assessment of prostate cell lines for ERβ expression. Prostate
cell lines lack ERβ expression at (A) protein and (B) mRNA level, with the
exception of PC3, which expressed a low level of ERβ mRNA (Data are mean +
S.D. of technical triplicate experiments).
Given the significant number of studies previously published using the LNCaP,
PC3 and PNT1a cell lines, these were further assessed for ERβ expression by
RIME using the validated MC10 ERβ antibody (Figure 3.4). As E2F1 is a
ubiquitously expressed protein, it was included as a positive control. No ERβ
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peptides were identified in any of these cell lines across two independent biological
replicate experiments (Figure 4.2).
ERβ RIME in Prostate cell lines"
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Figure 4.2: Assessment of ERβ expression in LNCaP, PC3 and PNT1a
prostate cell lines by RIME. ERβ protein was undetectable by RIME in
LNCaP, PC3 or PNT1a prostate cells.
Finally, Parallel Reaction Monitoring (PRM), an antibody-independent, targeted
proteomics approach [Gallien et al., 2012] was used in LNCaP and PNT1a cell
lines to search for expression of ERβ protein (Figure 4.3 and figure 4.4). Two
peptides unique to ERβ were identified from the published sequence of ERβ
(Peptide 1: SLEHTLPVNR; Peptide 2: SSITGSECSPAEDSK. The location of
the peptides within the full-length ERβ protein is shown in figure 4.5). Heavy-
labelled versions of these peptides were generated and ‘spiked in’ to the nuclear
pellet samples collected from the cell lines. The heavy-labelled peptides were used
to generate an ERβ-specific peptide fragmentation signature on MS, which then
served as a positive control for identification of the light, unlabelled, endogenous
protein in the sample. The technique was optimised using MDA-MB-231-ERβ+
and MDA-MB-231-ERβ- cells as additional positive and negative controls respec-
tively.
No ERβ peptides were identified in the MDA-MB-231-ERβ- negative control,
whereas a clear fragmentation pattern for each of the two endogenous (light) ERβ-
unique peptides was identified in the MDA-MB-231-ERβ+ cells. This finding
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further validated the results of the antibody validation experiments described in
Chapter 3 by providing additional, antibody-independent verification of inducible
ERβ expression in this experimental model. When using these validated ERβ
PRM probes, no endogenous (light) ERβ peptides were identified in either the
LNCaP or PNT1a cell lines. Taken together, these data confirm that a number of
prostate cell lines that have been used extensively to study ERβ, lack detectable
expression of ERβ.
4.2.2 Assessment of breast cancer cell line MCF-7 for ERβ
expression
These data from the prostate cell line models were somewhat surprising, given the
large number of studies of ERβ previously published using them as experimental
models [Bouchal et al., 2011; Chen et al., 2009; Colciago et al., 2014; Dey et al.,
2012, 2014; Ellem et al., 2014; Holbeck et al., 2010; Kim et al., 2002a,b; Lau
et al., 2000; Mak et al., 2013, 2015a,b; Nakajima et al., 2011; Shaaban et al.,
2003; Veldscholte et al., 1990; Weng et al., 2013; Yang et al., 2012, 2015; Zhou
et al., 2012]. We then decided to assess the MCF-7 breast cancer cell line for
ERβ expression using the same multimodal approach. This was done for two
reasons, firstly; to test the approach in a different disease model and ensure that
our data were not reflecting an ‘unknown prostate-specific’ effect that had not
been controlled for. Secondly; ERβ is implicated as an important factor in breast
cancer [Gruvberger-Saal et al., 2007; Jonsson et al., 2014; Rizza et al., 2014; Smart
et al., 2013] with a number of studies demonstrating ERβ expression in MCF-7
cells [Al-Bader et al., 2011; Fuqua et al., 1999; Hinsche et al., 2015; Shaaban
et al., 2003; Skliris et al., 2002]. It was thought, therefore that MCF-7 could be
a useful model system to begin generating data on ERβ’s mechanisms of action
at a genomic level where little is currently known.
Genotyped MCF-7 cells were assessed for ERβ expression by RT-qPCR (for
mRNA), as well as Western blotting, RIME and PRM (for protein) using MDA-
MB-231-ERβ+/- cells as positive and negative controls (Figure 4.6). These data
conclusively demonstrate that these MCF-7 cells do not express ERβ as assessed
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Figure 4.3: PRM confirms that LNCaP and PNT1a do not express ERβ
(Peptide 1). The ‘spiked-in’, heavy labelled peptides (blue arrows) show the
same retention time and fragmentation pattern as the light (endogenous) version
of the peptide (red arrows), which was only identified in the MDA-MB-231-ERβ
positive control and not in LNCaP or PNT1a cells.
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Figure 4.4: PRM confirms that LNCaP and PNT1a do not express ERβ
(Peptide 2). The second peptide unique to ERβ (SSITGSECSPAEDSK) was
also only identified in the MDA-MB-231-ERβ positive control and not in the
LNCaP and PNT1a samples.
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Figure 4.5: Location of PRM peptides within full-length ERβ protein
Peptide 1 is from the DBD, common to all ERβ isoforms, whereas peptide 2 is
specific to wtERβ.
by multiple experimental approaches. This cell line is therefore not an appropri-
ate model for the study of ERβ.
It is recognised that there is some variability in immortalised cell lines across
passage numbers, which may account for some of the conflicting data from one
study to another generated from the same cell line [Masters, 2000]. However,
having shown with multiple experimental approaches that these early passage and
genotype-verified LNCaP and MCF-7 cells do not express ERβ, it is likely that
much of the conflicting data regarding the role and expression of ERβ in prostate
and breast cancer has arisen as a consequence of using poorly validated antibodies
on these models. This is clearly demonstrated in figure 4.7, which compares
Western blots of the same LNCaP and MCF-7 nuclear lysates probed with the
validated CWK-F12 ERβ antibody and the commonly used but non-specific NCL-
ER-BETA antibody (Figure 3.4). This non-specific ∼59 kDa band detected by
NCL-ER-BETA may be the source of much of the controversy surrounding the
study and characterisation of ERβ in cell line models and tissue.
81
4. Establishing an experimental model
MDA-MB-231-ERβ–" MDA-MB-231-ERβ+" MCF-7"
Pe
pt
ide
 1
 (L
igh
t)!
Pe
pt
ide
 2
 (L
igh
t)!
D
qPCR
Cell line
ER
β
 m
RN
A
MD
A-M
B-2
31-
ER
β+
MD
A-M
B-2
31-
ER
β–
MC
F-7
0.0
0.2
0.4
0.6
1!
Peptide map"Cell line"
MCF-7!
Antibody"
ERβ: MC10!
MCF-7! E2F1!
C"
151! 301! 530!
Amino acid no.!
1! 151! 301! 437!
Coverage (%)"
0!
20.3!
75!
50!
M
DA
-M
B-
23
1-
ER
β–
!
M
DA
-M
B-
23
1-
ER
β+
!
LN
Ca
P!
M
CF
-7
!
Actin!
ERβ !
B"
kDa!
A"
In
te
ns
ity
 (1
0^
3)
!
In
te
ns
ity
 (1
0^
3)
!
In
te
ns
ity
 (1
0^
3)
!
In
te
ns
ity
 (1
0^
3)
!
In
te
ns
ity
 (1
0^
3)
!
In
te
ns
ity
 (1
0^
3)
!
Retention time! Retention time!Retention time!
Retention time! Retention time! Retention time!
Figure 4.6: Multimodal assessment of MCF-7 cells confirms no expres-
sion of ERβ. Using MDA-MB-231-ERβ+/- cells as controls, MCF-7 cells were
found to have no ERβ expression at (A) mRNA level (qRT-PCR) or protein level
by (B) Western blotting, (C) RIME or (D) PRM. Red arrows indicate the endoge-
nous (light) ERβ-specific peptides detected by MS in the MDA-MB-231-ERβ+
positive control.
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Figure 4.7: Direct comparison of CWK-F12 and NCL-ER-BETA anti-
bodies on LNCaP and MCF-7 nuclear lysates. The NCL-ER-BETA anti-
body produces a band on Western blot of ∼59 kDA, of appropriate size for ERβ.
However, the band is present in the MDA-MB-231-ERβ- control, confirming that
the antibody is non-specific. The validated CWK-F12 ERβ antibody reveals the
genuine result.
4.2.3 IHC confirms variable ERβ expression in differing
grades of prostate cancer
Tissue staining assessed by Dr. A.Y. Warren, Consultant Histopathologist, Cam-
bridge University Hospitals NHS Foundation Trust.
In light of the difficulties encountered with antibody specificity and the unsuc-
cessful search for an appropriate experimental model in which to study ERβ in
prostate cancer, it was necessary to confirm that prostate tissue does in fact ex-
press ERβ, and that some variability in tissue expression could be observed in
different grades of prostate cancer. This would reassert the rationale for pur-
suing ERβ as a potentially important factor in the biology of prostate cancer
development and progression.
A prostate TMA containing 10 cancers of differing grades and 5 benign controls
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was stained for ERβ using the validated and optimised CWK-F12 ERβ antibody
(Figure 4.8). This demonstrated high expression of ERβ in the basal epithelium
of benign glands, with no expression in Gleason grade 3 cancer. Gleason grade
4 cancer showed weak nuclear staining of ERβ and in areas of Gleason grade 5
cancer, ERβ nuclear expression was of moderate intensity. This is in contrast to
numerous previous reports, which have described an inverse correlation between
ERβ expression and increasing Gleason grade of prostate cancer [Asgari and
Morakabati, 2011; Attia and Ederveen, 2012; Dey et al., 2014; Horvath et al.,
2001; Leav et al., 2001; Risbridger et al., 2007], but is consistent with other
studies, which have reported an association between increased ERβ expression
and higher Gleason grade [Zellweger et al., 2013] or increased expression of ERβ
in bone and lymph node metastases [Bouchal et al., 2011; Zhu et al., 2004].
This analysis is limited by the small sample size of tissues stained and the lack
of formal statistical correlation with clinico-pathological parameters. However,
it serves as proof in principle that firstly; the CWK-F12 ERβ antibody can be
used on clinical material and secondly; that variable expression of ERβ can be
observed in differing grades of prostate cancer in keeping with some of the previ-
ously published data in the literature [Bouchal et al., 2011; Horvath et al., 2001;
Zellweger et al., 2013; Zhu et al., 2004].
4.2.4 Development of the LNCaP-ERβ cell line
Having established that none of the evaluated prostate cell lines expressed ERβ,
and having confirmed that ERβ is differentially expressed in benign versus malig-
nant tissue, a stable prostate cancer cell line model was developed with doxycycline-
inducible ERβ expression. As the potential interaction and genomic cross-talk
between ERβ and AR is an area of great interest [Rizza et al., 2014; Yang et al.,
2012, 2015; Zellweger et al., 2013], an androgen-sensitive cell line with endogenous
AR expression was used as the parental cell line. The two-step, T-RexTMsystem as
used to make the MDA-MB-231-ERβ cell line (plasmids donated by Dr. J. Hawse,
Mayo Clinic, Minnesota, USA) was used in genotyped, low passage LNCaP cells.
As the IHC data suggested that ERβ was highly expressed in benign disease, but
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Figure 4.8: IHC of prostate tissue with validated CWK-F12 ERβ an-
tibody. Variable ERβ expression was observed in differing grades of prostate
cancer. ERβ was highly expressed in basal and luminal epithelial cells of benign
glands (A), whereas there was no nuclear staining in Gleason grade 3 cancer (B).
In Grade 4 mucinous tumor (C) and high grade tumor (D) nuclei showed weak
to moderate expression of ERβ.
lost with the development of cancer, it seemed appropriate to use an androgen-
sensitive cell line model representative of early stage disease. The use of a stable,
inducible system allows for direct, reproducible comparisons of data obtained
from the ERβ-induced conditions, eliminating the variability in the efficiency of
transient transfection that may occur between replicate experiments. Further-
more, the non-induced LNCaP-ERβ- cells provide a matched negative control
condition.
The procedural workflow for the development of the LNCaP-ERβ cell line model
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was based on a previously published protocol [Monroe et al., 2003] and is shown
in figure 4.9. LNCaP cells were transfected with the linearised pcDNA6/TR c©
plasmid, which contains a blasticidin resistance gene to facilitate selection of cells
that have successfully incorporated the plasmid. Following 6 days of selection
with 5 µg/ml blasticidin discrete cell colonies that had arisen from single cell
clones were taken from the plates and seeded into 96-well plates. Approximately
80 clones of LNCaP-Tet-R cells were isolated in this way. Under continuous
blasticidin selection, 20 of these clones were expanded successfully and grown up
to 6-well plate format.
These 20 clones were transiently transfected with a pcDNA4/TO c© plasmid con-
taining luciferase to assess the activity of the Tet-R in each clone (Figure 4.10).
The primary aim was to select a clone that had minimal luciferase expression
from the ‘dox-off’ condition in order to create a clean system with no ‘leaky’
expression of ERβ. The secondary aim was to select a clone with a high -fold
change in the luciferase signal following addition of doxycycline. The B2 clone
satisfied both of these criteria, and was therefore used for subsequent transfection
of the ERβ plasmid.
Several initial attempts at transfecting the pcDNA4/TO c©-ERβ plasmid into the
LNCaP-Tet-R B2 clone were unsuccessful. A number of different strategies were
used to overcome this. Side-by-side transfections using linearised versus non-
linearised plasmid, and Lipofectamine R© 2000 versus Lipofectamine R© 3000 were
performed. Successful transfection was eventually achieved using non-linearised
plasmid transfected with Lipofectamine R© 2000. Further difficulties were en-
countered with zeocin selection of cells; treating the cells with 500 µg/ml dose
as previously described [Wu et al., 2012] did not produce enough cell death to
prevent plates from becoming fully confluent before selection had taken place.
However, if cells were then passaged and treated with 500 µg/ml zeocin they all
died.
In order to refine the zeocin selection process, a dose-response experiment was
performed in the LNCaP-Tet-R B2 cell line (Figure 4.11). This demonstrated
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Figure 4.9: Workflow for the development of the LNCaP-ERβ cell line.
LNCaP cells were transfected with a Tet-R construct, selected using blasticidin
and replated to grow single cell colonies. Individual colonies were reseeded in
96-well plates. Expanded clones were transiently transfected with luciferase to
measure Tet-R activity. The clone with the greatest -fold induction and lowest
‘dox-off’ activity was selected for transfection with ERβ-containing plasmid and
cells selected with zeocin.
that 1000 µg/ml zeocin was required to select successfully transfected cells within
6 days of treatment. Lower doses did not produce any cell death, whereas the
1,250 µg/ml dose killed almost all cells. Following selection, the dose of zeocin
was reduced to 250 µg/ml for maintenance of the cell line, as it was found that
continuous treatment with zeocin 500 µg/ml as used in the MDA-MB-231-ERβ
cell line [Wu et al., 2012] resulted in intractable cell senescence (Figure 4.12B)
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Figure 4.10: Luciferase assay of LNCaP-Tet-R clones. A total of 20 Tet-R
clones were screened. The B2 clone (*) had the lowest ‘dox-off’ signal and the
greatest -fold induction with 0.1 µg/ml doxycycline treatment. Data are mean
+/- S.D. of triplicate experiments.
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[Brandhagen et al., 2013]. Under the maintenance doses of blasticidin 2.5 µg/ml
and zeocin 250 µg/ml cells proliferated at the same rate and were subcultured
at the same ratios as parental LNCaP cells. Once proliferating, the LNCaP-ERβ
cell line was morphologically identical to the parental LNCaP cell line (Figure
4.12C).
4.2.5 Characterisation of the LNCaP-ERβ cell line
The same multimodal characterisation, utilising RT-qPCR, Western blotting,
RIME and PRM was then applied to the LNCaP-ERβ cell line to confirm firstly;
absence of ERβ expression in the ‘dox-off’ condition and secondly; detectable in-
duction of ERβ mRNA and protein following 24 hour treatment with 0.1 µg/ml
doxycycline. Induction of ERβ mRNA in the LNCaP-ERβ cell line was com-
pared to that of the MDA-MB-231-ERβ cell line (Figure 4.13A). Absolute levels
of ERβ mRNA were greater in the LNCaP-ERβ+ cell line than the MDA-MB-
231-ERβ+ cell line. However, due to a greater level of baseline ERβ expression
in the LNCaP-ERβ- cells, the fold-change of ERβ expression with doxycycline
treatment was greater in the MDA-MB-231-ERβ line than the LNCaP-ERβ cells
(81 fold increase in expression versus 15 fold respectively). Induction of ERβ
expression in the LNCaP-ERβ cell line had no effect on mRNA expression of
AR (Figure 4.13B). Western blotting with the validated CWK-F12 ERβ anti-
body confirmed strong ERβ protein expression in the LNCaP-ERβ+ condition,
with no detectable ERβ protein in the ERβ- condition. This result validated
the induction of ERβ in the LNCaP-ERβ cell line, confirmed the specificity of
this antibody, and provided additional evidence that non-induced LNCaP-ERβ
cells are ERβ negative. Protein expression of AR and FOXA1, an important
nuclear receptor co-factor [Carroll et al., 2005; Robinson et al., 2011, 2014], were
unaltered by induction of ERβ expression (Figure 4.13C).
Induction of ERβ protein expression in the LNCaP-ERβ cell line was confirmed
by PRM and RIME (Figure 4.14). In the PRM analysis, comparison of the
fragmentation pattern and retention time of the heavy-labelled ERβ with that
observed from the endogenous ERβ in the LNCaP-ERβ+ cells confirmed the
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Figure 4.11: Zeocin dose-response in LNCaP-Tet-R B2 cells. Cells were
treated with increasing doses of zeocin for 6 days. 1000 µg/ml resulted in signif-
icant cell death without killing all cells.
presence of ERβ peptide in the sample, although in lower abundance as had
been detected in the MDA-MB-231-ERβ+ cells (Figure 4.3). Furthermore, only
peptide 1 (SLEHTLPVNR) was detected in the LNCaP-ERβ+ cells. This is
likely due to lower abundance of ERβ protein in the LNCaP-ERβ+ cell line as
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LNCaP (parental)! LNCaP-ERβ (senescent)! LNCaP-ERβ (proliferating)!
Figure 4.12: Morphology of LNCaP-ERβ cells. LNCaP-ERβ cells treated
continuously with zeocin 500 µg/ml stopped proliferating, and developed long
neurite-like projections characteristic of a senescent phenotype (B). When doses
of blasticidin and zeocin were reduced (C) the LNCaP-ERβ cells behaved like
parental LNCaP cells (A).
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Figure 4.13: Characterisation of LNCaP-ERβ cell line. Doxycycline-
induced expression of ERβ was confirmed in the LNCaP-ERβ cell line at (A)
mRNA and (C) protein level. Comparison with the MDA-MB-231-ERβ cell line
showed 15-fold (p <0.0001) versus 81-fold (p = 0.005) increase in expression
respectively. AR mRNA (B) and protein, and FOXA1 protein (C) expression
were unaffected by ERβ induction. RT-qPCR data are mean + S.D. of triplicate
experiments. No ERβ protein was detected in the LNCaP-ERβ- condition.
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compared with the MDA-MB-231-ERβ+ cell line.
RIME and PRM analyses of LNCaP-ERβ- cells demonstrated no detectable
expression of ERβ proteins in keeping with the Western blot results, confirm-
ing the robust nature of the inducible LNCaP-ERβ cell line model system. In
LNCaP-ERβ+ cells, using the validated MC10 antibody, 30% peptide coverage
was achieved with a mean of 14.5 peptides unique to ERβ identified.
4.2.6 The ERβ protein interactome
The ERβ protein interactome is not well characterised in any disease or physio-
logical context. The RIME data obtained from the LNCaP-ERβ+ cells provide
the opportunity for a preliminary examination of protein interactions and net-
works relating to ERβ in a prostate cancer context. The BioGRID database
[Chatr-Aryamontri et al., 2015] was used to identify previously published interac-
tors of proteins pulled down by ERβ RIME (Table 4.1). These included 4 known
ERβ interactors; TRIM24, NRIP1, HMGB1 and HSP90, and 9 proteins known
to interact with other nuclear steroid hormone receptors (discussed in section
6.3.3). Network and pathway analysis of all specific peptides purified by ERβ
RIME was conducted using the STRING database [Szklarczyk et al., 2015] (Fig-
ure 4.15). A significant proportion of the proteins purified in the ERβ RIME
clustered into two nodal networks. Gene ontology (GO) term analysis revealed
that one node was strongly associated with RNA splicing (FDR 1.55 x 10−13) and
the second comprised proteins involved in translation initiation machinery (FDR
2.76 x 10−12). Three other functional networks were apparent in the interacting
proteins, DNA damage repair proteins (FDR 0.0145), regulation of gene expres-
sion (FDR 0.0114) and regulation of apoptosis (FDR 0.018). The four known
ERβ-interacting proteins identified in the BioGRID database (TRIM24, NRIP1,
HMGB1 and HSP90) were positively identified in this analysis. Interestingly, our
RIME data presents evidence of direct interaction between ERβ and AR (Table
4.1), which was confirmed by the STRING analysis.
Although RIME data are not quantitative, and further validation is required to
92
4. Establishing an experimental model
prove physical interaction between proteins purified by RIME, these data provide
an interesting insight into putative ERβ-interacting protein networks.
4.3 Summary
A panel of prostate cell lines commonly used to study ERβ were found to lack de-
tectable ERβ protein expression by Western blotting using the validated CWK-
F12 antibody. Only the PC3 cell line expressed any detectable ERβ mRNA.
Further assessment of the most commonly utilised prostate cancer cell lines in
the ERβ literature by RIME (LNCaP, PC3 and PNT1a) and PRM (LNCaP and
PNT1a) confirmed that no ERβ protein could be detected in these cell lines using
either validated antibody-based, or antibody-independent approaches. Further-
more, the breast cancer cell line MCF-7, which has also been extensively used to
study ERβ was also found to lack ERβ expression using the same multimodal
approach. These findings call into question any previously published data on the
role of ERβ generated using these cell line models.
Differential expression of ERβ protein in benign versus malignant prostate tissue
was confirmed by IHC using the validated CWK-F12 antibody, reaffirming the
case for studying the role of ERβ as a putative tumour-suppressor in prostate
cancer. In view of the IHC findings and the lack of an available cell line model
suitable for in vitro mechanistic studies of the role of ERβ, a prostate cancer
cell line with stable, inducible ERβ expression was developed and validated by
four independent methods. Importantly, no ERβ expression was detectable in
the uninduced, ERβ- condition by any technique, demonstrating that this is a
robust model that will enable controlled studies of the interplay between ERβ
and AR in an androgen-sensitive prostate cancer context.
A number of proteins known to interact with ERβ, along with other proteins
known to interact with other nuclear steroid hormone receptors were identified
by RIME in LNCaP-ERβ+ cells, further validating the model and revealing a
putative network of ERβ-interacting proteins, with multiple nodes of protein
networks revealed centring on RNA splicing mechanisms, translational machinery,
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Figure 4.14: Characterisation of LNCaP-ERβ cell line by PRM and
RIME. (A) PRM did not detect ERβ peptides in LNCaP-ERβ- cells. ERβ
peptides were identified in LNCaP-ERβ+ cells (red arrow), with the same frag-
mentation pattern and retention time as the heavy-labelled peptide (blue arrows).
(B) RIME confirmed no ERβ expression in LNCaP-ERβ- cells, but strong pull-
down of ERβ in LNCaP-ERβ+ cells, with mean coverage of 30% and 14.5 unique
peptides. AR acted as a positive control, with no difference in coverage or unique
peptides observed between ERβ- and ERβ+ conditions.
94
4. Establishing an experimental model
Description! Mean coverage! Mean peptides!
E3 UFM1-protein ligase 1 (UFL1)! 33.8! 22!
Estrogen receptor beta (ESR2)! 30.6! 14.5!
Protein arginine N-methyltransferase 3 (ANM3)! 21.8! 11!
T-complex protein 1 subunit alpha (TCPA)! 22.1! 10.5!
Transcription intermediary factor 1-beta (TIF1B)! 14.7! 9!
Probable ATP-dependent RNA helicase (DDX17)! 16.5! 8!
Signal transducer and activator of transcription 3 (STAT3)! 14.4! 8!
Heterogeneous nuclear ribonucleoprotein M (HNRNPM)! 13.4! 8!
Heterogeneous nuclear ribonucleoprotein A1 (ROA1)! 25.1! 7.5!
Poly [ADP-ribose] polymerase 1 (PARP1)! 8.3! 7.5!
Protein arginine N-methyltransferase 1 (ANM1)! 21.7! 6!
Protein O-linked-mannose beta-1,4-N-
acetylglucosaminyltransferase 2 (PMGT2)! 15.6! 6!
Far upstream element-binding protein 2 (FUBP2)! 12.1! 6!
Endoplasmin (HSP90/ENPL)! 8.9! 5.5!
Staphylococcal nuclease domain-containing protein 1 (SND1)! 6.8! 5.5!
Nuclear receptor-interacting protein 1 (NRIP1/RIP140)! 6.7! 5.5!
Eukaryotic translation initiation factor 3 subunit A (EIF3A)! 5.3! 5.5!
Creatine kinase B-type (KCRB)! 18.6! 5!
Peptidyl-prolyl cis-trans isomerase (FKBP5)! 15.5! 5!
WD repeat-containing protein 18 (WDR18)! 12.6! 5!
Peptidyl-prolyl cis-trans isomerase (FKBP4)! 13.3! 4.5!
X-ray repair cross-complementing protein 6 (XRCC6)! 10.0! 4.5!
Minor histocompatibility antigen H13 (HM13)! 12.7! 4!
Heat shock 70 kDa protein 4 (HSP74)! 5.8! 4!
Eukaryotic translation initiation factor 3 subunit B (EIF3B)! 4.2! 3.5!
DNA-dependent protein kinase catalytic subunit (PRKDC)! 1.3! 3.5!
High mobility group protein B1 (HMGB1)! 18.6! 3!
Transcription intermediary factor 1-alpha (TRIM24/TIF1A)! 4.1! 2!
FACT complex subunit (SSRP1) ! 2.4! 1.5!
Homeobox protein Hox-B13 (HOXB13)! 4.2! 1!
Metastasis-associated protein (MTA2)! 2.4! 1!
Androgen receptor (AR)! 2.2! 1!
Table 4.1: Interacting proteins identified by ERβ RIME in LNCaP-
ERβ+ cells. All proteins identified with ≥5 unique peptides are shown,
along with other interesting or previously published steroid hormone receptor-
interacting proteins (Mean of 2 independent biological replicates).
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Key:!
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!Experimental!
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Other!
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Colour key! GO term! Count in gene set! FDR!
RNA splicing! 19! 1.55 x 10-13!
Translation initiation! 18! 2.76 x 10-12!
DNA repair! 10! 0.0145!
Positive regulation of gene expression! 22! 0.0114!
Regulation of apoptosis! 19! 0.018!
Figure 4.15: ERβ-interacting protein networks identified by RIME in
LNCaP-ERβ+ cells. Five nodes of interacting proteins are apparent, with gene
ontology (GO) pathway analysis revealing functional correlations of the proteins
within the nodes. (FDR, false discovery rate).
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DNA damage response and apoptotic mechanisms.
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Chapter 5
Genomic crosstalk between ER
beta and AR
5.1 Introduction
5.1.1 Essential background information
Silencing of ERβ contributes to early events in prostate carcinogenesis
The early molecular events that drive the initial development of prostate cancer
are incompletely understood [Zhou et al., 2015]. Both the in utero development
and subsequent homeostatic regulation of the adult prostate are dependent upon
DHT-induced activity of AR [Hayward et al., 1998; Pointis et al., 1979]. In
benign prostate tissue, AR maintains luminal epithelial cell differentiation, pos-
sibly through a paracrine signalling network involving stromal cells [Wikstrom
et al., 1999]. Therefore, in order for AR to become an oncogene and the principle
driver of prostate cancer, its normal homeostatic role is disturbed. A number
of processes are thought to be involved in this change; reprogramming of the
AR cistrome by co-factors [Pomerantz et al., 2015], formation of fusion genes by
aberrant DNA-damage response mechanisms [Mani et al., 2009] with the resulting
deletion of PTEN leading to upregulation of the Akt/PI3K signalling pathway
[Carver et al., 2009], over-expression of AR [Zhou et al., 2013] or post-translational
modifications to AR [Coffey and Robson, 2012].
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It has been proposed that a decrease in systemic androgen levels may be the
initiating factor in this carcinogenic process [Zhou et al., 2015]. There is evidence
for this at an epidemiological level as it is well-established that the peak age
of prostate cancer incidence coincides with the age at which serum testosterone
levels decline [Vermeulen et al., 2002]. As discussed in section 1.3, this change
results in a decreased androgen:estrogen ratio, which is hypothesised to contribute
to prostate cancer risk [Bosland, 2013; Ellem and Risbridger, 2007]. Decreased
availability of androgen ligands leads to upregulation of AR expression in an
attempt to maintain normal AR signalling. This change in AR function leads to
DNA damage, through AR-mediated recruitment of topoisomerase 2β (TOP2β)
resulting in double-stranded DNA breaks [Mills, 2014]. The ensuing genome
instability leads to formation of E26 transformation-specific (ETS) family fusion
genes such as TMPRSS2:ERG, a common genetic lesion in early prostate cancer
development [Weischenfeldt et al., 2013] that results in cell cycle dysregulation,
increased DNA synthesis and upregulation of proinflammatory mediators such as
STAT3 and NF-κB [Mills, 2014] (Figure 5.1). As discussed in section 1.5.1, ERα
and ERβ (in particular loss of ERβ expression) play critical roles with respect
to inflammatory processes in the prostate that contribute to cancer development
and progression (Figure 1.6), and so one could hypothesise that loss of ERβ
expression in malignant transformation of the prostate may contribute to these
proinflammatory changes resulting from fusion gene formation.
A second key event in the initiation of prostate carcinogenesis is loss of the tumour
suppressor gene PTEN. This leads to upregulation of the Akt/PI3K signalling
pathway, which is known to be an important driver of changes that eventually
lead to CRPC [Phin et al., 2013]. As discussed in section 1.5.2, PTEN loss results
in decreased wtERβ expression (mediated through silencing of the 0N ESR2
promotor) and leads to predominance of the ERβ2 isoform (due to persistent
activity from the 0K ESR2 promotor) with subsequent upregulation of VEGF
signalling and inhibition of caspase-9 mediated apoptosis (Figure 1.7), all of which
contribute to the development and progression of prostate cancer [Dey et al.,
2014; Lee et al., 2013; Leung et al., 2006b; Mak et al., 2015a; Suzuki et al.,
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Figure 5.1: TMPRSS2:ERG fusion gene formation drives early prostate
carcinogenesis through genome instability and proinflammatory me-
diators. Decreased serum androgen results in upregulation of AR expression,
leading to double stranded DNA-breaks and formation of fusion genes. This
drives pro-inflammatory pathways known to be related to ERβ function. Figure
based on Mills 2014 and Zhou et al., 2015.
2008]. Furthermore, in a recent study that appears to mechanistically link these
two early genetic lesions it has been shown that activation of ERβ2 triggers
upregulation of another ETS-family fusion oncogene, TMPRSS2:ETV5a/5b in
androgen deplete conditions, which in turn mediates growth and cell migration
in CRPC [Kim et al., 2016].
Considering these three factors together: i) the change in the androgen:estrogen
ratio; ii) the resulting change in AR activity that drives the formation of the TM-
PRSS2:ERG fusion gene leading to genome instability and inflammation (Fig-
ure 1.6) and iii) the loss of PTEN expression, which silences wtERβ expres-
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sion and increases ERβ2 expression with subsequent upregulation of additional
TMPRSS2:ETS-family fusion genes, we can observe that ERβ is intimately in-
volved in each of these processes, and hypothesise that the loss of ERβ’s tumour
suppressive effect is a an important early event in prostate carcinogenesis. IHC
data showing that ERβ is highly expressed in benign prostate epithelium, but
not in cancer [Asgari and Morakabati, 2011; Bonkhoff et al., 1999; Dey et al.,
2014; Horvath et al., 2001; Leav et al., 2001] would support this hypothesis.
ERβ and AR modulate each other’s activity through nuclear receptor
crosstalk
As discussed in section 1.5.2, there is increasing evidence to show that individual
nuclear receptors do not function in isolation, but instead are interdependent and
able to modulate each other’s responses to stimuli [Arora et al., 2013; Mohammed
et al., 2015]. Previous work in breast and prostate cancer has shown evidence of
crosstalk between ERβ and AR by several mechanisms, but the exact nature of the
relationship between the two receptors remains unclear [Grubisha and DeFranco,
2013; Mizokami et al., 2004; Rizza et al., 2014; Teng et al., 2014; Thelen et al.,
2007; Weng et al., 2013], specifically whether ERβ regulates AR or vice versa.
The current lack of a coherent mechanism explaining the relationship between
these receptors may simply reflect the differing cell- and tissue-specific contexts
in which studies have been conducted. Alternatively, confusion in the literature
may have arisen as a consequence of the use of inadequately validated reagents
and experimental models as demonstrated in Chapters 3 and 4 of this thesis.
In the context of prostate cancer the details of ERβ’s mechanism of action must
be fully understood before it can be considered as a valid therapeutic target,
especially given the current disconnection between in vitro and in vivo data on
the use of SERMs in prostate cancer [Kim et al., 2002a,b; Nakamura et al., 2013;
Piccolella et al., 2014; Rossi et al., 2011] (Sections 1.3.3 and 1.3.4). From a clinical
perspective, the key question is whether maintaining ERβ signalling can alter or
reprogram the actions of AR to slow or even prevent the AR-mediated processes
that drive early prostate carcinogenesis. This strategy, by modifying AR activity
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early in the disease process in an indirect manner, may present an alternative
to conventional ADT, which by directly targeting AR once its oncogenic role
is already firmly established, inevitably exerts selection pressure to drive cancer
evolution and the development of lethal CRPC (Section 1.1.7) [Claessens et al.,
2014; Scher et al., 2004].
5.1.2 Aims
The aim of the work presented in this chapter is to understand the effect and
determine the mechanisms by which ERβ influences AR-driven prostate carcino-
genesis. To address this, a number of previously published clinical datasets were
interrogated to look for i) patterns of ERβ expression and associations with clin-
ical prognosis and ii) the effect of inhibiting AR with ADT on ERβ expression,
with a view to determining the relationship between ERβ and AR. Secondly, in
light of the previously described observations from published IHC studies showing
that ERβ is highly expressed in benign prostate epithelium and lost in malignant
epithelium [Asgari and Morakabati, 2011; Attia and Ederveen, 2012; Bonkhoff
et al., 1999; Horvath et al., 2001], we hypothesised that loss of ERβ results in
alteration of AR activity; specifically, the transition of AR from an agent of phys-
iological homeostasis to an oncogene. We therefore decided to reintroduce ERβ
into an androgen-sensitive, AR-driven prostate cancer context to determine the
effect of maintained ERβ signalling on oncogenic AR. In so doing, we aimed to
determine the mechanisms of crosstalk between these nuclear receptors in an early
disease context. The inducible LNCaP-ERβ cell line model described in Chapter
4 was therefore used to study the effects of activated ERβ at phenotypic, genomic
and transcriptional levels.
5.1.3 Key Findings
1. Interrogation of a large clinical dataset integrating gene expression data
with copy number aberrations [Ross-Adams et al., 2015] shows that in-
creased ERβ expression is associated with improved BCR-free survival and
greater genome stability.
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2. Interrogation of published gene expression data, combined with ERβ IHC
in prostatectomy specimens from clinical trials of ADT shows that ERβ
expression is inhibited by AR in vivo. AR knockdown in a prostate cancer
cell line results in upregulation of ERβ expression confirming this finding
in an in vitro setting.
3. Prostate cancer cell proliferation is inhibited by ligand-activated ERβ in
the presence of androgen-stimulated AR.
4. Stimulation of ERβ by its ligand results in widespread changes in AR-
dependent gene expression.
5. Mechanistically, this effect appears to be mediated by competition between
ERβ and AR for shared DNA-binding sites, which are highly enriched for
ERβ, AR and FOXA1 motifs. These binding sites are shown to be highly
transcriptionally active, with the result that ligand-activated ERβ repro-
grams a subset of androgen-dependent genes.
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5.2 Results
5.2.1 ERβ expression in clinical datasets
Greater ERβ expression is associated with improved BCR-free survival
Firstly, to establish whether ERβ expression levels in prostate tissue correlate
with clinical outcome, a large clinical dataset (CamCaP) [Ross-Adams et al.,
2015] was interrogated using a published, online software tool [Dunning et al.,
2017]. This dataset was generated by integration of copy number analysis and
transcriptomics data from 482 tumour, benign and germline samples obtained
from 259 men with primary prostate cancer. The integrated data were then used
to identify five prognostic groups (iClusters) with distinct transcript expression
profiles and genomic alterations.
ERβ expression was observed to vary significantly across the five prognostic
groups (ANOVA p = 0.04) (Figure 5.2A). Interestingly, ERβ expression was high-
est in iClusters 2 and 4, which are associated with significantly greater BCR-free
survival than iClusters 1 and 3 (p = 0.017 [Ross-Adams et al., 2015]). Further-
more, iClusters 2 and 4 feature fewer copy number abberations than the other
prognostic groups. Taken together, these findings suggest that sustained ERβ
expression in prostate cancer is associated with better clinical prognosis, poten-
tially mediated through greater genome stability. This association appears to
be independent of AR expression, which does not vary significantly across the
iClusters (Figure 5.2B). However, it is interesting to note a trend towards lower
AR expression in iClusters 2 and 4, where ERβ expression is greatest.
ERβ expression is inhibited by AR in vivo
Secondly, to investigate the relationship between ERβ and AR, gene expression
data from two clinical datasets [Rajan et al., 2014; Shaw et al., 2016] were in-
terrogated to determine the effect of AR inhibition (mediated by ADT) on ERβ
expression. Rajan et al. (2014) performed RNA-seq on prostate tumours ob-
tained from seven patients with locally advanced or metastatic disease before
and after initiation of ADT (GSE48403). Similarly, Shaw et al., (2016) obtained
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high-risk prostate cancer tissue from 27 patients treated with the LHRH antago-
nist degarelix and 20 matched, untreated controls (GSE72920). In both datasets,
inhibition of AR signalling with treatment resulted in significant upregulation of
ERβ mRNA expression (p = 0.04 and p = 0.02 respectively)(Figure 5.2C and
D). These data suggest that ERβ expression is negatively regulated by AR in
prostate cancer, a finding supported by previous observations showing that AR
is more highly expressed in malignant than benign prostate epithelium [Riccia-
rdelli et al., 2005]. Taken together, these observations may explain the decreased
ERβ expression observed in malignant versus benign prostate tissue in previously
published IHC studies [Asgari and Morakabati, 2011; Attia and Ederveen, 2012;
Bonkhoff et al., 1999; Horvath et al., 2001].
5.2.2 ERβ expression in degarelix-treated prostate tissue
Tissue staining assessed by Dr. A.Y. Warren, Consultant Histopathologist, Cam-
bridge University Hospitals NHS Foundation Trust.
To further investigate these findings, a TMA containing prostate biopsy cores
from the 27 degarelix-treated patients and 20 matched, untreated controls [Shaw
et al., 2016] was stained for ERβ using the validated CWK-F12 ERβ antibody.
Staining of luminal epithelial cells was scored using the Allred system, which has
been validated for assessment of ERα expression by IHC in breast cancer [Harvey
et al., 1999] (Table 5.1). Strong ERβ staining was noted in basal epithelial cells
of benign glands (Figure 5.3A), however these were not included in the analysis
as firstly, they are not used in the Allred score and secondly, de-differentiation
of basal epithelial cells is an early development in malignant transformation of
prostate epithelium [Bonkhoff, 1996; Korshak et al., 2016]. They would therefore
not be present in tumour samples to enable direct comparisons between benign
and malignant regions.
ERβ staining in degarelix-treated and untreated controls was compared using
a Wilcoxon rank sum test (Figure 5.3B). In both benign and tumour areas of
prostate tissue, there was a trend towards increased ERβ expression following
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Figure 5.2: ERβ expression in clinical datasets. (A) ERβ gene expression
in the CamCaP dataset is greatest in iClusters 2 and 4, which in turn are as-
sociated with greater BCR-free survival than iClusters 1 and 3. (B) There is
no variability in AR expression across iClusters (p = 0.71). (C) ERβ mRNA
expression data from matched tumour samples pre- and post-administration of
ADT shows upregulation of ERβ expression in response to AR inhibition [Rajan
et al., 2014]. (D) This was confirmed in a second cohort of patients treated with
the LHRH antagonist degarelix [Shaw et al., 2016], suggesting that AR represses
ERβ expression in vivo.
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Proportion scoring 
(Percentage cells 
ER positive)!
Staining intensity 
score!
0 (0)! 0 - Negative!
1 (≤1)! 1 - Weak!
2 (1-10)! 2 - Intermediate!
3 (11-33)! 3 - Strong!
4 (34-66)!
5 (67-100)!
Table 5.1: The Allred IHC Scoring System was originally validated for ERα
staining in breast cancer. The system combines the proportion of cells stained,
and the staining intensity to stratify breast cancer according to the likelihood of
disease response to hormonal therapy [Harvey et al., 1999].
degarelix treatment, although this was not statistically significant (p = 0.27 for
benign tissue, p = 0.77 for tumour). This non-significance at a protein level (in
contrast to the changes observed at a transcript level (Figure 5.2C and D)) may
be due to the small sample size.
5.2.3 ERβ expression is inhibited by AR in vitro
In order to confirm regulation of ERβ expression by AR in an in vitro model,
LNCaP cells were treated with siRNA to AR, and expression of ERβ mRNA
quantified by RT-qPCR. Silencing of AR in vitro resulted in significant upreg-
ulation of ERβ expression (p = 0.03), confirming the in vivo data and further
demonstrating that ERβ expression is inhibited by AR in malignant prostate
epithelial cells (Figure 5.4).
The work presented thus far demonstrates that sustained ERβ expression in clini-
cal samples is associated with improved BCR-free survival, and ERβ expression is
inhibited by AR in vitro and in vivo. The decrease in ERβ expression previously
observed in malignant transformation of the prostate [Asgari and Morakabati,
2011; Bonkhoff et al., 1999; Dey et al., 2014; Horvath et al., 2001; Leav et al.,
2001] is therefore likely to be a direct consequence of the increase in AR signalling
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Figure 5.3: ERβ expression in degarelix-treated prostate tissue. (A)
Strong ERβ expression is evident in the basal epithelial cells of benign glands.
(B) Although not statistically significant, in both benign and tumour tissue there
was a trend towards increased ERβ expression in luminal epithelial cells following
degarelix treatment.
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Figure 5.4: ERβ expression is inhibited by AR in vitro. 3.5-fold upreg-
ulation of ERβ expression occurred in response to AR knockdown in LNCaP
cells.
that occurs in early prostate carcinogenesis [Mills, 2014; Zhou et al., 2015] (Sec-
tion 5.1.1). We therefore wanted to investigate the effect of maintaining ERβ
signalling in a prostate cancer in vitro model at phenotypic, transcriptomic and
genomic levels, to determine if activation of ERβ can modulate this AR-driven
prostate carcinogenesis. The doxycycline-inducible LNCaP-ERβ cell line (Chap-
ter 4) was therefore used in subsequent experiments.
5.2.4 Ligand-activated ERβ inhibits prostate cancer cell
proliferation
To investigate the effect of ERβ signalling on prostate cancer cell growth, LNCaP-
ERβ+ cells (ERβ expression induced with 0.1 µg/ml doxycycline for 24 hours)
and LNCaP-ERβ- cells were treated with vehicle, 1 nM R1881, 10 nM 3β-adiol
or both R1881 and 3β-adiol following 3 days of hormone deprivation. R1881 is
a synthetic, non-aromatisable androgen, which binds to and stimulates AR (Na-
tional Center for Biotechnology Information. PubChem Compound Database;
CID=261000, https://pubchem.ncbi.nlm.nih.gov/compound/261000 (accessed Sept.
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15, 2017).). As it is non-aromatisable and therefore not converted to estrogenic
metabolites, potential cross-ligand activation of ERβ is avoided. 3β-adiol is an
ERβ-selective DHT metabolite thought to be the natural ligand for ERβ [Oliveira
et al., 2007; Weihua et al., 2002a,b]. It is found in high concentration in benign
prostatic tissue [Piccolella et al., 2014]. Cell proliferation was recorded for 7 days
following treatment (Figure 5.5).
The androgen-responsive nature of the LNCaP-ERβ cell line was confirmed by
treating LNCaP-ERβ- cells with R1881, which resulted in increased cell prolifer-
ation as compared with vehicle (Figure 5.5A). Interestingly, 3β-adiol treatment
in LNCaP-ERβ- cells resulted in a similar increase in cell proliferation. This may
be in keeping with previous reports showing that 3β-adiol can stimulate AR in
testosterone-deplete conditions [Mizokami et al., 2004].
LNCaP-ERβ+ cells treated with both R1881 and 3β-adiol showed significant de-
crease in cell proliferation compared firstly, to vehicle-treated cells (p = 0.006,
figure 5.5B) and secondly, to LNCaP-ERβ- cells treated with R1881 and 3β-adiol
(p = 0.02, figure 5.5F). Cell morphology did not change appreciably with any
of the treatment conditions (Figure 5.6). Intriguingly, in this experiment, cell
proliferation was only inhibited when i) ERβ is expressed; ii) ERβ is activated by
3β-adiol and iii) AR is stimulated by androgen. This suggested that the mech-
anism of growth inhibition could be related to competitive antagonism between
the two nuclear receptors. Interestingly, this mirrors work previously published
from the Carroll laboratory, showing that in breast cancer, progesterone is only
anti-proliferative when progesterone receptor (PR) is expressed in the presence
of estrogen-stimulated ERα [Mohammed et al., 2015].
5.2.5 Preliminary ERβ ChIP-seq to determine duration
of 3β-adiol treatment
Bioinformatic analysis of ChIP-seq data by Dr. I. Chernukhin, CRUK Cambridge
Institute
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Figure 5.5: Ligand-activated ERβ inhibits prostate cancer cell growth
in the presence of androgen-stimulated AR. (A) LNCaP-ERβ- cells retain
androgen responsiveness, as indicated by an increase in proliferation with R1881
treatment. (B) The presence of ERβ alone did not significantly alter proliferation
(c.f panel C), only with R1881 and 3β-adiol treatment was there any significant
change compared to vehicle (p = 0.006). (F) The inhibitory effect of R1881 and
3β-adiol combined treatment is mediated by the presence of ERβ.
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Figure 5.6: LNCaP-ERβ cell morphology did not change under treat-
ment conditions, suggesting that the differences in cell confluence detected by
the IncuCyteTM were due to inhibition of cell proliferation, rather than cytotox-
icity.
To investigate the mechanisms of these observed effects on cell growth at genomic
and transcriptomic levels it was necessary to determine the optimum duration of
hormone treatment for the LNCaP-ERβ cells, prior to conducting large-scale
RNA-seq and ChIP-seq experiments. Work previously published from the lab-
oratory suggested that 4 hours was the optimum duration of R1881 treatment
[Robinson et al., 2011], however the optimum duration of 3β-adiol treatment was
not clear from previously published literature.
LNCaP-ERβ+ cells were treated with 3β-adiol or vehicle for 1, 4 or 24 hours
prior to harvesting for ChIP-seq. Two of the validated ERβ antibodies (MC10
and CWK-F12), which are both monoclonal, were pooled in equal quantity to
be used for the immunoprecipitation. As these two antibodies bind to different
epitopes (Figure 2.1), we felt that this approach would increase the efficiency
of the IP by creating a ‘polyclonal-like’ effect. Average numbers of ERβ peaks
called in each condition are displayed in table 5.2. As the four-hour time point
generated both the greatest differential between vehicle and 3β-adiol conditions,
and the greatest number of peaks altogether, this was used for subsequent analysis
and experiments.
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Time (hrs)! Treatment! No. Peaks!
1! Vehicle! 15,132!
1! 3β-adiol! 15,057!
4! Vehicle! 16,182!
4! 3β-adiol! 18,899!
24! Vehicle! 16,216!
24! 3β-adiol! 17,600!
Table 5.2: Number of ERβ peaks called with 1, 4 or 24 hour 3β-adiol
treatments.
The distribution of ERβ binding sites across genomic features is shown in figure
5.7A. Genome-wide ERβ binding sites were subsequently overlapped with previ-
ously published AR and FOXA1 cistromes from LNCaP cells [Robinson et al.,
2011] (Figure 5.7B). Interestingly, this revealed 3,954 sites shared between ERβ
and AR, and 2,906 sites shared between ERβ, AR and FOXA1. This, to our
knowledge is the first genome-wide data in any cell- or tissue-context to suggest
that ERβ and AR share DNA-binding sites. This finding provided direct ev-
idence of nuclear receptor crosstalk at a genomic level, and an early indication
that ERβ may indeed be able to influence AR function in prostate cancer through
competition for DNA-binding sites. This in turn would begin to explain the ob-
served inhibition of cell proliferation in LNCaP-ERβ+ cells treated with R1881
and 3β-adiol (Figure 5.5B and F).
5.2.6 Ligand-activated ERβ alters the AR transcriptome
in prostate cancer
5.2.6.1 Experimental design
In order to further investigate the effects of ERβ on AR function a large com-
bined RNA-seq and ChIP-seq experiment was performed. LNCaP-ERβ cells were
cultured, treated and harvested simultaneously for each of the 4 replicates of
ChIP-seq and 4 of the RNA-seq replicates in order to obtain matched datasets.
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Figure 5.7: Analysis of ERβ binding following 4 hour treatment with
3β-adiol (A) Distribution of ERβ DNA binding sites across genomic features.
(B) Genome-wide ERβ binding in the 3β-adiol-treated LNCaP-ERβ+ cells was
overlapped with AR and FOXA1 cistromes generated in LNCaP cells [Robinson
et al., 2011]. This revealed 3,954 sites shared between ERβ and AR, and 2,906
sites shared between ERβ, AR and FOXA1.
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A further 2 replicates (to make a total of 6) were performed for RNA-seq. All
replicates were within 2 cell passages of the preceding replicate. Serum-starved
LNCaP-ERβ- cells and LNCaP-ERβ+ cells were treated with either vehicle, 1 nM
R1881, 10 nM 3β-adiol or both R1881 and 3β-adiol for 4 hours (Table 5.3). Dif-
ferential gene expression for each pair-wise comparison (total of 28 comparisons)
was generated in order that all control and test conditions could be contained
within a single experiment. This approach enabled detailed study of the effects
of each individual variable within the model.
Cell line! LNCaP-ERβ–! LNCaP-ERβ+!
!
!
Condition!
Vehicle! Vehicle!
R1881! R1881!
3β-adiol! 3β-adiol!
R1881 + 3β-adiol! R1881 + 3β-adiol!
Table 5.3: Experimental design for ERβ/AR crosstalk experiment.
Matched RNA-seq and ERβ ChIP-seq was performed according to these condi-
tions. By including all combinations of the conditions, it was possible to control
for the effects of each variable (i.e. each receptor +/- ligand) within a single
experiment.
5.2.6.2 RNA-sequencing - Key controls
In the absence of ERβ expression, LNCaP-ERβ- cells remain androgen-
responsive. In this positive control, we observed that treating LNCaP-ERβ-
cells with 1 nM R1881 resulted in significant changes in gene expression as com-
pared with vehicle treatment (115 genes, FDR <0.05). By way of validation,
many known AR target genes were observed in this group, for example KLK3,
HOXB13, KLK2, CAMKK2 and FKPB5 (Figure 5.8A and B).
In the absence of ERβ expression, 3β-adiol does not alter R1881-
mediated gene expression. There were no significant changes in gene ex-
pression (0 genes, FDR <0.05) when comparing R1881 alone versus R1881 and
115
5. Crosstalk between ERβ and AR
3β-adiol in LNCaP-ERβ- cells, indicating that 3β-adiol does not significantly
cross-react with AR in the presence of androgen (Figure 5.8C and D).
Unliganded ERβ only produces minor changes in R1881-mediated gene
expression. Thirty-five genes (FDR <0.05) were differentially expressed in
R1881-treated LNCaP-ERβ+ cells versus R1881-treated LNCaP-ERβ- cells (Fig-
ure 5.8E and F). This suggests that in this system ERβ may have some constitu-
tive activity, however major changes in gene expression are only observed when
ERβ is ligand-activated.
5.2.6.3 Ligand-activated ERβ downregulates AR target genes
Profound differences in gene expression were observed comparing R1881-treated
LNCaP-ERβ- cells versus LNCaP-ERβ+ cells treated with R1881 and 3β-adiol
(Figure 5.9). 1,312 genes were differentially expressed (FDR <0.05). This im-
portant result showed that ligand-activated ERβ, in androgen replete conditions
produces widespread and significant changes in gene expression in a prostate can-
cer cell line, reflecting the previously observed changes in cell proliferation (Figure
5.5B and F).
To further interrogate the effects of ligand-activated ERβ on AR-driven gene
expression, a set of 115 androgen-dependent genes was identified from the posi-
tive control (LNCaP-ERβ- with vehicle versus LNCaP-ERβ- with R1881)(Figure
5.8A). The effects of 3β-adiol-stimulated ERβ on the expression of genes within
this set were then determined (Figure 5.10A). Seventy percent of the 115 genes
upregulated by R1881 in LNCaP-ERβ- cells were subsequently downregulated in
the presence of ligand-activated ERβ, with an average 1.7-fold decrease in expres-
sion (p <0.0001). Interestingly, the expression of AR mRNA itself was seen to
decrease significantly (p = 0.002) in the presence of ligand-activated ERβ (Fig-
ure 5.10B), suggesting that the mechanism of this effect may be through direct
downregulation of AR expression by ERβ.
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Figure 5.8: Key controls in ERβ/AR crosstalk RNA-seq (A) LNCaP-
ERβ- cells remain androgen-responsive, with (B) 115 genes differentially regu-
lated (FDR <0.05) by R1881. (C, D) Without ERβ, 3β-adiol does not signifi-
cantly alter R1881-mediated gene expression. (E) Unliganded ERβ only produces
minor changes in R1881-mediated gene expression, with (F) 35 differentially ex-
pressed genes (FDR <0.05). Heatmaps show top 200 differentially expressed
genes.
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1312 genes, FDR <0.05"
LNCaP-ERβ+ "
R1881+3β-adiol"
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R 881"
Figure 5.9: Ligand-activated ERβ produces widespread change in gene
expression in R1881-tre ted prostate cancer cells. Introducing 3β-adiol-
stimulated ERβ into androgen-stimulated LNCaP cells resulted in significant dif-
ferential expression of 1,312 genes (FDR <0.05). Heatmap shows top 200 differ-
entially expressed genes.
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Figure 5.10: Ligand-activated ERβ downregulates AR-dependent genes.
(A) Of the 115 AR-dependent genes identified, 70% were significantly downreg-
ulated by ligand-activated ERβ. (B) Expression of AR mRNA was significantly
decreased by ERβ, suggesting that ERβ can directly suppress AR expression.
5.2.7 ERβ competes with AR for shared DNA-binding
sites to influence AR-dependent gene expression
Bioinformatic analysis of ChIP-seq, and integration with RNA-seq data by Dr. I.
Chernukhin, CRUK Cambridge Institute
Having demonstrated that ligand-stimulated ERβ downregulates AR-dependent
genes and decreases androgen-mediated cell proliferation, we wanted to determine
the genomic mechanisms by which ERβ and AR were influencing one another.
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Under experimental conditions matched to the RNA-seq experiment, ERβ and
AR ChIP-seq were performed to map the genome-wide DNA binding of these
receptors in the LNCaP-ERβ+ cell line model and determine the influence of the
hormone treatments (R1881 alone, 3β-adiol alone or both R1881 and 3β-adiol) on
their DNA-binding. As a control, ERβ ChIP-seq was also performed in LNCaP-
ERβ- cells. Importantly, there was a negligible number of ERβ peaks identified
in the LNCaP-ERβ- cells, further confirming the integrity of the experimental
model, this time at a genomic level (Table 5.4). Unfortunately the AR ChIPs
were unsuccessful, probably due to a failed batch of antibody, as further attempts
to use this antibody by ChIP-qPCR were also not successful (data not shown).
We are aware that other laboratories have simultaneously had similar difficulties
with failed batches of this particular AR antibody (Prof. W.D. Tilley, University
of Adelaide, personal communication).
In this cell line model, unliganded ERβ appears to have some constitutive binding
as 13,800 peaks were called in the vehicle-treated condition. Treatment with 3β-
adiol alone results in a strong increase in the number of peaks (17,327) and
motifs (21,748) identified. Interestingly, it appears that the addition of R1881 in
both 3β-adiol- and vehicle-treated conditions results in a decrease in the numbers
of ERβ peaks (14,190 and 10,643 respectively) and motifs (18,130 and 15,075
respectively)(Table 5.4). In all conditions, ERβ peaks were highly enriched for
consensus ERβ motifs (p < 0.001)(Figure 5.11).
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Figure 5.11: ERβ peaks are significantly enriched for the ERβ motif (p
<0.001).
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Sample! Number ERβ 
peaks!
Number 
ERβ Motifs!
Peaks with ERβ 
motif (%)!
LNCaP-ERβ- "
Veh"
3" -"
LNCaP-ERβ- "
3β-adiol"
3" -"
LNCaP-ERβ- "
R1881"
5" -"
LNCaP-ERβ- "
R1881+3β-adiol"
0" -"
LNCaP-ERβ+ "
Veh"
13800" 18844" 94"
LNCaP-ERβ+ "
3β-adiol"
17327" 21748" 90"
LNCaP-ERβ+ "
R1881"
10643" 15075" 96"
LNCaP-ERβ+ "
R1881+3β-adiol"
14190" 18130" 91"
Table 5.4: ERβ peaks and motifs called by ChIP-seq under the experi-
mental conditions tested. The absence of ERβ peaks called in LNCaP-ERβ-
cells confirms that ERβ is not expressed in the uninduced ERβ- condition. R1881
appears to decrease the number of ERβ peaks and motifs called in both vehicle
and 3β-adiol-stimulated conditions.
These differences in absolute numbers of peaks and motifs called were further re-
flected in the variability of signal intensities detected at ERβ binding sites. Tag
densities were measured in a +/- 2.5 kBp window, centred in the middle of peak
regions detected in each experimental condition (Figure 5.12A-D). With respect
to the peak intensities detected in each experimental condition, the pattern of
variability in intensity with hormonal treatment is consistent. The highest inten-
sity binding is in the 3β-adiol only treatment, followed by R1881 with 3β-adiol,
followed by vehicle and finally, R1881 alone resulted in the lowest signal intensity.
Taken together, these data suggest that that R1881-stimulated AR decreases ERβ
binding in both the presence and absence of 3β-adiol and furthermore, decreases
the signal intensity of conserved ERβ binding sites. This observation was partly
reflected in the RNA-seq data, where we observed that R1881 stimulation in the
absence of 3β-adiol resulted in differential expression of 94 genes (FDR <0.05)
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in LNCaP-ERβ+ cells (comparing LNCaP-ERβ+ with vehicle versus LNCaP-
ERβ+ with R1881)(Figure 5.13A). The same however was not true in the presence
of 3β-adiol (comparing LNCaP-ERβ+ with 3β-adiol versus LNCaP-ERβ+ with
R1881 and 3β-adiol), where no change in gene expression was detected (Figure
5.13B). The mechanism as to how R1881-stimulated AR represses ERβ bind-
ing in this model system is not presently clear. As the stably-transfected ERβ
transgene is not in its endogenous locus, these data would suggest that AR is
influencing ERβ mRNA or protein stability, rather than acting at the ESR2 gene
locus itself. Further study (in particular repeating the AR ChIP-seq intended as
part of this experiment) is required to understand the details of these particular
observations.
Distribution of DNA motifs across unique and shared binding sites
In view of two important factors; firstly, that LNCaP-ERβ+ cells treated with
both R1881 and 3β-adiol showed significant changes in proliferation and gene
expression and secondly, that the dual-hormone treatment is likely to be most
physiologically relevant to early-stage prostate cancer (i.e. androgen replete con-
ditions), further analyses focused on data obtained from LNCaP-ERβ+ cells
treated with both R1881 and 3β-adiol.
DNA-binding sites shared between ERβ, AR and FOXA1 were identified by
overlapping the ERβ cistrome from dual-hormone treated LNCaP-ERβ+ cells
with AR and FOXA1 binding sites obtained from R1881-stimulated LNCaP cells
[Robinson et al., 2011]. Under these treatment conditions, ∼14,200 ERβ binding
sites were identified, of which 3,480 were shared with AR (Figure 5.14A). Tag
densities measured within a +/- 2.5 kBp window (Figure 5.12) demonstrate the
precise co-localisation of the shared ERβ, AR and FOXA1 binding sites.
Motif analysis confirmed significant enrichment for ERβ, AR and FOXA1 consen-
sus motifs within these ERβ/AR shared binding sites (p <0.001)(Figure 5.14B).
FOXA1 is known to be an important nuclear receptor co-factor for AR [Robin-
son et al., 2011, 2014], so the presence of the motif in the shared binding sites
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Vehicle!
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LNCaP-ERβ+ R1881!
LNCaP-ERβ+ R1881/3β-adiol!
LNCaP-ERβ+ Vehicle!
LNCaP AR!
LNCaP FOXA1!
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Figure 5.12: ERβ ChIP-seq tag intensities, centred in the middle of peak
regions detected per experimental condition (A) vehicle; (B) 3β-adiol alone; (C)
R1881 alone; (D) R1881 and 3β-adiol. In both the presence and absence of 3β-
adiol, R1881 stimulation decreased the binding intensity of ERβ. ERβ binding
sites were overlapped with AR and FOXA1 sites from LNCaP cells, [Robinson
et al., 2011] revealing the precise co-localisation of ERβ/AR/FOXA1 binding at
these sites.
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Figure 5.13: AR-mediated changes in gene expression. (A) In LNCaP-
ERβ+ cells, R1881 results in altered expression of 94 genes (FDR <0.05), whereas
when ERβ is stimulated by 3β-adiol (B), no such response is seen. Thus, in the
presence of ERβ, R1881-stimulated AR only produces changes in gene expression
when ERβ is unliganded. Heatmaps show top 200 differentially expressed genes.
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was to be expected. Surprisingly however, the ERβ-unique binding sites were
also significantly enriched for FOXA1 motifs (p <0.001), suggesting that FOXA1
may serve as a co-factor to ERβ. To our knowledge, no association between ERβ
and FOXA1 has been described in the literature. Further study is necessary to
confirm a functional interaction between these factors.
To further understand the mechanisms governing the distribution of ERβ and
AR binding across the shared and unique sites, we determined the percentage of
AR-unique, ERβ/AR shared and ERβ-unique binding sites that contained ERβ
and/or AR motifs (Figure 5.14C). The distribution of ERβ and AR motifs under
peaks between the shared and unique sites indicates that the binding patterns
observed are sequence-driven, i.e. the proportion of AR peaks with AR motifs
was similar between the shared and AR-unique sites; the proportion of ERβ
peaks with ERβ motifs was similar between the shared and ERβ-unique sites but
the proportion of AR-unique sites with ERβ motifs was very low and vice versa.
Examples of ERβ and AR peaks called from shared and unique sites are shown in
figure 5.14D. The percentage of ERβ-unique binding regions containing FOXA1
motifs further suggests a role for this co-factor in the genomic function of ERβ
(Figure 5.14C).
Shared ERβ/AR binding sites are highly transcriptionally active
Integration of the ChIP-seq and RNA-seq data demonstrates that the 3,480 shared
binding sites are more transcriptionally active than ERβ-unique or AR-unique
binding sites (Figure 5.15). We used hierarchical clustering to rank expression of
androgen-regulated genes within 50 kb of identified DNA-binding sites. Treat-
ment with both R1881 and 3β-adiol results in an alternate pattern of gene ex-
pression from the shared binding sites as compared with either hormone alone,
or either ERβ- or AR-unique binding sites. This suggests that in the presence
of R1881-stimulated AR, ligand-activated ERβ reprograms androgen-dependent
gene expression, potentially by competing for these shared binding sites, or pos-
sibly by sequestration of available co-factors such as FOXA1. Further work is
required to understand these mechanisms in more detail.
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Figure 5.14: ChIP-seq reveals shared ERβ/AR binding sites. (A) ERβ
binding sites from LNCaP-ERβ+ cells treated with R1881 and 3β-adiol were
overlapped with AR binding sites from R1881-stimulated LNCaP [Robinson et al.,
2011], showing 3,480 shared binding sites. (B) Shared ERβ/AR binding sites were
significantly enriched (p <0.001) for AR, ERβ and FOXA1 motifs. Significant
enrichment for FOXA1 in ERβ-unique sites (p <0.001) suggests a co-factor role
for FOXA1 with respect to ERβ. (C) The percentage of AR-unique, ERβ/AR
shared and ERβ-unique binding sites containing ERβ, AR and FOXA1 motifs is
shown, suggesting that the distribution of ERβ/AR binding is sequence driven
with a potential role for FOXA1 in ERβ binding. (D) Examples of ERβ and
AR binding at shared and unique sites. DNase cluster data from UCSC genome
browser.
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5.3 Summary
On the basis of previously published studies suggesting that i) ERβ is a tu-
mour suppressor lost in malignant transformation of the prostate [Asgari and
Morakabati, 2011; Attia and Ederveen, 2012; Dey et al., 2014; Horvath et al.,
2001; Leav et al., 2001; Risbridger et al., 2007] and ii) ERβ and AR influence
each other through nuclear receptor crosstalk [Grubisha and DeFranco, 2013; Mi-
zokami et al., 2004; Rizza et al., 2014; Teng et al., 2014; Thelen et al., 2007;
Weng et al., 2013], a number of studies were undertaken to test the hypothesis
that ERβ modulates AR-driven prostate carcinogenesis. The aim of these stud-
ies was to investigate the relationship between ERβ and AR in both in vitro and
in vivo contexts and to explore whether a selective ERβ agonist could be used
therapeutically to modify early prostate cancer progression.
A large clinical dataset integrating gene expression data and copy number aberra-
tions was examined for correlation between ERβ expression and clinical outcome.
This revealed that greater ERβ expression was associated with improved BCR-
free survival. This association was observed to be independent of AR expression,
which did not vary across the prognostic groups. Interrogation of gene expression
data from two clinical studies of ADT showed that ERβ mRNA expression in-
creases following inhibition of AR signalling. This finding was confirmed in vitro
by silencing AR expression in wild-type LNCaP prostate cancer cells.
The inducible LNCaP-ERβ cell line model was used to investigate the effect of
sustaining ERβ signalling in early prostate cancer at phenotypic, transcriptomic
and genomic levels. This revealed that when stimulated by a selective agonist
(3β-adiol) in the presence of androgen-stimulated AR, ERβ decreases prostate
cancer cell proliferation by widespread alteration of AR-dependent gene expres-
sion. Mechanistically, this reprogramming appears to occur by competition for
key, highly transcriptionally active DNA-binding sites. A further possibility may
be that ERβ sequesters nuclear receptor co-factors such as FOXA1 to modulate
the activity of AR. These studies reveal for the first time two important find-
ings that will inform future work in the field. Firstly, genome-wide ERβ bind-
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ing in a prostate cancer context and secondly, genome-wide evidence of shared
ERβ/AR binding sites detected in any cell- or tissue-context. Taken together,
these findings suggest that activation of ERβ by a selective agonist in the early,
androgen-sensitive stages of prostate cancer may slow or even abrogate disease
progression.
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Chapter 6
Discussion
6.1 The clinical rationale for studying estrogen
biology in prostate cancer
Despite recent advances in all aspects of the clinical management of prostate can-
cer, ranging from improved imaging-guided diagnostics [Nelson et al., 2013], to
the introduction of robotic-assisted radical prostatectomy [Abbou et al., 2001] and
IMRT [Sheets et al., 2012] in primary treatment, men with prostate cancer remain
at high risk of relapse following primary therapy [Paller and Antonarakis, 2013].
For those men that relapse and go on to develop CRPC, this disease remains
incurable despite recent advances with the development of the AR-targeting ther-
apies Enzalutamide and Abiraterone (reviewed in [Lamb et al., 2013]). There is
therefore a clear need to further our understanding of the biology driving the
development and progression of prostate cancer in order that the natural history
of the disease can be modified early in its course to improve clinical outcomes.
Previous literature has established that estrogen, as well as androgen is essential
for the development of prostate cancer and that estrogen exposure is a significant
epidemiological risk factor for the disease (Section 1.3.1). A range of SERMs have
already been developed and are in regular clinical use for the treatment of breast
cancer. As these drugs are already approved for human use, they could be used to
treat prostate cancer as long as the preclinical and clinical trial data are support-
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ive. However, despite promising in vitro data showing a benefit to manipulating
estrogen signalling in prostate cancer cell lines, there is no definitive clinical trial
evidence proving that targeting estrogen receptor function can improve clinical
outcomes (Sections 1.3.3 and 1.3.4). There is therefore, a disconnection between
the in vitro and in vivo data, which requires explanation in order to further ad-
vance the field. The data presented in the current work suggests that both the
use of inadequately validated antibodies and insufficiently characterised cell line
models in previously published literature may have contributed to this position
and actively hindered progress in furthering the understanding of ERβ biology
in prostate cancer.
6.2 Validation of ERβ antibodies
Contradictions in expression profiles as determined by IHC and reported mech-
anisms of action and interactors as determined by antibody-based molecular bi-
ology methods have contributed to the uncertainty regarding the role of ERβ
in prostate cancer. The lack of clear consensus regarding tissue expression of
ERβ and correlation with clinico-pathological parameters such as Gleason grade
is particularly problematic [Asgari and Morakabati, 2011; Attia and Ederveen,
2012; Bouchal et al., 2011; Dey et al., 2014; Horvath et al., 2001; Leav et al.,
2001; Risbridger et al., 2007; Zellweger et al., 2013; Zhu et al., 2004].
The first aim of this study, therefore was to undertake a detailed assessment of
ERβ antibodies using a multi-modal approach in a robust experimental model.
This has demonstrated marked variation in the specificity of commonly used,
commercially available ERβ antibodies for accurate detection of ERβ by Western
blotting and the ChIP-based technique RIME. Arguably the most important
finding of this work has been to show that NCL-ER-BETA, a very commonly
used ERβ antibody was not specific to ERβ by either Western blotting or RIME
(Figures 3.3 and 3.4). Much of the confusion in the ERβ field may be attributable
to this antibody, which yields bands on a Western blot of appropriate size for ERβ,
but we have now shown to be a non-specific interaction (Figure 4.7).
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A further important finding has been to show clear experimental evidence of the
fact that a particular antibody can be specific in one experimental approach but
not another. The PPG5/10 antibody, which has been previously validated for
IHC [Wu et al., 2012] and demonstrated detection of ERβ by RIME, but not
Western blotting perfectly illustrates this. Our findings reassert the importance
of validating antibodies for individual experimental assays [Baker, 2015; Bordeaux
et al., 2010].
RIME was initially developed as a discovery tool to study the interacting pro-
teomes of transcription factors in an unbiased manner [Mohammed et al., 2013].
The advantage of using RIME in antibody validation arises from being able to
identify specific, named peptides purified by a particular antibody, rather than
relying on the presence of a protein band of approximate size on a Western blot,
or comparing tissue expression determined by IHC. Furthermore, RIME facili-
tates a head-to-head comparison of antibodies, to aid in the selection of which
antibody to use in subsequent biological experiments. The identification of known
ERβ interactors further validates the findings (Figure 3.5). HSP90 is a nuclear
receptor chaperone protein known to interact with both ERα and ERβ [Powell
et al., 2010]. Powell et al. showed (using the sc8974 antibody, which was specific
to ERβ by Western blotting) that HSP90 is essential for the formation of ERα/α
homodimers and ERα/β heterodimers. Ligand binding to the nuclear receptor
results in a conformational change and dissociation from the HSP90 complex,
leading to active transcription. The role of HSP90 with respect to the formation
of ERβ/β homodimers however, is less clear. Powell et al. [Powell et al., 2010]
suggest that whilst HSP90 is needed for estrogen-dependent ERβ/β transcrip-
tional activity, perturbation of the HSP90 complex would be minimally disrup-
tive to the formation of ERβ/β homodimers. Similarly, Schu¨lke et al. showed
that inhibiting HSP90 has little effect on ERβ activity, suggesting that ERα and
ERβ may operate independently of HSP90 [Schu¨lke et al., 2010]. DDX54 is a
regulator of nuclear receptor transcriptional activity, and has been shown to be
a co-repressor of ERβ transcription [Rajendran et al., 2003]. In the presence of
estradiol, DDX54 was shown to repress the transcriptional activity of ERβ by
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60-90% [Rajendran et al., 2003].
The antibody validation approach outlined in this work addresses the two previ-
ously mentioned, flawed assumptions made in previous antibody validation stud-
ies. Firstly, assessing an antibody by IHC relies upon a priori knowledge of the
tissue-specific expression profile of the factor of interest, against which the stain-
ing of the antibody undergoing assessment can be compared. If however, as in
the case of ERβ the tissue expression is not well-characterised or varies from one
study to another, then any comparison made has the potential to be mislead-
ing. This also holds true for Western blotting-based approaches using cell lines
‘known’ to express ERβ, as demonstrated in section 4.2. An alternative to using
RIME for antibody validation would be to use siRNA against the factor of inter-
est in a cell line thought to express said factor, to provide positive and negative
controls that can be tested by Western blotting and validated by RT-qPCR.
In conclusion, this antibody validation study facilitated an informed decision-
making process with respect to selection of reliable antibodies for use in subse-
quent biological experiments. ERβ antibodies CWK-F12 and MC10 were pre-
viously validated by other approaches [Choi et al., 2001; Wu et al., 2012], and
the results described here provide further confidence in their use for Western
blotting, IP-based methods and IHC (for CWK-F12). Given that ERβ has been
implicated as an important factor in breast, kidney, bladder, ovarian, colorectal,
endometrial and non-small cell lung malignancies [Ciucci et al., 2014; Dey et al.,
2013; Han et al., 2015; He et al., 2015; Hsu et al., 2013; Luo et al., 2015; Suzuki
et al., 2008; Yu et al., 2013], the impact of this antibody validation work is likely
to be wide-reaching.
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6.3 Establishing an experimental model to study
ERβ
6.3.1 Characterisation of existing prostate and breast can-
cer cell line models
This study has conclusively demonstrated that the low passage, genotyped prostate
and breast cancer cell lines characterised do not express detectable levels of ERβ
mRNA or protein. This multimodal approach has utilised four independent meth-
ods, two of which are antibody-dependent (Western blotting and RIME), and
two of which are not (RT-qPCR and PRM) to provide thorough validation of
the findings. It is particularly striking that LNCaP cells were not found to ex-
press ERβ, as this cell line model has been used extensively in previous studies
of ERβ, with a wide and variable range of conclusions regarding its function
drawn from the data. For example, Kim et al. showed that raloxifene, a se-
lective estrogen-receptor modulator (SERM) induced apoptosis in LNCaP cells
through activation of ERβ and induction of caspase-8 and -9 pathways [Kim
et al., 2002b]. This same growth-inhibitory effect of raloxifene has been observed
in other prostate cell lines thought to express ERβ (not included in the present
study) [Rossi et al., 2011], suggesting it is reproducible. Others have shown that
ERβ-mediated apoptosis in LNCaP cells may occur through the intrinsic path-
way and upregulation of FOXO3a [Dey et al., 2014], reinforcing the view that
ERβ has a predominantly growth-suppressive and pro-apoptotic role in prostate
cancer. In direct contrast however, ERβ has been directly implicated as an onco-
gene and driver of non-androgenic, AR-dependent gene transcription in LNCaP
cells [Yang et al., 2012]. In this study, the authors proposed that in castrate
conditions, estrogen-stimulated ERβ can drive AR activity by indirect binding
to AR with PELP1 acting as a linker protein. Whilst acknowledging the known
variability across strains of immortalised cell lines [Masters, 2000], the work pre-
sented in this chapter suggests that previously published studies of the role of
ERβ conducted in the most commonly used prostate cancer cell lines should be
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interpreted with caution.
This study and others have suggested that tissue expression of ERβ is greatest
in the basal epithelium of benign prostate glands (Figure 4.8A) [Horvath et al.,
2001; Leav et al., 2001]. Expression then declines with the development of Glea-
son 3 prostate adenocarcinoma (Figure 4.8B), an observation that underpins the
hypothesis that ERβ is predominantly tumour-suppressive. It is therefore log-
ical that immortalised prostate cancer cell lines, which have been derived from
metastatic tumour deposits originating from luminal epithelial cells will have lost
ERβ expression as part of the transformation from benign to malignant pheno-
type. The moderate expression of ERβ observed in high grade prostate cancer
(Figure 4.8D) may reflect increased expression of ERβ isoform 2, which has been
reported in advanced and castrate-resistant disease [Dey et al., 2012; Leung et al.,
2010]. However, our IHC data are not able to provide a definitive answer to this
question as the CWK-F12 antibody recognises the N-terminal region common to
all ERβ isoforms. Clearly, this is an important area for further investigation.
6.3.2 Development and validation of the LNCaP-ERβ cell
line
In order to better understand the relationship between ERβ and AR and their
respective roles in suppression or promotion of cancer progression it was there-
fore apparent that a new cell line model was required. In view of a number of
studies implicating direct interplay and crosstalk between these receptors [Gru-
bisha and DeFranco, 2013; Rizza et al., 2014; Yang et al., 2012] a system with
inducible ERβ expression was derived to enable detailed study of the effects of
each receptor upon the other. This cell line was developed in a lengthy, two-step
process with introduction of the tetracycline-repressor, followed by clonal selec-
tion and assessment of the inducible ‘switch’ by luciferase assay. The clone with
the lowest signal from the ‘dox-off’ condition was then selected for subsequent
introduction of the ERβ plasmid. The multimodal characterisation of the result-
ing LNCaP-ERβ model comprehensively demonstrates expression of ERβ in the
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‘dox-on’ condition and importantly, absence of ERβ expression in the ‘dox-off’
condition. This process ensured a clean model system, with no contamination of
experimental controls by leaky ERβ expression. Morphologically the cells behave
like parental LNCaP cells and have maintained expression of key factors such as
FOXA1 and AR, which is important when considering the translational relevance
of any data generated from this model system [Robinson et al., 2014].
6.3.3 Exploring the ERβ protein interactome in LNCaP-
ERβ cells
The ERβ protein interactome is not well characterised, particularly in the context
of prostate cancer. The RIME data presented permit a preliminary investigation
into protein networks that may interact with ERβ in prostate cancer. Further-
more, the identification of 4 proteins known to interact with ERβ provides ad-
ditional verification of the validity of the LNCaP-ERβ cell line model (Figure
4.1).
The known interaction between HSP90 and ERβ [Powell et al., 2010; Schu¨lke
et al., 2010] has previously been discussed (Section 6.2). TRIM24 (TIF1α) is a
transcriptional co-activator, which is known to interact with a number of nuclear
receptors, including ERβ [Thenot et al., 1999]. Thenot et al. (1999) showed that
in the presence of estrogen TRIM24 was shown to interact with ERα bound to
ERE, whereas in the absence of hormone, TRIM24 interacted preferentially with
ERβ independently of the ERE, suggesting differing roles for the co-factor and two
receptors under differing hormonal contexts. NRIP1 (RIP140) is a co-regulator
of transcriptional activation by nuclear receptors such as glucocorticoid receptor
(GR) [Windahl et al., 1999], mineralocorticoid receptor (MR) [Hellal-Levy et al.,
2000] and ERα [Cavailles et al., 1995]. In MCF-7 cells stably expressing ERβ,
NRIP1 has been shown to be part of a network of proteins interacting with ERβ,
which also includes PELP1 [Nassa et al., 2011]. Furthermore, ERβ and NRIP1
have been shown to share approximately 9000 DNA binding sites in MCF-7-ERβ
cells, with many of the shared sites relating to apoptosis, growth suppression and
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metabolic factors such as fatty acid metabolism, inflammation and regulation of
NFκB for example. Interestingly, the authors describe an ERβ/NRIP1-related
gene signature, which is predictive of better outcome in breast cancer [Madak-
Erdogan et al., 2013]. HMGB1 is a chromatin regulatory factor, which has been
shown to be downregulated by ligand-activated ERβ [Dey et al., 2012]. Down-
regulation of HMGB1 has been shown to contribute towards apoptosis in LNCaP
cells [Tang et al., 2010] and it is known to interact with the other nuclear steroid
hormone receptors AR, PR and GR [Boonyaratanakornkit et al., 1998].
A number of proteins identified in the RIME data are not currently known to
interact with ERβ, but are known to interact with other nuclear steroid hormone
receptors. For example, FKBP5 is part of the HSP90 chaperone complex respon-
sible for trafficking AR [Schu¨lke et al., 2010] and ERα [Nair et al., 1996] from
the cytoplasm into the cell nucleus upon ligand activation. Another co-chaperone
protein, FKBP4 is known to participate in the HSP90 complex and interact with
GR, ERα, MR, PR and AR [Nair et al., 1996; Schu¨lke et al., 2010; Taipale et al.,
2014]. HOXB13 is involved in embryological development of the prostate [Eeles
et al., 2013] and has been shown recently to interact with AR in the earliest stages
of malignant transformation, acting with FOXA1 to reprogram the AR cistrome
to a cancer-associated phenotype [Pomerantz et al., 2015]. Furthermore, a rare
variant of HOXB13 has been shown to significantly increase prostate cancer risk
and has been found in families with multiple cases of prostate cancer [Eeles et al.,
2013].
Signal transducer and activator of transcription (STAT) 3 is an important tran-
scriptional activator that mediates cells’ responses to interleukins and other growth
factors. It is known to interact with nuclear receptors GR [Zhang et al., 1997],
ERα [Wang et al., 2001], PR [Proietti et al., 2011] and AR [Matsuda et al., 2001].
Inhibition of STAT3 in a prostate cell line (DU145) xenograft model reduced tu-
mour growth, cell viability and invasion by induction of caspase-dependent and
-independent apoptosis [Canesin et al., 2016]. STAT3 is also known to inter-
act with a number of established ERβ interactors; namely TWIST1 [Grossmann
et al., 2015] and RUNX2 [Fan et al., 2007]. These markers of EMT are thought
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to be downregulated by ERβ. As ERβ expression falls with the development of
cancer, expression of TWIST1 and RUNX1 increase leading to activation of the
EMT program and increased propensity to metastatic progression [Dey et al.,
2012].
These data provide the opportunity to begin building up a putative network of
ERβ interacting proteins. Further work would be required to prove definitive
physical interactions between these proteins and understand the functional con-
sequences and interrelationships of the component proteins within the network.
The LNCaP-ERβ cell line model developed in this work has been shown to be
a valid in vitro preclinical model system for testing the overall study hypothesis
that ERβ modulates processes involved in prostate carcinogenesis.
6.4 Genomic crosstalk between ERβ and AR
As discussed throughout this thesis, there has been confusion in the published
literature regarding the predominant role of ERβ in prostate, and other cancer
types. The present work clearly demonstrates that much of this confusion has
arisen as a consequence of using poorly validated reagents and inadequately char-
acterised cell line models. Having developed a ‘toolbox’ of validated reagents and
a fully characterised cell line model, the original study hypothesis could then be
tested in a robust manner, with the principle aim of further understanding the
relationship between ERβ and AR in prostate cancer development.
6.4.1 Findings from clinical data
The clinical rationale for investigating ERβ was established afresh by demon-
strating variability in ERβ expression across prognostic groups generated from
clinical material [Ross-Adams et al., 2015], which clearly showed that greater
ERβ expression is associated with improved prognosis (in terms of BCR-free sur-
vival). This finding is in keeping with most of the previous literature, which
suggests that ERβ is a tumour-suppressor in prostate cancer. Secondly, by show-
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ing an increase in ERβ expression following silencing of AR activity by ADT,
[Rajan et al., 2014; Shaw et al., 2016] we gain initial insight into the relationship
between ERβ and AR. These data indicate that AR represses ERβ expression,
suggesting that as AR expression increases during malignant transformation of
the prostate, there is a resulting decrease in ERβ expression and subsequent loss
of its tumour-suppressive effect. This would explain the previously observed pat-
tern of greater ERβ expression in benign versus malignant tissues [Asgari and
Morakabati, 2011; Bonkhoff et al., 1999; Dey et al., 2014; Horvath et al., 2001;
Leav et al., 2001].
6.4.2 Revealing the genomic activity of ERβ in prostate
cancer
There is however, a paucity of data on the detailed mechanisms by which ERβ acts
in the prostate, particularly at a genomic level. In the present study, genome-
wide DNA binding of ERβ in a prostate cancer context has been successfully
demonstrated for the first time. Furthermore, to our knowledge this is the first
genome-wide study in any context to show that ERβ and AR compete for DNA-
binding sites, resulting in widespread changes in gene expression and inhibition
of cell proliferation (Figure 6.1).
In the nuclear receptor field, it is becoming increasingly apparent that crosstalk
between different receptors is a biologically and clinically important phenomenon
that needs to be accounted for in future studies and clinical trials [Arora et al.,
2013; Mohammed et al., 2015; Rizza et al., 2014]. From the data presented here, it
was very interesting to note that ERβ only exerts its effects on proliferation, gene
expression and DNA-binding when it is ligand-bound in the presence of androgen-
activated AR. This mirrors exactly previously published work regarding the effect
of PR on ERα-dependent breast cancer, whereby PR is anti-proliferative when
bound by its natural ligand in the presence of estrogen-stimulated ERα [Mo-
hammed et al., 2015]. It is, however important to ensure that the effects of dual-
hormone stimulation observed in this work are not the consequence of overloading
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Figure 6.1: Possible models of competitive antagonism between ERβ
and AR. (A) Under androgen-stimulated conditions, AR dimerises and binds to
DNA response elements to activate AR-dependent transcription. The presence
of ligand-activated ERβ is likely to perturb this mechanism by one of two ways.
Either ERβ homodimers displace AR from the chromatin (B) or ERβ and AR
co-bind at shared binding sites (C). A further, although less probable mechanism
is that ERβ/AR heterodimers form and bind to shared sites, with resulting inhi-
bition of AR-dependent transcription (D). Further study is required to determine
these mechanisms in detail. AR, androgen receptor; DHT, dihydrotestosterone;
ERβ, estrogen receptor β.
the model system with active nuclear receptors, such that pro-proliferative doses
of ligands become anti-proliferative or vice versa; a phenomenon that has been
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previously described in prostate cancer xenograft models [Chen et al., 2004]. Re-
peating the LNCaP-ERβ cell line studies presented in Chapter 5 with reducing
doses of R1881 and 3β-adiol would address this concern.
Our findings support the view that ERβ is tumour-suppressive in prostate cancer
and that targeting it with an agonist may be a viable way of modifying progression
of the disease early in its natural history. The data presented in this work suggest
that ERβ and AR reciprocally inhibit one another. The exact mechanistic details
of this remain unclear, however competition for shared DNA-binding sites and
key co-transcription factors such as FOXA1 are likely to be important factors.
Further studies are required to test and validate these findings.
Two recently published studies [Gehrig et al., 2017; Wu et al., 2017] confirm
a number of our findings. Wu et al. (2017) showed that agonist-stimulated
ERβ down-regulates AR signalling through increased expression of an AR co-
repressor complex (DACH1/2), and upregulates expression of the tumour sup-
pressor PTEN. Secondly, Gehrig et al. (2017) showed that AR represses ERβ
expression, and activation of ERβ with a selective agonist decreases AR expres-
sion leading to decreased cell survival. Interestingly, these findings were generated
from androgen-resistant cell lines representative of CRPC, which is in contrast
to our own data which suggest that targeting ERβ is only effective in androgen-
replete conditions. Clearly, further study is required, as understanding the details
of this biology will have implications for how and and when an ERβ agonist could
be used clinically.
6.5 Future directions
Experimental validation
With the assistance of collaborators Dr. Luke Selth and Prof. Wayne Tilley
(University of Adelaide, Australia) a number of further experiments are planned
to further test the study hypothesis and validate the data presented in this work.
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1. AR ChIP-seq in LNCaP-ERβ cells. As discussed in section 5.2.7,
our original intention was to perform both ERβ and AR ChIP-seq in the
LNCaP-ERβ cell line under androgen-, estrogen- and dual-hormone-treated
conditions in order to demonstrate reciprocal changes in the DNA-binding
patterns of each factor as influenced by the other. Due to the scale of this
experiment, it was not possible to repeat this within the available timeframe
after failure of the AR antibody. This is a key experiment, which should
reveal further mechanistic insight into the relationship between ERβ and
AR at a genomic level.
2. ERβ and AR RIME in LNCaP-ERβ cells. In order to establish
whether ERβ and AR compete for key co-factors such as FOXA1 under
the various hormone treatments, quantitative RIME under matched exper-
imental conditions to the RNA- and ChIP-seq experiments will reveal and
quantify the protein interactome of each nuclear receptor. This will estab-
lish whether ligand activation of each receptor sequesters available co-factors
to alter the genomic activity of the other.
3. Treatment of ex vivo prostate tumours with an ERβ agonist, with
or without AR inhibition. The aim of this experiment is to validate the
findings generated from the LNCaP-ERβ cell line in an in vivo context
and provide data from a more clinically-relevant experimental model. The
results of this experiment would provide a key link from the in vitro to an
in vivo context, and potentially provide the basis for a clinical trial of an
ERβ-specific agonist in prostate cancer.
Therapeutic output
If these validations are successful in confirming the findings presented in this the-
sis, then there will be a clear rationale for a clinical trial of an ERβ agonist in men
with prostate cancer. These data suggest that activated ERβ inhibits cell pro-
liferation and alters AR-dependent gene expression in the presence of androgen-
activated AR. It would therefore seem logical that an ERβ agonist would be most
useful in the early, androgen-sensitive stage of prostate cancer. An ERβ agonist
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could foreseeably be administered to men with intermediate risk disease on ac-
tive surveillance (Section 1.1), with the intention that this would slow or prevent
further progression of the disease by modulating the activity of oncogenic AR in
an indirect manner to alter the natural history of the disease. Alternatively, men
with high risk or locally advanced disease who are commenced on ADT could
receive an ERβ agonist concurrently to further suppress the disease and reduce
the inevitable selection pressure towards CRPC exerted by conventional ADT
alone [Claessens et al., 2014; Scher et al., 2004]. An ERβ agonist may have an
additional anti-inflammatory effect, which could also contribute towards reducing
disease progression (Section 1.5.1) [Warner et al., 2017].
6.6 Conclusions
The work presented in this thesis has demonstrated that much of the confusion
in the existing literature regarding the role of ERβ is likely to be the result of
utilisation of inadequately validated antibodies. Using a robust cell line model
with inducible ERβ expression, two ERβ antibodies have been validated by mul-
tiple experimental methods for use in Western blotting, immunoprecipitation and
IHC.
Using these validated antibodies and additional antibody-indepent methods, mul-
tiple cell line models previously used to study ERβ have been shown to lack
its expression. This casts doubt on many studies previously published on ERβ
biology. An androgen-sensitive prostate cancer cell line with inducible ERβ ex-
pression was developed and validated by multiple experimental techniques. A
putative network of ERβ-interacting proteins has been revealed, providing op-
portunities for further study and validation of the findings in a prostate cancer
context. This cell line model will be a vital resource for ongoing studies of the
role of ERβ in prostate cancer.
In clinical samples, ERβ appears to be down-regulated by AR. This may result
from increased expression of AR known to occur in malignant transformation
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of prostate epithelium. In cases where ERβ expression is maintained, there is
an associated improvement in BCR-free survival. In vitro studies demonstrated
that ligand-activated ERβ decreases cell proliferation and down-regulates AR-
dependent gene expression through competition for transcriptionally active bind-
ing sites shared by ERβ and AR. These studies have demonstrated both genome-
wide ERβ binding sites in a prostate cancer context and ERβ/AR cross-talk
mediated by competition for shared binding sites for the first time. The data
presented in this thesis suggest that in future, it may be possible to administer
an ERβ agonist to men with prostate cancer to slow or abrogate progression of
their disease.
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Abstract
Prostate cancer is the commonest, non-cutaneous cancer in men. At present, there is no cure
for the advanced, castration-resistant form of the disease. Estrogen has been shown to be
important in prostate carcinogenesis, with evidence resulting from epidemiological, cancer
cell line, human tissue and animal studies. The prostate expresses both estrogen receptor
alpha (ERA) and estrogen receptor beta (ERB). Most evidence suggests that ERAmediates the
harmful effects of estrogen in the prostate, whereas ERB is tumour suppressive, but trials of
ERB-selective agents have not translated into improved clinical outcomes. The role of ERB in
the prostate remains unclear and there is increasing evidence that isoforms of ERB may be
oncogenic. Detailed study of ERB and ERB isoforms in the prostate is required to establish
their cell-specific roles, in order to determine if therapies can be directed towards
ERB-dependent pathways. In this review, we summarise evidence on the role of ERB in
prostate cancer and highlight areas for future research.
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Introduction
Prostate cancer is the commonest, non-cutaneous cancer in
men, affecting 214 per 1000 Europeanmen. It is the second
commonest cause of cancer death, accounting for 15% of
all male cancers in developed countries (Heidenreich et al.
2011, Mottet et al. 2011). Ever since the landmark research
of Huggins and Hodges (Huggins 1943, Huggins & Hodges
1972) demonstrating the importance of steroid hormones
in the development and treatment of prostate cancer, there
has been interest in the effects of estrogen on the prostate
gland. Initially, hormone treatment for prostate cancer
involved manipulation of systemic hormone levels with
exogenous estrogen therapy (in the form of high-dose
diethylstilbestrol) to suppress androgen production
indirectly via the hypothalamo–pituitary–gonadal axis
(Huggins & Hodges 1972). However, the unacceptably
high rates of cardiovascular side effects associated with
systemic estrogen therapy, coupled with the advent of
alternative treatment options, resulted in reduced use of
this therapy (Morales & Pujari 1975). Consequently, for
a period of time, interest in understanding the effects
of estrogen in the prostate also declined. Hormonal
suppression of prostate cancer is now primarily
achieved with androgen deprivation therapy (ADT) invol-
ving synthetic leutinising-hormone-releasing-hormone
(LHRH) analogues, which suppress androgen production
via negative feedback inhibition of the hypothalamic–
pituitary–gonadal axis (Heidenreich et al. 2011). Although
most prostate tumours initially respondwell to ADT, after a
period of time prostate cancer inevitably ceases to respond
to androgen deprivation. Disease progression with ADT is
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termed castration-resistant prostate cancer (CRPC) (Scher
et al. 2004), and is characterised by altered androgen
receptor (AR) signalling. Possible mechanisms for this
include amplification (Bubendorf et al. 1999) or mutation
of the AR gene, stabilisation of AR protein (Holzbeierlein
et al. 2004), altered expression of AR-coregulators (Chmelar
et al. 2007), generation of constitutively active AR splice
variants (Dehm et al. 2008, Hu et al. 2012) and increased
intratumoural androgen biosynthesis (Cai & Balk 2011,
Ishizaki et al. 2013), all of which contribute to the
maintenance of AR-dependent transcription in a castrate
environment (Knudsen & Penning 2010). Genome-wide
mapping of AR DNA-binding has shown that in CRPC AR
binds to new sites on the DNA, resulting in an alternative
transcriptional programme to that seen in primary disease
(Sharma et al. 2013). CRPC carries a poor prognosis and a
median survival of 18 months from diagnosis (Wu et al.
2007). New generation chemotherapeutics agents target-
ing AR signalling such as abiraterone and enzalutamide
have led to modest improvement in prostate cancer
survival, but they are not curative (Attard et al. 2011,
Lamb et al. 2013).
In recent years, with advances in the understanding
of AR function in CRPC and the cross-talk that
occurs between AR and estrogen receptor alpha (ERA) in
prostate cancer (Grubisha & Defranco 2013) and specific
subtypes of breast cancer (Robinson et al. 2011), there
has been renewed interest in understanding ER biology
in the prostate and its role in prostate cancer.
Further interest has arisen as a result of recent phase 2
clinic trial evidence supporting the use of transdermal
estrogen therapy in prostate cancer, which avoids
first-pass liver metabolism and has an improved side-effect
profile over both parenteral estrogens and LHRH
analogues (Langley et al. 2013). It is now known that
the prostate gland expresses both ERA and estrogen
receptor beta (ERB) (Horvath et al. 2001, Celhay et al.
2010). ERB is expressed in a wide range of reproductive and
non-reproductive tissues including the CNS, cardio-
vascular system, gastrointestinal tract, urogenital tract
(male and female) and skeleton (Bottner et al. 2014). The
physiological role of ERB in each of these tissues has not
been fully elucidated, but it has been implicated in the
regulation of glucose homeostasis and insulin signalling
and may also modulate immunologically mediated
inflammatory pathways (Harris et al. 2003, Foryst-Ludwig
et al. 2008). In addition, ERB is considered a negative
regulator of ERA, acting to modulate transcriptional
responses to estrogen in a tissue- and cell-context
dependent manner (Bottner et al. 2014).
The traditional paradigm regarding the roles of the
two ERs in the prostate is that ERB is predominantly
protective, being anti-carcinogenic and pro-apoptotic
(Chang & Prins 1999, Horvath et al. 2001, Zhu et al.
2004, Ellem & Risbridger 2007, McPherson et al. 2010,
Muthusamy et al. 2011, Nakajima et al. 2011, Attia &
Ederveen 2012), whereas ERA is oncogenic and promotes
cell proliferation and survival (Ellem & Risbridger 2007,
Risbridger et al. 2007, McPherson et al. 2008, Bonkhoff &
Berges 2009, Celhay et al. 2010, Attia & Ederveen 2012).
This view is based on a range of observations including
epidemiological and in vivo studies, preclinical drug trials
and expression profiles of the two ERs in human prostate
cancer. However, much of the published data regarding
the role and function of ERB appear to be conflicting, with
studies conducted in cancer cell lines (McPherson et al.
2010, Dey et al. 2012, Yang et al. 2012), rodent models
(Ricke et al. 2008, Attia & Ederveen 2012) or human tissues
(Horvath et al. 2001, Celhay et al. 2010, Leung et al. 2010,
Hussain et al. 2012) generating apparently contradictory
results. Thus the precise actions of ERB in the prostate
remain to be completely elucidated (Shaaban et al. 2003,
Risbridger et al. 2007, Zhao et al. 2007, Celhay et al. 2010,
Nelles et al. 2011, Dey et al. 2012, Yang et al. 2012). In this
article, we review recent research in the area of ERB
biology, with particular attention to its relevance in
clinical aspects of human prostate cancer, and highlight
areas for future research.
Evidence for the role of estrogen in prostate cancer:
epidemiological
It is well established that European men have a lower risk
of developing prostate cancer than African-American
men, and that for Japanese men the lifetime risk of
developing prostate cancer is lower still (de Jong et al.
1991, Ross et al. 1992, Ellem & Risbridger 2007). Two
interesting observations are noteworthy in this respect.
First, there are no significant differences in levels of
circulating testosterone between these three ethnic groups
(Ross et al. 1992), whereas levels of serum estrogens are
higher in black men as compared with Caucasian men
(Rohrmann et al. 2007, Abd Elmageed et al. 2013).
However, a direct correlation between serum estrogen
levels and prostate cancer risk has not been demonstrated
(Yao et al. 2011, Bosland 2013). Secondly, the age of peak
prostate cancer incidence occurs at a time when serum
testosterone levels are in decline, but estrogen levels
remain constant (Vermeulen et al. 2002). This has lead to
the hypothesis that it is the ratio of serum estrogen to
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testosterone, rather than the absolute values of each,
which gives rise to the observed differences in prostate
cancer risk between the various ethnic groups (Ellem &
Risbridger 2007, Bosland 2013). However, recent techno-
logical advances, which now permit more accurate
measurement of both ultra-low and intra-tissue hormone
levels, mean that a contemporary reassessment of this
subject is needed (Barth et al. 2010, Hickey & Norman
2010, Stener-Victorin et al. 2010). Determining the actual
levels of estrogen and androgen metabolites in the
prostate will be essential for understanding ERA, ERB and
AR behaviour. Racial differences in levels of prostatic ERB
expression as measured by immunohistochemistry have
been demonstrated by Abd Elmageed et al. (2013) who
showed that the frequency of ERB immunostaining in
prostate tumours was significantly higher in black men
than in Caucasian men, which in turn, correlated with
poorer clinical outcome.
Estrogen-related prostate cancer risk has been linked
to dietary factors (Hori et al. 2011). The traditional
Japanese diet contains high levels of dietary phytoestro-
gens, which have been shown in prostate cancer cell lines
to upregulate ERB activity resulting in decreased
expression of AR (Thelen et al. 2005, 2007, Stettner et al.
2007) and induction of G1-cell cycle block (Shen et al.
2000). In rat models, phytoestrogens can induce prostate
epithelial cell apoptosis (Attia & Ederveen 2012), thereby
demonstrating protective effects against prostate cancer.
Phytoestrogens, along with other dietary estrogens such as
lignans, flavonoids and lipoflavinoid are known to have
up to 30-fold greater affinity for ERB than ERA, and are
thought to promote the beneficial, protective effects of
estrogen in the prostate (Kuiper et al. 1998, Ellem &
Risbridger 2007, Thelen et al. 2014). A large population-
based case–control study from Sweden demonstrated a
reduced incidence of prostate cancer in those with a diet
rich in phytoestrogens (Hedelin et al. 2006). Incidence of
prostate cancer in Japan has been rising since the 1940s,
coinciding with increased ‘westernisation’ of the Japanese
diet. Specifically, it has been proposed that the 20-fold
increase in the consumption of milk and animal fat, both
of which contain estrogens with a high affinity for ERA
(mediating the adverse effects of estrogen) may explain
some of the recent rise in prostate cancer incidence among
Japanese men (Ganmaa et al. 2003, Carruba 2007). There
are, however, conflicting results in the literature regarding
the effects of phytoestrogens in prostate cancer, as
genistein (a highly ERB-specific isoflavone (Jiang et al.
2013)) has been shown in a study of prostate cancer
xenograft-bearing mice to promote the development of
metastatic disease progression in an ERB-dependent
manner (Nakamura et al. 2013) (discussed further in
section ‘Evidence for the role of estrogen in prostate
cancer: drug trials’).
Evidence for the role of estrogen in prostate cancer:
animal studies
Some of the most compelling evidence for the importance
of estrogen in prostate carcinogenesis comes from a series of
animal studies (Ricke et al. 2008) (Fig. 1). Ricke et al.
demonstrated in mice that androgen, estrogen, aromatase
and ERA are all required for prostate carcinogenesis.
Aromatase is a highly substrate-specific cytochrome p450
enzyme, found in the membrane of the endoplasmic
reticulum, which has the unique function in vertebrates of
being able to convert androgens to estrogens (Ghosh et al.
2009). In normal prostate, aromatase is expressed in the
stromal cells and is responsible for local paracrine conver-
sion of androgen to estrogen (Risbridger et al. 2007).
The necessity for estrogen in prostate carcinogenesis
was demonstrated in experiments where either androgen
alone, or androgen and estrogen were administered to
aromatase knockout (ArKO) mice (Ricke et al. 2008). ArKO
mice given androgen and estrogen developed prostatic
intraepithelial neoplasia (PIN – a premalignant histo-
logical phenotype which, especially when high grade or
multifocal, is a recognised risk factor for the development
of invasive prostate cancer (Nelson et al. 2003, Merrimen
et al. 2009)), whereas ArKO mice given androgen alone
had no such change (Ricke et al. 2008). From this, the
authors concluded that local production of estrogen
within the prostate, facilitated by aromatase-mediated
conversion of androgen to estrogen, was likely to be
Mouse genetic
background
Hormonal conditions Prostatic pathological
phenotype
ArKO
mouse
A
Androgen No PIN
Androgen
+ estrogen PIN
aERKO
mouse
bERKO
mouse
B Androgen
+ estrogen No PIN
Androgen
+ estrogen PIN
Figure 1
Summary of animal studies conducted by Ricke et al. (2008), demonstrat-
ing: (A) in order for prostate intraepithelial neoplasia (PIN) to arise it is
necessary for androgen, estrogen and functional aromatase all to be
present; (B) this is an ERA-mediated process, which is suppressed by ERB.
ArKO, aromatase knockout; aERKO, ERA knockout; bERKO, ERB knockout.
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a significant factor in prostate carcinogenesis. Epithelial
expression of aromatase is upregulated in prostate cancer
(Ellem et al. 2004, Celhay et al. 2010), a process that is
driven by gene promoters (I.3, I.4 and PII) responsive to
inflammatory cytokines (Santen et al. 1997, Zhao et al.
1997, Shozu et al. 2000). The implication of this is twofold;
first, increased local production of estrogens with resulting
carcinogenesis and, secondly, the establishment of a
‘positive feedback loop’ between aromatase, estrogen and
tissue inflammation (Ellem & Risbridger 2007). Indeed,
high expression levels of aromatase and aromatase gene
polymorphisms in early onset primary human prostate
cancer have been found to correlate with decreased time to
disease relapse, further underlining its importance in
prostate carcinogenesis (Cussenot et al. 2007, Celhay
et al. 2010).
In order to determine which of the ERs is responsible
for mediating adverse effects of estrogen, Ricke et al. (2008)
administered testosterone and estrogen to ERB knockout
(bERKO) or ERA knockout (aERKO) mice. There was no
difference between wild type (WT) and bERKO mice
receiving hormone treatment, whereas aERKO mice did
not develop PIN, suggesting that ERA mediated this
particular adverse effect of estrogen in the prostate (Ricke
et al. 2008). Similar studies in intact rats demonstrated that
testosterone alone is insufficient for the development of
PIN; it was only with the addition of the selective ERA
agonist, ERA-45, that PIN developed (ERA-45 is reported to
have a 286-fold greater affinity for ERA than ERB (Attia &
Ederveen 2012)). However, with the administration of
testosterone, ERA-45 and an ERB-selective agonist (ERB-
26), the onset of PINwas prevented (Attia&Ederveen2012),
demonstrating the differential function of the two ERs in
prostate carcinogenesis. These findings must be interpreted
with some caution due to the ongoing debate in the
field regarding the phenotypic variability and validity of the
bERKOmousemodels used in previous studies (Harris 2007).
Evidence for the role of estrogen in prostate cancer:
drug trials
ERs are attractive targets for prostate cancer treatment as
therapeutic agents are already in existence and are widely
used in hormone-dependent breast cancer (Lumachi et al.
2011). Raloxifene, a selective ER modulator (SERM), has
been shown to induce cellular apoptosis and nuclear
fragmentation in both androgen-sensitive and androgen-
independent prostate cancer cell lines through activation
of ERB, suppression of ERA and subsequent induction of the
caspase-8 and -9 pathways (Kim et al. 2002a,b, Rossi et al.
2011). Studies of selective ERB agonists on prostate cancer
cell lines have also been encouraging. Several investigators
have demonstrated that selective ERB agonists will induce
cystic atrophy in basal cells of the prostatic epithelium
(McPherson et al. 2010, Hussain et al. 2012). These basal
cells do not express AR (Ruizeveld de Winter et al. 1991),
and therefore, are unaffected by conventional ADT. Thus,
once ADT is withdrawn, the prostatic epithelium is able to
regenerate from this basal cell population. Administration
of an ERB agonist, however, perturbs this regenerative
process resulting in cellular apoptosis via the extrinsic
pathway, mediated by tumour necrosis factor a (TNFA).
This, importantly, is an androgen-independent process
and may therefore be relevant to the treatment of CRPC
(McPherson et al. 2010, Hussain et al. 2012). Recent
research has shown that ERB-mediated cellular apoptosis
may also occur through the intrinsic pathway, via
upregulation of the Forkhead protein, FOXO3a, which
itself is regulated by PTEN. Deletion mutations of PTEN
result in inhibition of the apoptotic mechanism of FoxO3a,
providing a possible ERB-mediated mechanism by which
PTEN mutations in prostate cancer contribute to cancer
growth (Dey et al. 2013b).
In vitro studies of the effects of dietary phytoestrogens
on prostate cancer cell lines have shown conflicting
results. On the one hand it has been shown that
administration of ERB-selective phytoestrogens in CRPC
will revert cancer cells to a less malignant phenotype
(Wuttke et al. 2002, Messina 2010, Andres et al. 2011,
Reiter et al. 2011). This may be due to a number of
mechanisms. It is known that mutated forms of AR are
upregulated in CRPC allowing AR to continue driving
prostate cancer growth and progression in the absence of
androgen (Scher et al. 2004, Waltering et al. 2012).
Upregulation of ERB in response to phytoestrogens results
in down-regulation of AR, with a subsequent decline in
serum levels of prostate-specific antigen (PSA) and other
AR-dependent genes (Thelen et al. 2005, 2007). ERB may
therefore function as a negative regulator of AR, as well as
ERA. However, as previously mentioned, in a study
conducted using a patient-derived prostate cancer tissue
line mouse xenograft model (maintained by serial
transplantation of sub-renal capsule xenografts)
(Andersen et al. 2010), the ERB-selective phytoestrogen
genistein has been shown to promote development of
metastatic disease (Nakamura et al. 2013). The explanation
for these conflicting results is not presently clear; however
it has been hypothesised that in the mouse xenograft
tumours, increased expression of metallothionein
proteins in response to genistein-induced ERB activity
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may contribute to tumour invasion and metastasis
(Nakamura et al. 2013); an interaction, which may not
be reflected in cell-line studies where the tumour
microenvironment is absent.
A promising clinical study was published by Price et al.
(2006). In a phase 2b clinical trial of 514 men with biopsy-
proven high-grade PIN, toremifene, an ERA-selective
antagonist (Kangas 1990), was shown to reduce the
incidence of invasive prostate cancer at 12 months by
48% vs placebo, thus preventing 6.8% cancers per
100 men per year. However, the outcome of this trial
was reported after only a 12-month study period and no
long-term data on the use of toremifene in prostate cancer
have since been generated to address potential long-term
side effects or duration of treatment benefit.
Trials of other ER modulators have also been
unsuccessful. Fulvestrant, an ERA antagonist, has been
shown to be effective in preclinical models with growth
inhibition of prostate cancer cell lines (Lau et al. 2000,
Leung et al. 2006a). However, in a phase 2 study of 20 men
with CRPC, fulvestrant failed to produce either a clinical
or biochemical (PSA) response (Chadha et al. 2008).
Similarly, tamoxifen, a mixed ERA agonist/antagonist
has been shown to be ineffective in men with CRPC
(Bergan et al. 1999) despite inhibiting the growth of
prostate cancer cell lines in preclinical studies (Rohlff et al.
1998). The reasons underlying these observations are not
presently clear; however, it is likely that prostate cancer
cell lines used in the preclinical studies are not reflecting
the complex cross-talk between AR, ERA and ERB, and
other stromal–epithelial interactions known to occur
in vivo (Hanahan & Weinberg 2011, Robinson et al. 2011,
Grubisha & Defranco 2013, Madak-Erdogan et al. 2013).
These studies highlight the critical need for improved
preclinical models of prostate cancer, in which to test new
therapeutic agents targeted to the ERs.
ERs in the prostate
ERB was first identified by Kuiper et al. (1996) in the rat
prostate. In humans, it is a 55 kDa protein encoded by the
ESR2 gene located on chromosome 14 (Enmark et al.
1997). Expression of ERB is regulated epigenetically by a
CpG island in the promotor region (Zhu et al. 2004) and
ERB expression is silenced by DNA-hypermethylation of
the promotor (Zhao et al. 2003, Rody et al. 2005). ERB is
strongly expressed in the basal and secretory compart-
ments of benign prostate epithelium in both rodents and
humans (Horvath et al. 2001). The principle ligand of ERB
in the prostate is 5a-androstane-3b,17b-diol (3b-diol),
a metabolite of 5a-dihydrotestosterone (DHT) (Oliveira
et al. 2007). In prostate cell lines (benign and cancer) ERB
has been shown to maintain differentiation of epithelial
cells by regulation of epithelial–mesenchymal transition
(EMT) genes such as Twist via hypoxia-inducible factor 1
alpha (HIF-1A) (Mak et al. 2013).
The gene coding human ERA (ESR1) is located on
chromosome 6 (Menasce et al. 1993). In the prostate
(rodent and human) ERA is predominantly expressed in
the stroma (Celhay et al. 2010, Attia & Ederveen 2012).
In utero studies of prostate development in rodents have
shown that ERA expression appears before ERB, and
excessive estrogenisation of the developing prostate
(mediated via ERA) results in permanent changes in the
prostate including squamous metaplasia, inflammation
and epithelial dysplasia (Arai et al. 1978, Prins & Birch
1997). This ‘imprinting’ results in increased risk of a
premalignant phenotype and prostate carcinogenesis
(Prins et al. 2006, 2007, McPherson et al. 2008, Prins &
Korach 2008). Although expressed from different genes,
ERA and ERB share substantial sequence homology, in
particular the DNA-binding domains (DBD) of the two
receptors are 97% identical. This allows both ERs to
recognise a consensus estrogen response element (ERE)
on DNA with equal affinity (Le et al. 2013).
The advent of genome-wide transcription factor
mapping by chromatin immunoprecipitation coupled
with high-throughput sequencing (ChIP-seq) has enabled
detailed study of how transcription factors such as steroid
hormone receptors function, by revealing the locations of
their DNA-binding sites (Carroll et al. 2006). We now
know, for example, that in addition to proximal gene
promotors, ERA and AR bind to distal enhancer elements,
far from gene-transcription start sites, and by recruitment
of co-regulatory factors initiate gene transcription by long-
range chromatin interactions (Carroll et al. 2005, Wang
et al. 2007, Massie et al. 2011). For ERA and AR, a number
of these co-regulatory factors are now well-characterised
and represent potential therapeutic targets (Carroll et al.
2005, Wang et al. 2007, 2009, 2011, Hurtado et al. 2011,
Robinson et al. 2011, Sahu et al. 2011). Genome-wide
mapping of both tagged (Zhao et al. 2010) and force-
expressed recombinant ERB (Madak-Erdogan et al. 2013)
DNA-binding in the MCF7 breast cancer cell line has
demonstrated significant overlap between ERA and ERB
DNA-binding sites, inferring complex cross-talk between
the two receptors. In addition, there is evidence that ERB
binds to distal enhancer elements in the same manner as
ERA and AR to regulate gene expression (Carroll et al.
2005, Zhao et al. 2010, Massie et al. 2011). Despite these
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significant insights, there is still very limited under-
standing of the mechanisms and co-regulators by which
ERB activity may be modulated and thus the resulting
effects on ERB transcription.
ER expression in prostate cancer
In normal prostate, ERA expression is confined to the
prostatic stroma (Tilley et al. 1985, Wernert et al. 1988,
Leav et al. 2001). In contrast to ERB, ERA mRNA has been
detected in high-grade PIN of the prostate, and ERA
expression is upregulated in prostatic epithelium of
intermediate- and high-grade tumours and in CRPC
(Bonkhoff & Berges 2009, Celhay et al. 2010, Nelles et al.
2011). Stromal ERA expression and elevated expression of
aromatase have been shown to be independent predictors
of shorter time to relapse in CRPC (Celhay et al. 2010).
Expression of the TMPRSS2–ERG fusion gene, which has
been suggested to be a marker of an aggressive tumour
phenotype found in up to 50% of prostate cancer (Qu et al.
2013, Razzak 2013), increased in the NCI-H660 prostate
cancer cell line following treatment with an ERA agonist
(Setlur et al. 2008). NCI-H660 is an AR-negative prostate
cancer cell line expressing the TMPRSS2-ERG fusion gene
(Mertz et al. 2007), derived from the lymph node
metastasis of a small-cell prostate tumour with neuro-
endocrine differentiation (Johnson et al. 1989, Lai et al.
1995). Expression of ERA and aromatase with the R264C
polymorphism has been shown to result in shorter
progression-free survival and an increased risk of develop-
ing CRPC in a study of 115 men treated with docetaxel
(Sissung et al. 2011). Taken together, these observations
support the hypothesis that ERA can act as an oncogene by
mediating the adverse effects of estrogen in the prostate.
Declining levels of ERB have been observed with
progression from benign prostatic hyperplasia to
malignant disease (Horvath et al. 2001), with a further
decrease associated with increasing Gleason grade of
prostate cancer (Leav et al. 2001, Asgari & Morakabati
2011, Attia & Ederveen 2012, Dey et al. 2013b). ERB
expression is low in high-grade PIN of the prostate
(Risbridger et al. 2007), reflecting its pre-malignant
phenotype. It has been shown that as ERB expression
declines with the development of prostate cancer,
levels of HIF-1A increase, resulting in epithelial de-
differentiation and growth of high-grade, aggressive
tumours (Mak et al. 2013).
Horvath et al. (2001) showed in a study of 159 prostates
obtained by radical prostatectomy that over 75% of
tumours in their cohort did not express ERB. However, in
low-grade (Gleason 3) tumours, ERB expression was
maintained, and correlated positively with disease-free
survival (Horvath et al. 2001). In an additional finding
that seems to contradict these results, where ERB expression
was maintained, there was a higher rate of disease relapse
irrespective of tumour grade (Horvath et al. 2001). Other
studies have demonstrated high ERB expression in bone
and lymph node metastases (Zhu et al. 2004, Bouchal et al.
2011). A recent study has shown that the combination of
ERB expression and AR phosphorylation in hormone-naı¨ve
prostate cancer correlates with poor clinical outcome
(Zellweger et al. 2013). In that study, increased expression
ofWT ERB (ERB1) was associated with higher Gleason grade
and greater proliferative activity. Fifty percent of the
patients in the study cohort showed a significant increase
in ERB expression with subsequent development of CRPC
(Zellweger et al. 2013).
The variability of ERB expression in differing grades
and stages of prostate cancer presents some difficulty in
deciphering the underlying mechanisms and role of ERB
in prostate carcinogenesis. If ERB is tumour-suppressive,
then it is logical that its expression declines with
advancing carcinogenesis. However, this does not explain
why ERB expression is then high in lymph node or bone
metastases ( Zhu et al. 2004, Bouchal et al. 2011), or the
observed correlation between high ERB expression and
poor prostate cancer prognosis (Horvath et al. 2001,
Zellweger et al. 2013). This may be due to varying levels
of promotor methylation throughout the carcinogenic
process introducing reversible, stage- and tissue-specific
changes in ERB expression and altering its transcriptional
role (Risbridger et al. 2007, Cotrim et al. 2013). In addition,
it has been proposed that ERB expression may confer a
selective advantage for subclones of prostate cancer cells
to metastasise (Zhu et al. 2004), resulting in the main-
tenance of ERB expression inmetastatic deposits. A further
possible explanation for this discrepancy is variability in
the specificity and sensitivity of commercially available
ERB antibodies (Skliris et al. 2002, Hartman et al. 2012).
Different ERB antibodies have been shown to only be
suitable for particular experimental applications
(Weitsman et al. 2006), creating some difficulty in the
interpretation of results from different studies.
More recently, there is increasing evidence that
expression of the ERB isoform, ERB2, is increased in high-
grade and metastatic prostate cancer (Dey et al. 2012).
ERB2 may act as an oncogene and has been implicated
specifically in the process of cancer metastasis (Chen et al.
2009, Leung et al. 2010, Dey et al. 2012). If the antibodies
used in the abovementioned studies (Horvath et al. 2001,
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Zhu et al. 2004, Bouchal et al. 2011, Zellweger et al. 2013)
are in fact detecting ERB2, rather than ERB1, some of
the abovementioned contradictions may be explained.
Further detailed study is required to answer this
definitively.
The role of ERB isoforms
At least five splice variants of ERB have been identified
(Leung et al. 2006b) (Fig. 2). Expression of ERB3 is limited
to the testis (Moore et al. 1998), but ERB1, ERB2, ERB4 and
ERB5 are known to be expressed in the prostate, and there
is increasing evidence indicating that ERB2 in particular
acts as an oncogene in direct opposition to ERB1 (Chen
et al. 2009). ERB1 is composed of eight exons, the first six
of which are common to the five isoforms. The isoforms
share the same first four functional domains with ERB1
(including the DBD), but the LBD differs (Moore et al.
1998, Hanstein et al. 1999, Leung et al. 2010). ERB2 and
ERB5 have been studied in detail in prostate cancer and
shown to correlate with poor prognosis (Leung et al. 2010,
Dey et al. 2012). Specifically, co-expression of nuclear
ERB2 and cytoplasmic ERB5 was shown in a study of 144
patients with long-term follow up to be an independent
prognostic marker for biochemical relapse, postoperative
metastasis and time to metastasis following radical
prostatectomy for localised prostate cancer (Leung et al.
2010). While ERB2 is the dominant isoform in prostate
cancer, its mechanism of action remains unclear as it lacks
the LBD. ERB2 seems to act as a transcriptional repressor of
ERB1, thus disabling the usual, protective effect of ERB1
(Cotrim et al. 2013). One hypothesis proposed by Leung
et al. (2006b) is that whilst ERB1 functions as a
homodimer, ERB isoforms function only when hetero-
dimerised with ERB1. These ERB heterodimers form
preferentially under the influence of oestradiol (E2) and
have higher transcriptional activity than the ERB1
homodimer. Interestingly, phytoestrogens such as genis-
tein promote formation of the ERB1 homodimer. As ERB2
lacks a LBD, it is proposed that when it is heterodimerised
with ERB1, transcription is inhibited. In this model, ERB2
may therefore function as a dominant-negative regulator
of ERB1 activity. This may explain one way that ERB
transcription can be modulated in cell- and tissue-specific
contexts (Leung et al. 2006b, Cotrim et al. 2013).
In ovarian carcinoma, levels of ERB5 mRNA are
elevated, compared with benign tissues, suggesting it has
an oncogenic role in that particular context (Suzuki et al.
2008). A study of stable tetracycline-inducible ERB2-
expressing MCF7 breast cancer cells has suggested that
ERB2 can also heterodimerise with ERA to induce ERA
degradation and inhibition of ERA transcription (Zhao
et al. 2007).
The influence of ERB2 in both prostate and breast
cancer metastasis is thought to result from regulation of
genes responsible for EMT (Leung et al. 2010, Dey et al.
2012, Roy et al. 2012, Yang et al. 2012). EMT is a marker
of early oncological change, which enables cancer cells to
Exon 2
DBD LBD
31 4 5 6 7 8
Amino acid number: 121 178 216 317 364 408 469 530
121 178 216 317 364 408 469 490
121 178 216 317 364 408 417
121 178 216 317 364 408 472
121 178 216 317 364 408 530
ERB1
ERB2
ERB3
ERB4
ERB5
Figure 2
Schematic showing the structure of ERB isoforms. ERB1 (WT) contains
eight exons, the first six of which are common to the other isoforms. All five
isoforms share common DNA-binding domains (DBD), but the
ligand-binding domains (LBD) differ. Data from Uniprot (http://www.
uniprot.org/) and ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
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invade surrounding tissues and eventually metastasise to
distant sites (Hanahan & Weinberg 2011). Although
well-characterised in vitro, there is still some controversy
as to whether the EMT programme occurs in vivo or is an
artefact of cell line studies, principally because of
difficulties differentiating transformed epithelial cells from
the surrounding tumour stromal tissue, and the fact that
metastatic deposits often closely resemble the epithelial
tissue of origin (Hollier et al. 2009). Nevertheless, evidence
is emerging that EMT markers can be observed in
circulating tumour cells, suggesting that it does occur
in vivo (Li et al. 2013).
In a study conducted in prostate cancer cell lines,
expression of ERB2 was shown to result in upregulation of
the EMT genes TWIST1 (which correlates with high-grade
prostate cancer) and RUNX2 (normally repressed by ERB1)
(Dey et al. 2012). This interaction between ERB2 and EMT
genes is facilitated by a proto-oncogene, PELP1, which
interacts with a number of steroid hormone receptors
including ERA (Vadlamudi et al. 2001), ERB and AR (Yang
et al. 2012). In breast cancer, PELP1 has been shown
to interact with histones to remodel chromatin and
modulate expression of key EMT genes such as TWIST1,
SNAIL and ZEB (Roy et al. 2012). It is therefore possible
that PELP1 and ERB2 have a role in the promotion of
prostate cancermetastasis. If correct, this hypothesis could
explain the previously discussed findings of high ERB
expression in bone and lymph node metastases, and the
correlation between persistent ERB expression in high-
grade prostate cancer and greater risk of disease relapse
(Horvath et al. 2001, Zhu et al. 2004, Bouchal et al. 2011,
Zellweger et al. 2013). This is an important area for further
investigation.
The role of ER-mediated inflammation in
mechanisms of cancer progression
Inflammation is a well-established process in the develop-
ment and progression of cancer (Hanahan & Weinberg
2011) (Fig. 3). Several inflammatory mechanisms, center-
ing on ER function, have been implicated in the
development and progression of prostate cancer. Loss of
E-cadherin is a well-established marker of EMT, with
associated loss of cell adhesion and a resulting increase in
cell motility (Guarino et al. 2007, Grubisha & Defranco
2013). ERB has been shown to be a negative regulator of
inflammatory processes (Harris et al. 2003) and in the
prostate its expression is known to correlate with
E-cadherin levels. One hypothesis is that as ERB expression
declines during the progression from benign to low-grade,
↑
↑Aromatase
↑WBC migration
Inflammation
↑Epithelial proliferation
↑NO
↑E2
↓E-cadherin
↑ TWIST1
↑HIF-1A
COX2
↑H2O2
ERB ERA
EMT program
↓ERB
PCa progression
↑ERA
Loss of direct
repressive function
Tissue inflammation
Tissue inflammation
Figure 3
Proinflammatory positive feedback loops in prostate cancer progression,
centering on ERB and ERA function. In response to tissue inflammation,
decreased ERB expression results in upregulation of EMT programme genes
leading to prostate cancer metastasis. Tissue inflammation leads to
increased aromatase expression and increased inflammatory-cell epithelial
infiltration. Decreased ERB transcription results in loss of direct repression
of ERA. WBC, white blood cell; E2, oestradiol; NO, nitric oxide; H2O2,
hydrogen peroxide; COX2, cyclo-oxygenase-2; PCa, prostate cancer.
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to high-grade cancer (Leav et al. 2001, Celhay et al. 2010,
Asgari & Morakabati 2011), the resulting decline in
E-cadherin leads to an increased propensity to develop
metastatic disease. ERB transcriptional activity is sensitive
to oxidation resulting from tissue inflammatory processes
and a local paracrine signalling network (Grubisha et al.
2012). When ERB is oxidised by H2O2 and other reactive
oxygen species, DNA binding is lost and expression of
E-cadherin is reduced. The pro-inflammatory enzyme
COX2, expressed by prostatic stroma, generates sufficient
H2O2 to inactivate ERB. As COX2 is overexpressed in
prostate cancer, a pro-inflammatory positive feedback
loop is established (Grubisha & Defranco 2013).
ERA and aromatase also play a critical role in tissue
inflammation in prostate cancer and expression of these
two factors in tumour cells is an independent predictor of
time to biochemical relapse (defined as two consecutive
rises in serum PSA) in men treated with ADT (Celhay et al.
2010). In prostate cancer, expression of aromatase is
increased, particularly in epithelial cells resulting in
increased levels of intraprostatic estrogen, which acts
via ERA to promote tissue inflammation via local gener-
ation of nitric oxide (Pinzone et al. 2004, Ellem&Risbridger
2007, Risbridger et al. 2007, Celhay et al. 2010, Nelles et al.
2011). Pro-inflammatory mediators such as TNFA and
prostaglandin E2 in turn upregulate CYP19 expression,
resulting in increased aromatase activity (Subbaramaiah
et al. 2011). Thus an additional pro-inflammatory
positive feedback loop centering on ERA function is
established (Ellem & Risbridger 2007). Evidence of
neutrophil and leucocyte migration from the stroma to
the epithelium in mouse models confirms the presence of
this inflammatory process (Bianco et al. 2002, 2006).
Inflammatory cytokines released by the migrating immune
cells result in abnormal proliferation of prostate epithelium
and increase the risk of further premalignant change
(Bianco et al. 2006).
A change in perspective: an oncogenic
role for ERB?
ERB1 has been implicated directly as an oncogene (Yang
et al. 2012). In that study, ERB1-mediated, non-androgenic
AR signalling was demonstrated in several prostate cancer
cell lines in hormone-deplete (castrate) conditions (Fig. 4).
In the presence of DHT, AR binds to androgen-responsive
elements (AREs) on DNA to initiate AR-dependent
transcription. In these conditions, ERB1 and PELP1 form
a complex in the nucleus. However, in the absence of DHT
and with addition of E2, the ERB1–PELP1 complex binds
to AR (with PELP1 acting as a bridge between the two
nuclear receptors) and is recruited to an ARE, resulting in
the transcription of AR-dependent genes. This ERB1–
PELP1–AR complex was shown to facilitate cellular prolifer-
ation in response to E2 treatment, demonstrating a clear
mechanism by which estrogens might continue to drive
prostate cancer growth and progression in the castrate
environment, thereby highlighting the potential onco-
genic role of ERB1. Furthermore, it has been proposed that
ERB1 may have a role in mediating the ‘switch’ from
hormone-sensitive prostate cancer to CRPC (Zellweger et al.
2013). It may be that ERB is only tumour-suppressive in
early stages of the disease until, by means of a currently
unknown mechanism, it subsequently becomes an
oncogene. This is an important question for detailed
investigation, as therapeutic silencing of such a ‘switch’
could theoretically reduce the risk of developing CRPC.
Our understanding of the role of ERB in the
development and progression of prostate cancer is
evolving, but there are many unresolved issues. Given the
divergent activity of ERB isoforms and the potential for an
oncogenic role for ERB1 (Yang et al. 2012), we can no longer
hold to the classical paradigm of estrogen signalling in the
prostate, which surmises that ERA is tumour promoting
and ERB is tumour suppressive. In order to progress our
understanding of estrogen biology in cancer it is critical
that the mechanisms underlying the differential functions
of ERA, ERB and the various ERB isoforms are elucidated in
detail (Madak-Erdogan et al. 2013). Recent advances in
PELP1
B
ERB
AR AR gene transcription
E2
A
ERB
AR AR gene transcription
PELP1
DHT
ARE
ARE
Figure 4
A hypothesis of non-androgenic, ERB-mediated transcription of
AR-dependent genes via interaction with PELP1, as proposed by Yang et al.
(2012). (A) In the presence of DHT ERB-PELP1 forms a complex, which
does not bind to AR. (B) In the absence of DHT, and with oestradiol (E2)
treatment, the ERB-PELP1-AR complex binds to the androgen-responsive
element (ARE) to initiate AR-dependent gene transcription.
Figure adapted from Yang L, Ravindranathan P, Ramanan M, Kapur P,
Hammes SR, Hsieh JT & Raj GV 2012 Central role for PELP1 in
nonandrogenic activation of the androgen receptor in prostate cancer.
Molecular Endocrinology 26 550–561.
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understanding the function of the two ERs at the genomic
level have been beginning to provide insights into this
complex area. Madak-Erdogan et al. (2013) used ChIP-seq
to demonstrate the genome-wide chromatin binding
profiles and differing transcriptional responses of ERA or
ERB in the MCF7 breast cancer cell line. Their data
confirmed the previous finding using the tagged ERB
ChIP-seq approach (Zhao et al. 2010) demonstrating
significant overlap between the binding sites of ERA and
ERB. Specifically, when each of the receptors was present
alone, there was a 40% overlap between ERA and ERB
DNA-binding sites. However, when co-expressed, the
number of binding sites available for each ER dropped by
w50%. This suggests a complex mechanism where each ER
restricts the total number of binding sites available to the
other, but when the activity of one ER is reduced,
chromatin binding by the other is increased. While the
functional consequences of altered ERA and ERB chromatin
binding in these different contexts remain to be fully
elucidated, the proliferative effects of estrogen acting via
ERA were reduced with the co-expression of ERB. When
expressed in isolation, ERA regulates cell cycle genes,
helping push cells from growth-arrested states into DNA
synthesis and subsequent mitosis. However, when ERB is
co-expressed, ERA’s ability to respond to ligand is reduced
and cell proliferation decreases. ERB’s anti-proliferative
function was demonstrated to occur through direct
binding to apoptosis and cell-cycle regulation genes
(Madak-Erdogan et al. 2013). Similar results were demon-
strated by Le et al. (2013) in ChIP-seq of MCF7/C4-12 cells
(derivative of MCF7 with no ERA expression) transfected to
stably express ERB. These data support the previously
discussed hypothesis that ERB is tumour-suppressive and
a negative regulator of ERA, functioning in a variable
manner according to the particular cellular context (Zhao
et al. 2010, Bottner et al. 2014, Cotrim et al. 2013). However,
as these data were generated using breast cancer cell lines,
it is important that the hypothesis is further tested in
appropriate prostate cancer models. The isoform specifi-
cities of the antibodies used in the ChIP-seq study
(Madak-Erdogan et al. 2013) are unknown and therefore
it is not clear how these findings in MCF7 cells are
applicable to the previously discussed differential functions
of ERB isoforms (Leung et al. 2010, Dey et al. 2012).
Clearly, there is an urgent need to develop specific
antibodies to ERB and its isoforms to address these
questions (Haldosen et al. 2014).
Conclusions
Despite a number of promising preclinical studies
showing efficacy of ERB-selective agents in prostate cancer
(Kim et al. 2002a,b, McPherson et al. 2010), there is
currently no evidence of clinical benefit from the use of
these treatments in terms of disease-specific or overall
survival. The underlying reasons for this necessitate
further investigation. One possibility is insufficient dosing
of the therapeutic agents in question (Chadha et al. 2008).
Most of the preclinical studies of ERB-selective agents and
much of our current knowledge of ERB biology results
from studies conducted in various prostate cancer cell
lines. The expression profiles of the nuclear receptors AR,
ERA and ERB vary between each of the commonly used cell
lines and different authors report contrasting results in
individual cell lines (Table 1) (Veldscholte et al. 1990, Kim
et al. 2002b, Holbeck et al. 2010, Nakajima et al. 2011).
None of these commonly used cell lines are entirely
representative of human tissue, as exemplified by the
fact that in the human prostate ERA expression is
predominantly stromal, whereas luminal epithelial cells
express ERB and AR, and basal epithelial cells only
express ERB (Ruizeveld de Winter et al. 1991, Bonkhoff &
Berges 2009). Cell line models, therefore, cannot
reproduce the stromal–epithelial interactions known to
be important in cancer development and progression
(Hanahan & Weinberg 2011), or the complex interplay
that has been observed between ERA and ERB, and how
transcription from activation of one receptor impacts
the availability of DNA-binding sites to the other
(Madak-Erdogan et al. 2013). Studies conducted in ex vivo
Table 1 Variability of reported nuclear receptor expression in commonly used prostate cancer cell lines
References Cell line AR ERA ERB
Veldscholte et al. (1990) and
Kim et al. (2002a,b)
LNCaP Positive (mutant) Negative Positive
Nakajima et al. (2011) DU145 Negative Negative Positive
Holbeck et al. (2010) DU145 Negative Negative Negative
Holbeck et al. (2010) and
Nakajima et al. (2011)
PC3 Negative Positive Positive
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primary human tissue culture (Centenera et al. 2012) or
xenografts of human tumours (Lawrence et al. 2013) may
be helpful in this regard.
Estrogen-related pathways are clearly of great import-
ance in the development and progression of hormone-
dependent cancers such as prostate cancer, but the role of
ERB remains controversial, with numerous contradictions
in the published literature. Our current understanding of
ER biology in the prostate is insufficient to facilitate precise
manipulation of the molecular machinery in a meaningful
fashion (Abd Elmageed et al. 2013). Recent developments
in the understanding of apparently opposing ERB isoforms
(Leung et al. 2010) and the mechanisms governing ERB
transcription are beginning to provide greater insights into
ERB biology with implications not just for prostate cancer
but also for colon, breast and ovarian cancers (Suzuki et al.
2008, Chantzi et al. 2013, Dey et al. 2013a). In order to
determine whether ERB represents a useful therapeutic
target in prostate cancer, and more specifically in CRPC, it
is vital that these mechanisms are fully elucidated. Given
that ERA and ERB can homo- or heterodimerise with ERB
isoforms, the cross-reactivity between different estrogenic
ligands, the differing effects of ERB in specific cellular
contexts, and the fact that ERA and ERB can recognise the
same DNA-binding sites and interact with common
co-regulators, this is likely to be a difficult task (Shaaban
et al. 2003, Zhao et al. 2010, Cotrim et al. 2013, Le et al.
2013, Madak-Erdogan et al. 2013). The challenge will be
to identify and characterise the ERA- and ERB-unique
DNA-binding sites, and furthermore, to define the ERB
isoform-specific DNA binding sites in order to determine
their respective functions. To improve outcomes for
patients, there is an urgent need for detailed understanding
of the mechanisms governing the differential functions of
the two ERs in tissue- and disease-specific contexts aswell as
investigation of novel therapeutic agents that selectively
target ERA- and ERB-dependent pathways.
Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the review.
Funding
A W Nelson is supported by The Medical Research Council (MR/L00156X/1)
and The Urology Foundation Scholarship (RESCH1302); W D Tilley is
supported by grants from the National Health and Medical Research
Council of Australia (ID 627185), Cancer Australia (ID 627229) and the
Prostate Cancer Foundation of Australia; D E Neal is supported by Cancer
Research UK, The Medical Research Council and The National Institute for
Health Research; J S Carroll is supported by an ERC starting grant and an
EMBO Young investigator award.
Author contribution statement
A W Nelson and W D Tilley conceptualised and designed the structure of
the article. AW Nelson conducted the literature review. AW Nelson and W
D Tilley co-wrote the manuscript. D E Neal and J S Carroll provided critical
review and revision of the manuscript.
Acknowledgements
AWNelson is an Honorary Research Training Fellow of the Royal College of
Surgeons of England/Prostate Cancer UK and acknowledges their support.
References
Abd Elmageed ZY, Moroz K, Srivastav SK, Fang Z, Crawford BE, Moparty K,
Thomas R & Abdel-Mageed AB 2013 High circulating estrogens and
selective expression of ERb in prostate tumors: implications for racial
disparity of prostate cancer. Carcinogenesis 34 2017–23. (doi:10.1093/
carcin/bgt156)
Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T,
Yang YC, Banuelos CA et al. 2010 Regression of castrate-recurrent
prostate cancer by a small-molecule inhibitor of the amino-terminus
domain of the androgen receptor. Cancer Cell 17 535–546. (doi:10.1016/
j.ccr.2010.04.027)
Andres S, Abraham K, Appel KE & Lampen A 2011 Risks and benefits of
dietary isoflavones for cancer. Critical Reviews in Toxicology 41 463–506.
(doi:10.3109/10408444.2010.541900)
Arai Y, Chen CY & Nishizuka Y 1978 Cancer development in male
reproductive tract in rats given diethylstilbestrol at neonatal age. Gann
69 861–862.
Asgari M &Morakabati A 2011 Estrogen receptor b expression in prostate
adenocarcinoma.Diagnostic Pathology661. (doi:10.1186/1746-1596-6-61)
Attard G, Richards J & de Bono JS 2011 New strategies inmetastatic prostate
cancer: targeting the androgen receptor signaling pathway. Clinical
Cancer Research 17 1649–1657. (doi:10.1158/1078-0432.CCR-10-0567)
Attia DM&Ederveen AG 2012 Opposing roles of ERa and ERb in the genesis
and progression of adenocarcinoma in the rat ventral prostate. Prostate
72 1013–1022. (doi:10.1002/pros.21507)
Barth JH, Field HP, Yasmin E & Balen AH 2010 Defining hyperandrogenism
in polycystic ovary syndrome: measurement of testosterone and
androstenedione by liquid chromatography–tandem mass spectrometry
and analysis by receiver operator characteristic plots. European
Journal of Endocrinology 162 611–615. (doi:10.1530/EJE-09-0741)
Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD,
Tompkins A, Linehan WM, Kohler D et al. 1999 A phase II study of
high-dose tamoxifen in patients with hormone-refractory prostate
cancer. Clinical Cancer Research 5 2366–2373.
Bianco JJ, Handelsman DJ, Pedersen JS & Risbridger GP 2002 Direct
response of the murine prostate gland and seminal vesicles to estradiol.
Endocrinology 143 4922–4933. (doi:10.1210/en.2002-220493)
Bianco JJ, McPherson SJ, Wang H, Prins GS & Risbridger GP 2006 Transient
neonatal estrogen exposure to estrogen-deficient mice (aromatase
knockout) reduces prostate weight and induces inflammation in late
life. American Journal of Pathology 168 1869–1878. (doi:10.2353/
ajpath.2006.050623)
Bonkhoff H & Berges R 2009 The evolving role of oestrogens and their
receptors in the development and progression of prostate cancer.
European Urology 55 533–542. (doi:10.1016/j.eururo.2008.10.035)
E
n
d
o
cr
in
e-
R
e
la
te
d
C
a
n
ce
r
Thematic Review A W Nelson et al. ER-beta: friend or foe? 21 :2 T11
http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0508 Printed in Great Britain
Published by Bioscientifica Ltd.
156
Bosland MC 2013 A perspective on the role of estrogen in hormone-
induced prostate carcinogenesis. Cancer Letters 334 28–33.
(doi:10.1016/j.canlet.2012.08.027)
Bottner M, Thelen P & Jarry H 2014 Estrogen receptor b: tissue distribution
and the still largely enigmatic physiological function. Journal of Steroid
Biochemistry and Molecular Biology 139 245–51. (doi:10.1016/j.jsbmb.
2013.03.003)
Bouchal J, Santer FR, Hoschele PP, Tomastikova E, Neuwirt H & Culig Z
2011 Transcriptional coactivators p300 and CBP stimulate estrogen
receptor-b signaling and regulate cellular events in prostate cancer.
Prostate 71 431–437. (doi:10.1002/pros.21257)
Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC,Willi N,
MihatschMJ, SauterG&KallioniemiOP1999Surveyofgeneamplifications
during prostate cancer progression by high-throughout fluorescence in situ
hybridization on tissue microarrays. Cancer Research 59 803–806.
Cai C & Balk SP 2011 Intratumoral androgen biosynthesis in prostate
cancer pathogenesis and response to therapy. Endocrine-Related Cancer
18 R175–R182. (doi:10.1530/ERC-10-0339)
Carroll JS, LiuXS, BrodskyAS, LiW,MeyerCA, Szary AJ, Eeckhoute J, ShaoW,
Hestermann EV, Geistlinger TR et al. 2005 Chromosome-wide mapping
of estrogen receptor binding reveals long-range regulation requiring
the forkhead protein FoxA1. Cell 122 33–43. (doi:10.1016/j.cell.2005.
05.008)
Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS,
Keeton EK, Fertuck KC, Hall GF et al. 2006 Genome-wide analysis of
estrogen receptor binding sites. Nature Genetics 38 1289–1297. (doi:10.
1038/ng1901)
Carruba G 2007 Estrogen and prostate cancer: an eclipsed truth in an
androgen-dominated scenario. Journal of Cellular Biochemistry 102
899–911. (doi:10.1002/jcb.21529)
Celhay O, Yacoub M, Irani J, Dore B, Cussenot O & Fromont G 2010
Expression of estrogen related proteins in hormone refractory prostate
cancer: association with tumor progression. Journal of Urology 184
2172–2178. (doi:10.1016/j.juro.2010.06.089)
Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP,
Sutherland PD, Scher HI, Raj GV, Knudsen KE et al. 2012 Evidence for
efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human
prostate tumors. Clinical Cancer Research 18 3562–3570. (doi:10.1158/
1078-0432.CCR-12-0782)
Chadha MK, Ashraf U, Lawrence D, Tian L, Levine E, Silliman C, Escott P,
Payne V & Trump DL 2008 Phase II study of fulvestrant (Faslodex) in
castration resistant prostate cancer. Prostate 68 1461–1466.
(doi:10.1002/pros.20813)
Chang WY & Prins GS 1999 Estrogen receptor-b: implications for the
prostate gland. Prostate 40 115–124. (doi:10.1002/(SICI)1097-
0045(19990701)40:2!115::AID-PROS7O3.0.CO;2-3)
ChantziNI, TiniakosDG, PalaiologouM,GoutasN, FilippidisT,Vassilaros SD,
Dhimolea E, Mitsiou DJ & Alexis MN 2013 Estrogen receptor b2 is
associated with poor prognosis in estrogen receptor a-negative breast
carcinoma. Journal of Cancer Research and Clinical Oncology 139
1489–1498. (doi:10.1007/s00432-013-1467-4)
ChenM, Ni J, Chang HC, Lin CY, MuyanM& Yeh S 2009 CCDC62/ERAP75
functions as a coactivator to enhance estrogen receptor b-mediated
transactivation and target gene expression in prostate cancer cells.
Carcinogenesis 30 841–850. (doi:10.1093/carcin/bgn288)
Chmelar R, Buchanan G, Need EF, Tilley W & Greenberg NM 2007
Androgen receptor coregulators and their involvement in the
development and progression of prostate cancer. International Journal of
Cancer 120 719–733. (doi:10.1002/ijc.22365)
Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, Lanari
C & Helguero LA 2013 Estrogen receptor b growth-inhibitory effects are
repressed through activation ofMAPK and PI3K signalling inmammary
epithelial and breast cancer cells. Oncogene 32 2390–2402.
(doi:10.1038/onc.2012.261)
Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L,
Fournier G, Valeri A, Larre S, Thibault F et al. 2007 Combination of
polymorphisms from genes related to estrogen metabolism and risk of
prostate cancers: the hidden face of estrogens. Journal of Clinical
Oncology 25 3596–3602. (doi:10.1200/JCO.2007.11.0908)
Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing
of a novel androgen receptor exon generates a constitutively active
androgen receptor that mediates prostate cancer therapy resistance.
Cancer Research 68 5469–5477. (doi:10.1158/0008-5472.CAN-08-0594)
Dey P, Jonsson P, Hartman J, Williams C, Strom A & Gustafsson JA 2012
Estrogen receptors b1 and b2 have opposing roles in regulating
proliferation and bonemetastasis genes in the prostate cancer cell line
PC3.Molecular Endocrinology 26 1991–2003. (doi:10.1210/me.2012.1227)
Dey P, Barros RP, Warner M, Strom A & Gustafsson JA 2013a Insight into
the mechanisms of action of estrogen receptor b. Journal of Molecular
Endocrinology 51 T61–T74. (doi:10.1530/JME-13-0150)
Dey P, Strom A & Gustafsson JA 2013b Estrogen receptor b upregulates
FOXO3a and causes induction of apoptosis through PUMA in prostate
cancer. Oncogene. (doi:10.1038/onc.2013.384)
Ellem SJ & Risbridger GP 2007 Treating prostate cancer: a rationale
for targeting local oestrogens. Nature Reviews. Cancer 7 621–627.
(doi:10.1038/nrc2174)
Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M & Risbridger GP 2004 Local
aromatase expression in human prostate is altered in malignancy.
Journal of Clinical Endocrinology and Metabolism 89 2434–2441.
(doi:10.1210/jc.2003-030933)
Enmark E, Pelto-HuikkoM, Grandien K, Lagercrantz S, Lagercrantz J, Fried G,
Nordenskjold M & Gustafsson JA 1997 Human estrogen receptor
b-gene structure, chromosomal localization, and expression pattern.
Journal of Clinical Endocrinology and Metabolism 82 4258–4265.
Foryst-Ludwig A, Clemenz M, Hohmann S, Hartge M, Sprang C, Frost N,
Krikov M, Bhanot S, Barros R, Morani A et al. 2008 Metabolic actions of
estrogen receptor b (ERb) are mediated by a negative cross-talk with
PPARg. PLoS Genetics 4 e1000108. (doi:10.1371/journal.pgen.1000108)
Ganmaa D, Li XM, Qin LQ, Wang PY, Takeda M & Sato A 2003 The
experience of Japan as a clue to the etiology of testicular and prostatic
cancers. Medical Hypotheses 60 724–730. (doi:10.1016/S0306-
9877(03)00047-1)
Ghosh D, Griswold J, Erman M & Pangborn W 2009 Structural basis for
androgen specificity and oestrogen synthesis in human aromatase.
Nature 457 219–223. (doi:10.1038/nature07614)
Grubisha MJ & Defranco DB 2013 Local endocrine, paracrine and redox
signaling networks impact estrogen and androgen crosstalk in the
prostate cancer microenvironment. Steroids 78 538–541. (doi:10.1016/
j.steroids.2013.01.005)
Grubisha MJ, Cifuentes ME, Hammes SR & Defranco DB 2012 A local
paracrine and endocrine network involving TGFb, Cox-2, ROS, and
estrogen receptor b influences reactive stromal cell regulation of
prostate cancer cell motility. Molecular Endocrinology 26 940–954.
(doi:10.1210/me.2011-1371)
Guarino M, Rubino B & Ballabio G 2007 The role of epithelial–
mesenchymal transition in cancer pathology. Pathology 39 305–318.
(doi:10.1080/00313020701329914)
Haldosen LA, Zhao C & Dahlman-Wright K 2014 Estrogen receptor b
in breast cancer. Molecular and Cellular Endocrinology 382 665–72.
(doi:10.1016/j.mce.2013.08.005)
Hanahan D &Weinberg RA 2011 Hallmarks of cancer: the next generation.
Cell 144 646–674. (doi:10.1016/j.cell.2011.02.013)
Hanstein B, Liu H, Yancisin MC & Brown M 1999 Functional analysis of a
novel estrogen receptor-b isoform.Molecular Endocrinology 13 129–137.
Harris HA 2007 Estrogen receptor-b: recent lessons from in vivo studies.
Molecular Endocrinology 21 1–13. (doi:10.1210/me.2005-0459)
Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP,
Kharode YP,Marzolf J, KommBS,Winneker RC et al. 2003 Evaluation of
an estrogen receptor-b agonist in animal models of human disease.
Endocrinology 144 4241–4249. (doi:10.1210/en.2003-0550)
E
n
d
o
cr
in
e-
R
e
la
te
d
C
a
n
ce
r
Thematic Review A W Nelson et al. ER-beta: friend or foe? 21 :2 T12
http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0508 Printed in Great Britain
Published by Bioscientifica Ltd.
157
Hartman J, Strom A & Gustafsson JA 2012 Current concepts and
significance of estrogen receptor b in prostate cancer. Steroids 77
1262–1266. (doi:10.1016/j.steroids.2012.07.002)
Hedelin M, Balter KA, Chang ET, Bellocco R, Klint A, Johansson JE,
Wiklund F, Thellenberg-Karlsson C, Adami HO & Gronberg H 2006
Dietary intake of phytoestrogens, estrogen receptor-b polymorphisms
and the risk of prostate cancer. Prostate 66 1512–1520. (doi:10.1002/
pros.20487)
Heidenreich A, Bellmunt J, BollaM, Joniau S,MasonM,Matveev V,Mottet N,
Schmid HP, van der Kwast T, Wiegel T et al. 2011 EAU guidelines on
prostate cancer, Part 1: screening, diagnosis, and treatment of clinically
localised disease. European Urology 59 61–71. (doi:10.1016/j.eururo.
2010.10.039)
Hickey TE & Norman RJ 2010 Biomarkers: polycystic ovary syndrome:
steroid assessment for diagnosis. Nature Reviews. Endocrinology 6
305–307. (doi:10.1038/nrendo.2010.68)
Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ & Martinez ED
2010 Expression profiling of nuclear receptors in the NCI60 cancer cell
panel reveals receptor–drug and receptor–gene interactions. Molecular
Endocrinology 24 1287–1296. (doi:10.1210/me.2010-0040)
Hollier BG, Evans K & Mani SA 2009 The epithelial-to-mesenchymal
transition and cancer stem cells: a coalition against cancer therapies.
Journal of Mammary Gland Biology & Neoplasia 14 29–43. (doi:10.1007/
s10911-009-9110-3)
Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C,
Smith S, Scher H, Scardino P et al. 2004 Gene expression analysis of
human prostate carcinoma during hormonal therapy identifies
androgen-responsive genes and mechanisms of therapy resistance.
American Journal of Pathology 164 217–227. (doi:10.1016/
S0002-9440(10)63112-4)
Hori S, Butler E & McLoughlin J 2011 Prostate cancer and diet: food for
thought? BJU International 107 1348–1359. (doi:10.1111/j.1464-410X.
2010.09897.x)
Horvath LG,Henshall SM, LeeCS,HeadDR,QuinnDI,Makela S,DelpradoW,
Golovsky D, Brenner PC, O’Neill G et al. 2001 Frequent loss of
estrogen receptor-b expression in prostate cancer. Cancer Research 61
5331–5335.
Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C,
Edwards J, Isaacs WB, Nelson PS, Bluemn E et al. 2012 Distinct
transcriptional programsmediated by the ligand-dependent full-length
androgen receptor and its splice variants in castration-resistant prostate
cancer. Cancer Research 72 3457–3462. (doi:10.1158/0008-5472.
CAN-11-3892)
Huggins C 1943 Endocrine control of prostatic cancer. Science 97 541–544.
(doi:10.1126/science.97.2529.541)
Huggins C & Hodges CV 1972 Studies on prostatic cancer. I. The effect of
castration, of estrogen and androgen injection on serum phosphatases
in metastatic carcinoma of the prostate. CA: A Cancer Journal for
Clinicians 22 232–240. (doi:10.3322/canjclin.22.4.232)
Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D & Carroll JS 2011 FOXA1
is a key determinant of estrogen receptor function and endocrine
response. Nature Genetics 43 27–33. (doi:10.1038/ng.730)
Hussain S, Lawrence MG, Taylor RA, Lo CY, Frydenberg M, Ellem SJ, Furic L
& Risbridger GP 2012 Estrogen receptor b activation impairs prostatic
regeneration by inducing apoptosis in murine and human
stem/progenitor enriched cell populations. PLoS ONE 7 e40732.
(doi:10.1371/journal.pone.0040732)
Ishizaki F,NishiyamaT, Kawasaki T,Miyashiro Y,HaraN, Takizawa I,NaitoM
& Takahashi K 2013 Androgen deprivation promotes intratumoral
synthesis of dihydrotestosterone from androgen metabolites in
prostate cancer. Scientific Reports 3 1528. (doi:10.1038/srep01528)
Jiang Y, Gong P, Madak-Erdogan Z, Martin T, Jeyakumar M, Carlson K,
Khan I, Smillie TJ, Chittiboyina AG, Rotte SC et al. 2013 Mechanisms
enforcing the estrogen receptor b selectivity of botanical estrogens.
FASEB Journal 27 4406–4418. (doi:10.1096/fj.13-234617)
Johnson BE,Whang-Peng J, Naylor SL, Zbar B, Brauch H, Lee E, Simmons A,
Russell E, Nam MH & Gazdar AF 1989 Retention of chromosome 3 in
extrapulmonary small cell cancer shown by molecular and cytogenetic
studies. Journal of the National Cancer Institute 81 1223–1228.
(doi:10.1093/jnci/81.16.1223)
de JongFH,OishiK,HayesRB,Bogdanowicz JF,Raatgever JW,vanderMaasPJ,
Yoshida O & Schroeder FH 1991 Peripheral hormone levels in
controls and patients with prostatic cancer or benign prostatic
hyperplasia: results from the Dutch-Japanese case–control study.
Cancer Research 51 3445–3450.
Kangas L 1990 Review of the pharmacological properties of toremifene.
Journal of Steroid Biochemistry 36 191–195. (doi:10.1016/0022-
4731(90)90003-B)
Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Hong YJ, KimHT,Morton RA&
Kim SJ 2002a Raloxifene, a mixed estrogen agonist/antagonist, induces
apoptosis in androgen-independent human prostate cancer cell lines.
Cancer Research 62 5365–5369.
Kim IY, SeongDH,KimBC, LeeDK,RemaleyAT, Leach F,MortonRA&KimSJ
2002b Raloxifene, a selective estrogen receptor modulator, induces
apoptosis in androgen-responsive human prostate cancer cell line
LNCaP through an androgen-independent pathway. Cancer Research 62
3649–3653.
KnudsenKE&PenningTM2010Partners in crime: deregulationofARactivity
and androgen synthesis in prostate cancer. Trends in Endocrinology and
Metabolism 21 315–324. (doi:10.1016/j.tem.2010.01.002)
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996
Cloning of a novel receptor expressed in rat prostate and ovary. PNAS
93 5925–5930. (doi:10.1073/pnas.93.12.5925)
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT,
van der Burg B & Gustafsson JA 1998 Interaction of estrogenic
chemicals and phytoestrogens with estrogen receptor b. Endocrinology
139 4252–4263.
Lai SL, Brauch H, Knutsen T, Johnson BE, Nau MM, Mitsudomi T, Tsai CM,
Whang-Peng J, Zbar B, Kaye FJ et al. 1995 Molecular genetic
characterization of neuroendocrine lung cancer cell lines. Anticancer
Research 15 225–232.
Lamb AD, Massie CE & Neal DE 2013 The transcriptional program of
the androgen receptor (AR) in prostate cancer. BJU International.
(doi:10.1111/bju.12415)
Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC,
Pollock P, Jinks RC, Godsland IF, Kockelbergh R et al. 2013
Cardiovascular outcomes in patients with locally advanced and
metastatic prostate cancer treated with luteinising-hormone-releasing-
hormone agonists or transdermal oestrogen: the randomised, phase 2
MRC PATCH trial (PR09). Lancet Oncology 14 306–316. (doi:10.1016/
S1470-2045(13)70025-1)
Lau KM, LaSpina M, Long J & Ho SM 2000 Expression of estrogen receptor
(ER)-a and ER-b in normal and malignant prostatic epithelial cells:
regulation by methylation and involvement in growth regulation.
Cancer Research 60 3175–3182.
Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW,
Frydenberg M, Papargiris MM, Niranjan B, Richards MG et al. 2013 A
preclinical xenograft model of prostate cancer using human tumors.
Nature Protocols 8 836–848. (doi:10.1038/nprot.2013.043)
Le TP, Sun M, Luo X, Kraus WL & Greene GL 2013 Mapping ERb genomic
binding sites reveals unique genomic features and identifies EBF1 as
an ERb interactor. PLoS ONE 8 e71355. (doi:10.1371/journal.pone.
0071355)
Leav I, Lau KM, Adams JY, McNeal JE, TaplinME,Wang J, Singh H&Ho SM
2001 Comparative studies of the estrogen receptors b and a and the
androgen receptor in normal human prostate glands, dysplasia, and in
primary and metastatic carcinoma. American Journal of Pathology 159
79–92. (doi:10.1016/S0002-9440(10)61676-8)
Leung YK, Gao Y, Lau KM, Zhang X & Ho SM 2006a ICI 182,780-regulated
gene expression in DU145 prostate cancer cells is mediated by estrogen
E
n
d
o
cr
in
e-
R
e
la
te
d
C
a
n
ce
r
Thematic Review A W Nelson et al. ER-beta: friend or foe? 21 :2 T13
http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0508 Printed in Great Britain
Published by Bioscientifica Ltd.
158
receptor-b/NFkB crosstalk. Neoplasia 8 242–249. (doi:10.1593/
neo.05853)
Leung YK, Mak P, Hassan S & Ho SM 2006b Estrogen receptor (ER)-b
isoforms: a key to understanding ER-b signaling. PNAS 103
13162–13167. (doi:10.1073/pnas.0605676103)
Leung YK, LamHM,Wu S, Song D, Levin L, Cheng L,Wu CL&Ho SM 2010
Estrogen receptor b2 and b5 are associated with poor prognosis in
prostate cancer, and promote cancer cell migration and invasion.
Endocrine-Related Cancer 17 675–689. (doi:10.1677/ERC-09-0294)
LiYM,XuSC,Li J,HanKQ,PiHF,ZhengL,ZuoGH,HuangXB,LiHY,ZhaoHZ
et al. 2013 Epithelial–mesenchymal transition markers expressed in
circulating tumor cells in hepatocellular carcinoma patients with
different stages of disease. Cell Death & Disease 4 e831. (doi:10.1038/
cddis.2013.347)
Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A & Camozzi V 2011
Endocrine therapy of breast cancer. Current Medicinal Chemistry 18
513–522. (doi:10.2174/092986711794480177)
Madak-Erdogan Z, Charn TH, Jiang Y, Liu ET, Katzenellenbogen JA &
Katzenellenbogen BS 2013 Integrative genomics of gene and metabolic
regulation by estrogen receptors a and b, and their coregulators.
Molecular Systems Biology 9 676. (doi:10.1038/msb.2013.28)
Mak P, Chang C, Pursell B &Mercurio AM 2013 Estrogen receptor b sustains
epithelial differentiation by regulating prolyl hydroxylase 2
transcription. PNAS 110 4708–4713. (doi:10.1073/pnas.1221654110)
Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A,
Scott H, Madhu B, Sharma N et al. 2011 The androgen receptor fuels
prostate cancer by regulating central metabolism and biosynthesis.
EMBO Journal 30 2719–2733. (doi:10.1038/emboj.2011.158)
McPherson SJ, Ellem SJ & Risbridger GP 2008 Estrogen-regulated
development and differentiation of the prostate. Differentiation 76
660–670. (doi:10.1111/j.1432-0436.2008.00291.x)
McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M,
Chandrasiri UP, Toivanen R, Wang Y, Taylor RA et al. 2010 Estrogen
receptor-b activated apoptosis in benign hyperplasia and cancer of the
prostate is androgen independent and TNFa mediated. PNAS 107
3123–3128. (doi:10.1073/pnas.0905524107)
Menasce LP, White GR, Harrison CJ & Boyle JM 1993 Localization of the
estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a
simple post-FISH banding technique. Genomics 17 263–265.
(doi:10.1006/geno.1993.1320)
Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR & Srigley JR 2009
Multifocal high grade prostatic intraepithelial neoplasia is a significant
risk factor for prostatic adenocarcinoma. Journal of Urology 182 485–490
discussion 490. (doi:10.1016/j.juro.2009.04.016)
Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S,
Tchinda J, Laxman B, Vessella RL, Beroukhim R et al. 2007 Molecular
characterization of TMPRSS2-ERG gene fusion in the NCI-H660
prostate cancer cell line: a new perspective for an oldmodel.Neoplasia 9
200–206. (doi:10.1593/neo.07103)
Messina M 2010 Insights gained from 20 years of soy research. Journal of
Nutrition 140 2289S–2295S. (doi:10.3945/jn.110.124107)
Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL,
Kliewer SA, Lehmann JM & Willson TM 1998 Cloning and character-
ization of human estrogen receptor b isoforms. Biochemical and
Biophysical Research Communications 247 75–78. (doi:10.1006/
bbrc.1998.8738)
Morales A & Pujari B 1975 The choice of estrogen preparations in the
treatment of prostatic cancer. Canadian Medical Association Journal 113
865–867.
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP,
Van der Kwast T, Wiegel T, Zattoni F et al. 2011 EAU guidelines on
prostate cancer. Part II: treatment of advanced, relapsing, and
castration-resistant prostate cancer. European Urology 59 572–583.
(doi:10.1016/j.eururo.2011.01.025)
Muthusamy S, Andersson S, Kim HJ, Butler R, Waage L, Bergerheim U &
Gustafsson JA 2011 Estrogen receptor b and 17b-hydroxysteroid
dehydrogenase type 6, a growth regulatorypathway that is lost inprostate
cancer. PNAS 108 20090–20094. (doi:10.1073/pnas.1117772108)
Nakajima Y, Akaogi K, Suzuki T, Osakabe A, Yamaguchi C, Sunahara N,
Ishida J, Kako K, Ogawa S, Fujimura T et al. 2011 Estrogen regulates
tumor growth through a nonclassical pathway that includes the
transcription factors ERb and KLF5. Science Signaling 4 ra22.
(doi:10.1126/scisignal.2001551)
Nakamura H, Wang Y, Xue H, Romanish MT, Mager DL, Helgason CD &
Wang Y 2013 Genistein versus ICI 182, 780: an ally or enemy in
metastatic progression of prostate cancer. Prostate 73 1747–1760.
(doi:10.1002/pros.22712)
Nelles JL, Hu WY & Prins GS 2011 Estrogen action and prostate cancer.
Expert Review of Endocrinology & Metabolism 6 437–451. (doi:10.1586/
eem.11.20)
Nelson WG, De Marzo AM & Isaacs WB 2003 Prostate cancer. New England
Journal of Medicine 349 366–381. (doi:10.1056/NEJMra021562)
Oliveira AG, Coelho PH, Guedes FD, Mahecha GA, Hess RA & Oliveira CA
2007 5a-Androstane-3b,17b-diol (3b-diol), an estrogenic metabolite of
5a-dihydrotestosterone, is a potent modulator of estrogen receptor ERb
expression in the ventral prostrate of adult rats. Steroids 72 914–922.
(doi:10.1016/j.steroids.2007.08.001)
Pinzone JJ, Stevenson H, Strobl JS & Berg PE 2004 Molecular and cellular
determinants of estrogen receptor a expression. Molecular and Cellular
Biology 24 4605–4612. (doi:10.1128/MCB.24.11.4605-4612.2004)
Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D,
Bostwick D & Steiner M 2006 Toremifene for the prevention of prostate
cancer in men with high grade prostatic intraepithelial neoplasia:
results of a double-blind, placebo controlled, phase IIB clinical trial.
Journal of Urology 176 965–970 discussion 970-961. (doi:10.1016/j.juro.
2006.04.011)
Prins GS & Birch L 1997 Neonatal estrogen exposure up-regulates estrogen
receptor expression in the developing and adult rat prostate lobes.
Endocrinology 138 1801–1809.
Prins GS & Korach KS 2008 The role of estrogens and estrogen receptors in
normal prostate growth and disease. Steroids 73 233–244. (doi:10.1016/
j.steroids.2007.10.013)
Prins GS, Huang L, Birch L & Pu Y 2006 The role of estrogens in normal and
abnormal development of the prostate gland. Annals of the New York
Academy of Sciences 1089 1–13. (doi:10.1196/annals.1386.009)
Prins GS, Birch L, Tang WY & Ho SM 2007 Developmental estrogen
exposures predispose to prostate carcinogenesis with aging. Reproduc-
tive Toxicology 23 374–382. (doi:10.1016/j.reprotox.2006.10.001)
Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I,
Mostaghel E, Higano CS, Porter C, Vessella R et al. 2013 A three-marker
FISH panel detects more genetic aberrations of, and in castration-
resistant or metastatic prostate cancers than in primary prostate
tumors. PLoS ONE 8 e74671. (doi:10.1371/journal.pone.0074671)
Razzak M 2013 Prostate cancer: not guilty-TMPRSS2-ERG does not sensitize
cells to radiation. Nature Reviews. Urology 10 556. (doi:10.1038/nrurol.
2013.188)
Reiter E, Gerster P & Jungbauer A 2011 Red clover and soy isoflavones – an
in vitro safety assessment. Gynecological Endocrinology 27 1037–1042.
(doi:10.3109/09513590.2011.588743)
Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y & Risbridger GP
2008 Prostatic hormonal carcinogenesis is mediated by in situ estrogen
production and estrogen receptor a signaling. FASEB Journal 22
1512–1520. (doi:10.1096/fj.07-9526com)
RisbridgerGP, EllemSJ&McPherson SJ 2007 Estrogen actionon theprostate
gland: a critical mix of endocrine and paracrine signaling. Journal of
Molecular Endocrinology 39 183–188. (doi:10.1677/JME-07-0053)
Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG &
Carroll JS 2011 Androgen receptor driven transcription in molecular
apocrine breast cancer is mediated by FoxA1. EMBO Journal 30
3019–3027. (doi:10.1038/emboj.2011.216)
Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K,
Kissler S, Gatje R, Karn T & Kaufmann M 2005 Methylation of estrogen
E
n
d
o
cr
in
e-
R
e
la
te
d
C
a
n
ce
r
Thematic Review A W Nelson et al. ER-beta: friend or foe? 21 :2 T14
http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0508 Printed in Great Britain
Published by Bioscientifica Ltd.
159
receptor b promoter correlates with loss of ER-b expression in
mammary carcinoma and is an early indication marker in
premalignant lesions. Endocrine-Related Cancer 12 903–916.
(doi:10.1677/erc.1.01088)
Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F,
Trepel J & Bergan RC 1998 Prostate cancer cell growth inhibition by
tamoxifen is associated with inhibition of protein kinase C and
induction of p21(waf1/cip1). Prostate 37 51–59. (doi:10.1002/
(SICI)1097-0045(19980915)37:1!51::AID-PROS8O3.0.CO;2-B)
Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD
& Platz EA 2007 Serum estrogen, but not testosterone, levels differ
between black and white men in a nationally representative sample of
Americans. Journal of Clinical Endocrinology and Metabolism 92
2519–2525. (doi:10.1210/jc.2007-0028)
Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC &
Henderson BE 1992 5-a-reductase activity and risk of prostate cancer
among Japanese and US white and black males. Lancet 339 887–889.
(doi:10.1016/0140-6736(92)90927-U)
Rossi V, Bellastella G, De Rosa C, Abbondanza C, Visconti D, Maione L,
Chieffi P, Della Ragione F, Prezioso D, De Bellis A et al. 2011 Raloxifene
induces cell death and inhibits proliferation throughmultiple signaling
pathways in prostate cancer cells expressing different levels of estrogen
receptor a and b. Journal of Cellular Physiology 226 1334–1339.
(doi:10.1002/jcp.22461)
Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A,
Ahn JM, Raj GV, Tekmal RR, Sun L & Vadlamudi RK 2012 Significance
of PELP1 in ER-negative breast cancer metastasis. Molecular Cancer
Research 10 25–33. (doi:10.1158/1541-7786.MCR-11-0456)
Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND &
van der Kwast TH 1991 Androgen receptor expression in human tissues:
an immunohistochemical study. Journal of Histochemistry and Cyto-
chemistry 39 927–936. (doi:10.1177/39.7.1865110)
Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A,
Turunen JP, Lundin M, Konsti J et al. 2011 Dual role of FoxA1 in
androgen receptor binding to chromatin, androgen signalling and
prostate cancer. EMBO Journal 30 3962–3976. (doi:10.1038/emboj.
2011.328)
Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, Hamilton C,
Yue W &Wang JP 1997 Estrogen production via the aromatase enzyme
in breast carcinoma: which cell type is responsible? Journal of Steroid
Biochemistry and Molecular Biology 61 267–271. (doi:10.1016/
S0960-0760(97)80022-2)
Scher HI, Buchanan G, Gerald W, Butler LM & Tilley WD 2004 Targeting
the androgen receptor: improving outcomes for castration-resistant
prostate cancer. Endocrine-Related Cancer 11 459–476. (doi:10.1677/
erc.1.00525)
Setlur SR,Mertz KD, Hoshida Y, Demichelis F, LupienM, Perner S, Sboner A,
Pawitan Y, Andren O, Johnson LA et al. 2008 Estrogen-dependent
signaling in a molecularly distinct subclass of aggressive prostate
cancer. Journal of the National Cancer Institute 100 815–825.
(doi:10.1093/jnci/djn150)
Shaaban AM, O’Neill PA, Davies MP, Sibson R, West CR, Smith PH & Foster
CS 2003 Declining estrogen receptor-b expression defines malignant
progression of human breast neoplasia. American Journal of Surgical
Pathology 27 1502–1512. (doi:10.1097/00000478-200312000-00002)
Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD,
MacArthur S, Stark R, Warren AY, Mills IG et al. 2013 The androgen
receptor induces a distinct transcriptional program in castration-
resistant prostate cancer in man. Cancer Cell 23 35–47. (doi:10.1016/
j.ccr.2012.11.010)
Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S &
Hursting SD 2000 Low-dose genistein induces cyclin-dependent kinase
inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.
Molecular Carcinogenesis 29 92–102. (doi:10.1002/1098-
2744(200010)29:2!92::AID-MC6O3.0.CO;2-Q)
Shozu M, Zhao Y & Simpson ER 2000 TGF-b1 stimulates expression of the
aromatase (CYP19) gene in human osteoblast-like cells and THP-1 cells.
Molecular and Cellular Endocrinology 160 123–133. (doi:10.1016/
S0303-7207(99)00233-6)
Sissung TM, Danesi R, Kirkland CT, BaumCE, Ockers SB, Stein EV, VenzonD,
Price DK & Figg WD 2011 Estrogen receptor a and aromatase
polymorphisms affect risk, prognosis, and therapeutic outcome in men
with castration-resistant prostate cancer treated with docetaxel-based
therapy. Journal of Clinical Endocrinology and Metabolism 96 E368–E372.
(doi:10.1210/jc.2010-2070)
Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ & Speirs V 2002
Evaluation of seven oestrogen receptor b antibodies for immuno-
histochemistry, western blotting, and flow cytometry in human breast
tissue. Journal of Pathology 197 155–162. (doi:10.1002/path.1077)
Stener-Victorin E, Holm G, Labrie F, Nilsson L, Janson PO & Ohlsson C
2010 Are there any sensitive and specific sex steroid markers for
polycystic ovary syndrome? Journal of Clinical Endocrinology and
Metabolism 95 810–819. (doi:10.1210/jc.2009-1908)
Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH &
Thelen P 2007 The relevance of estrogen receptor-b expression to the
antiproliferative effects observed with histone deacetylase inhibitors
and phytoestrogens in prostate cancer treatment. Molecular Cancer
Therapeutics 6 2626–2633. (doi:10.1158/1535-7163.MCT-07-0197)
SubbaramaiahK,HoweLR,BhardwajP,DuB,GravaghiC,YantissRK,ZhouXK,
Blaho VA, Hla T, Yang P et al. 2011 Obesity is associated with
inflammation and elevated aromatase expression in the mouse
mammary gland. Cancer Prevention Research 4 329–346. (doi:10.1158/
1940-6207.CAPR-10-0381)
Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H& Yaegashi
N 2008 Loss of estrogen receptor b isoform expression and its
correlation with aberrant DNA methylation of the 5’-untranslated
region in human epithelial ovarian carcinoma. Cancer Science 99
2365–2372. (doi:10.1111/j.1349-7006.2008.00988.x)
Thelen P, Scharf JG, Burfeind P, Hemmerlein B, Wuttke W, Spengler B,
Christoffel V, Ringert RH & Seidlova-Wuttke D 2005 Tectorigenin and
other phytochemicals extracted from leopard lily Belamcanda chinensis
affect new and established targets for therapies in prostate cancer.
Carcinogenesis 26 1360–1367. (doi:10.1093/carcin/bgi092)
Thelen P, Peter T, Hunermund A, Kaulfuss S, Seidlova-Wuttke D, Wuttke W,
Ringert RH & Seseke F 2007 Phytoestrogens from Belamcanda chinensis
regulate the expression of steroid receptors and related cofactors in
LNCaP prostate cancer cells. BJU International 100 199–203.
(doi:10.1111/j.1464-410X.2007.06924.x)
Thelen P, Wuttke W & Seidlova-Wuttke D 2014 Phytoestrogens selective
for the estrogen receptor b exert anti-androgenic effects in castration
resistant prostate cancer. Journal of Steroid Biochemistry and Molecular
Biology 139 290–3. (doi:10.1016/j.jsbmb.2013.06.009)
Tilley WD, Horsfall DJ, McGee MA, Henderson DW & Marshall VR 1985
Distribution of oestrogen and androgen receptors between the stroma
and epithelium of the guinea-pig prostate. Journal of Steroid Biochemistry
22 713–719. (doi:10.1016/0022-4731(85)90276-6)
Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A & Kumar R
2001 Molecular cloning and characterization of PELP1, a novel human
coregulator of estrogen receptor a. Journal of Biological Chemistry 276
38272–38279.
Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E,
van Rooij HC, Trapman J, Brinkmann AO &Mulder E 1990 A mutation
in the ligand binding domain of the androgen receptor of human
LNCaP cells affects steroid binding characteristics and response to
anti-androgens. Biochemical and Biophysical Research Communications
173 534–540. (doi:10.1016/S0006-291X(05)80067-1)
Vermeulen A, Kaufman JM, Goemaere S & van Pottelberg I 2002 Estradiol
in elderly men. Aging Male 5 98–102.
Waltering KK, Urbanucci A & Visakorpi T 2012 Androgen receptor (AR)
aberrations in castration-resistant prostate cancer. Molecular and
Cellular Endocrinology 360 38–43. (doi:10.1016/j.mce.2011.12.019)
E
n
d
o
cr
in
e-
R
e
la
te
d
C
a
n
ce
r
Thematic Review A W Nelson et al. ER-beta: friend or foe? 21 :2 T15
http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0508 Printed in Great Britain
Published by Bioscientifica Ltd.
160
Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM,
Pienta KJ & Brown M 2007 A hierarchical network of transcription
factors governs androgen receptor-dependent prostate cancer growth.
Molecular Cell 27 380–392. (doi:10.1016/j.molcel.2007.05.041)
WangQ, LiW, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R,WangH,
Lupien M et al. 2009 Androgen receptor regulates a distinct
transcription program in androgen-independent prostate cancer. Cell
138 245–256. (doi:10.1016/j.cell.2009.04.056)
Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W,
Kaikkonen MU, Ohgi KA et al. 2011 Reprogramming transcription by
distinct classes of enhancers functionally defined by eRNA. Nature 474
390–394. (doi:10.1038/nature10006)
Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH & Murphy
LC 2006 Assessment of multiple different estrogen receptor-b
antibodies for their ability to immunoprecipitate under chromatin
immunoprecipitation conditions. Breast Cancer Research and Treatment
100 23–31. (doi:10.1007/s10549-006-9229-5)
Wernert N, Gerdes J, Loy V, Seitz G, Scherr O & Dhom G 1988
Investigations of the estrogen (ER-ICA-test) and the progesterone
receptor in the prostate and prostatic carcinoma on immuno-
histochemical basis. Virchows Archiv. A, Pathological Anatomy and
Histopathology 412 387–391. (doi:10.1007/BF00750267)
Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD & Dahut WL 2007
Routine interval computed tomography to detect new soft-tissue
disease might be unnecessary in patients with androgen-independent
prostate cancer and metastasis only to bone. BJU International 99
525–528. (doi:10.1111/j.1464-410X.2006.06654.x)
Wuttke W, Jarry H, Westphalen S, Christoffel V & Seidlova-Wuttke D 2002
Phytoestrogens for hormone replacement therapy? Journal of Steroid
Biochemistry and Molecular Biology 83 133–147. (doi:10.1016/
S0960-0760(02)00259-5)
Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT &
Raj GV 2012 Central role for PELP1 in nonandrogenic activation of the
androgen receptor in prostate cancer. Molecular Endocrinology 26
550–561. (doi:10.1210/me.2011-1101)
Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA,
Stanczyk FZ, Reichardt JK, Tang L et al. 2011 Serum estrogen levels and
prostate cancer risk in the prostate cancer prevention trial: a nested
case–control study. Cancer Causes & Control 22 1121–1131.
(doi:10.1007/s10552-011-9787-7)
ZellwegerT, SturmS,ReyS, Zlobec I,Gsponer JR,RentschCA, TerraccianoLM,
Bachmann A, Bubendorf L & Ruiz C 2013 Estrogen receptor b
expression and androgen receptor phosphorylation correlate with a
poor clinical outcome in hormone-naive prostate cancer and are
elevated in castration-resistant disease. Endocrine-Related Cancer 20
403–413. (doi:10.1530/ERC-12-0402)
Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1997 Transcriptional
regulation of CYP19 gene (aromatase) expression in adipose stromal
cells in primary culture. Journal of Steroid Biochemistry and Molecular
Biology 61 203–210. (doi:10.1016/S0960-0760(97)80013-1)
Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC,
Gustafsson JA & Dahlman-Wright K 2003 Expression of estrogen
receptor b isoforms in normal breast epithelial cells and breast cancer:
regulation by methylation. Oncogene 22 7600–7606. (doi:10.1038/
sj.onc.1207100)
Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, Lam EW,
Cheng G, Gustafsson JA & Dahlman-Wright K 2007 Estrogen receptor
b2 negatively regulates the transactivation of estrogen receptor a in
human breast cancer cells.Cancer Research 67 3955–3962. (doi:10.1158/
0008-5472.CAN-06-3505)
Zhao C, Gao H, Liu Y, Papoutsi Z, Jaffrey S, Gustafsson JA & Dahlman-
Wright K 2010 Genome-wide mapping of estrogen receptor-b-binding
regions reveals extensive cross-talk with transcription factor activator
protein-1. Cancer Research 70 5174–5183. (doi:10.1158/0008-5472.
CAN-09-4407)
Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE & Ho SM 2004
Dynamic regulation of estrogen receptor-b expression by DNA
methylation during prostate cancer development and metastasis.
American Journal of Pathology 164 2003–2012. (doi:10.1016/
S0002-9440(10)63760-1)
Received in final form 31 December 2013
Accepted 6 January 2014
Made available online as an Accepted Preprint
8 January 2014
E
n
d
o
cr
in
e-
R
e
la
te
d
C
a
n
ce
r
Thematic Review A W Nelson et al. ER-beta: friend or foe? 21 :2 T16
http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0508 Printed in Great Britain
Published by Bioscientifica Ltd.
161
Comprehensive assessment of estrogen receptor beta antibodies in
cancer cell line models and tissue reveals critical limitations in reagent
speciﬁcity
Adam W. Nelson a, b, c, Arnoud J. Groen a, Jodi L. Miller a, Anne Y. Warren d,
Kelly A. Holmes a, Gerard A. Tarulli e, Wayne D. Tilley e, Benita S. Katzenellenbogen f,
John R. Hawse g, Vincent J. Gnanapragasam b, c, Jason S. Carroll a, *
a Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 ORE, UK
b Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge, CB2 0QQ, UK
c Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK
d Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UK
e Dame Roma Mitchell Cancer Research Laboratories, Hanson Institute Building, School of Medicine, Faculty of Health Sciences, The University of Adelaide,
SA 5005, Australia
f Departments of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
g Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905 USA
a r t i c l e i n f o
Article history:
Received 7 September 2016
Received in revised form
1 November 2016
Accepted 20 November 2016
Available online 23 November 2016
Keywords:
Estrogen receptor beta
Prostate
Breast
Cancer
Antibody
a b s t r a c t
Estrogen Receptor-b (ERb) has been implicated in many cancers. In prostate and breast cancer its function
is controversial, but genetic studies implicate a role in cancer progression. Much of the confusion around
ERb stems from antibodies that are inadequately validated, yet have become standard tools for deci-
phering its role. Using an ERb-inducible cell system we assessed commonly utilized ERb antibodies and
show that one of the most commonly used antibodies, NCL-ER-BETA, is non-speciﬁc for ERb. Other
antibodies have limited ERb speciﬁcity or are only speciﬁc in one experimental modality. ERb is
commonly studied in MCF-7 (breast) and LNCaP (prostate) cancer cell lines, but we found no ERb
expression in either, using validated antibodies and independent mass spectrometry-based approaches.
Our ﬁndings question conclusions made about ERb using the NCL-ER-BETA antibody, or LNCaP and MCF-
7 cell lines. We describe robust reagents, which detect ERb across multiple experimental approaches and
in clinical samples.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Estrogen receptor beta (ERb) was ﬁrst discovered in the rat
prostate (Kuiper et al., 1996). Since then, there has been consider-
able interest in understanding its role in both breast and prostate
cancer. Despite a large body of literature, the function of ERb in
these two cancers remains unclear (Haldosen et al., 2014; Nelson
et al., 2014). Most authors agree that ERb has a predominantly
antiproliferative, pro-apoptotic and tumor-suppressive role (Attia
and Ederveen, 2012; Bottner et al., 2014; Chang and Prins, 1999;
Ellem and Risbridger, 2007; Horvath et al., 2001; Madak-Erdogan
et al., 2013; McPherson et al., 2010; Muthusamy et al., 2011;
Nakajima et al., 2011; Rizza et al., 2014; Ruddy et al., 2014; Zhu et al.,
2004), however ERb has also been implicated as an oncogene. This
is particularly in the context of Castrate Resistant Prostate Cancer
(CRPC) where it has been proposed as a driver of androgen receptor
(AR)-dependent gene transcription (Yang et al., 2012, 2015), along
with a potential role in mediating the transition from hormone-
sensitive to CRPC (Zellweger et al., 2013). In breast cancer, it has
been suggested that ERbmay have a ‘bi-faceted role’ and should not
simply be considered a tumor-suppressor (Jonsson et al., 2014). ERb
has been reported to ‘cross-talk’ with androgen receptor-positive
breast cancer (Rizza et al., 2014) and may be an important factor
in ERa-negative breast cancer (Gruvberger-Saal et al., 2007; Smart
et al., 2013).
Inconsistencies in the reported expression of ERb in breast and* Corresponding author.
E-mail address: Jason.carroll@cruk.cam.ac.uk (J.S. Carroll).
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prostate cancers as determined by immunohistochemistry (IHC)
have contributed to this uncertainty. In prostate, most data support
the conclusion that ERb is highly expressed in benign epithelial
cells, with expression declining in cancer development and
inversely correlating with increasing Gleason grade (Asgari and
Morakabati, 2011; Attia and Ederveen, 2012; Dey et al., 2014;
Horvath et al., 2001; Leav et al., 2001; Risbridger et al., 2007).
However, it has also been reported that ERb expression is high in
bone and lymph node metastases (Bouchal et al., 2011; Zhu et al.,
2004) and that high ERb expression correlates with poor clinical
prognosis (Horvath et al., 2001; Zellweger et al., 2013). In breast
cancer, high ERb expression has been described both as a poor (Guo
et al., 2014) and favorable (Esslimani-Sahla et al., 2004;
Gruvberger-Saal et al., 2007; Hieken et al., 2015; Leygue and Mur-
phy, 2013; Myers et al., 2004; Omoto et al., 2002; Roger et al., 2001)
prognostic marker, with others ﬁnding no association between
clinico-pathological parameters and ERb expression (Umekita et al.,
2006).
It is recognized that there is wide variability in the sensitivity
and speciﬁcity of ERb antibodies, which may contribute to the
uncertainties surrounding its molecular action and tissue expres-
sion (Choi et al., 2001; Hartman et al., 2012; Skliris et al., 2002;
Weitsman et al., 2006; Wu et al., 2012). Previous ERb antibody
validation studies have been published (Carder et al., 2005; Choi
et al., 2001; Skliris et al., 2002; Weitsman et al., 2006; Wu et al.,
2012), however some of them are limited by reliance on two key
assumptions. Firstly, that when assessing an antibody by Western
blotting in a cell line model, the factor of interest is expressed and
secondly, when assessing an antibody's speciﬁcity by IHC in tissue,
the tissue expression of the factor has been well characterized. In
the case of ERb, these assumptions are problematic, as its expres-
sion in commonly used cell line models and in tissues is not uni-
versally accepted (Al-Bader et al., 2011; Asgari and Morakabati,
2011; Attia and Ederveen, 2012; Bouchal et al., 2011; Dey et al.,
2014; Gruvberger-Saal et al., 2007; Guo et al., 2014; Hieken et al.,
2015; Holbeck et al., 2010; Horvath et al., 2001; Leav et al., 2001;
Nakajima et al., 2011; Omoto et al., 2002; Risbridger et al., 2007;
Shaaban et al., 2003; Skliris et al., 2002; Umekita et al., 2006;
Zellweger et al., 2013; Zhou et al., 2012; Zhu et al., 2004).
In light of this, we sought to test and validate six commonly
used, commercially available ERb antibodies and two non-
commercially available ERb antibodies (Choi et al., 2001; Wu
et al., 2012) in a systematic manner that addresses these assump-
tions. To achieve this, we employed a number of assays for antibody
validation, including a novel proteomic-based pull down method
called Rapid Immunopreciptation Mass spectrometry of Endoge-
nous protein (RIME) (Mohammed et al., 2013). We then applied
successfully validated antibodies to cell line models of breast and
prostate cancer commonly used for studies of ERb to assess them
for ERb expression. ERb expression in the cell lines was validated by
a non-antibody dependent, targeted proteomics method known as
Parallel Reaction Monitoring (PRM) (Gallien et al., 2012). Finally,
benign and malignant prostate and breast tissues were stained
with the validated ERb antibody to assess tissue expression of ERb
by IHC.
2. Materials and methods
2.1. Cell culture
The cancer cell line MDA-MB-231 with doxycycline-inducible
ERb expression (MDA-MB-231-ERb) (Reese et al., 2014) was
cultured in Dulbeccos Modiﬁed Eagle Medium with F12 supple-
ment (DMEM/F12) with 10% heat-inactivated tetracycline-free fetal
bovine serum (FBS) (Fisher-Scientiﬁc), 2 mM L-glutamine, 50 U/ml
penicillin, 50 mg/ml streptomycin, 5 mg/ml blasticidin S (Invivogen)
to select for the tetracycline repressor and 500 mg/ml zeocin
(Invitrogen) to select for the ERb expression vector. To induce ERb
expression in MDA-MB 231-ERb cells, 15 cm2 plates were seeded
with 5 ! 106 cells and doxycycline added at either 0.1 mg/ml (for
Western blot, real-time polymerase chain reaction (qRT-PCR) and
PRM) or 0.5 mg/ml (for RIME) for 24 h. The MCF-7 breast cancer cell
line was cultured in Dulbecco's Modiﬁed Eagle Medium (DMEM)
with 10% heat-inactivated FBS (Fisher-Scientiﬁc), 2 mM L-gluta-
mine, 50 U/ml penicillin and 50 mg/ml streptomycin. The LNCaP
prostate cancer cell line was cultured in RPMI 1640 with 10% heat-
inactivated FBS (Fisher-Scientiﬁc), 2 mM L-glutamine, 50 U/ml
penicillin and 50 mg/ml streptomycin. All cells were incubated at
37 "C with 5% CO2 and cultured to 80e90% conﬂuence. LNCaP and
MCF-7 cell lines were obtained from ATCC (Middlesex, UK) and
validated by STR genotyping.
2.2. Preparation of mRNA and qRT-PCR
MDA-MB-231-ERbþ, MDA-MB-231-ERbe, MCF-7 and LNCaP
cells were harvested for collection of mRNA using the RNEasy Mini
Kit (Qiagen, California USA). On-column DNase digestion was per-
formed to remove contaminating genomic DNA. RNA was quanti-
ﬁed with the NanoDrop 8000 (Thermo Scientiﬁc, Delaware USA).
Samples containing 250 ng random primers, 1 mg RNA, 1 ml 10 mM
dNTP mix and water to a total volume of 13 ml were heated to 65 "C
for 5 min, followed by 1 min incubation on ice. To each sample 4 ml
5X First-strand buffer, 1 ml 0.1 M DTT, 1 ml RNaseOUT and 1 ml Su-
perScript III reverse transcriptase (RT) (Thermoﬁsher Scientiﬁc,
Leicestershire, UK) were added and incubated at 25 "C for 5 min
then 50 "C for 60 min followed by heating at 70 "C for 15 min qRT-
PCR primers for wild type ERb (Table 1) were designed based on
published sequence of ESR2 (available from USCS genome browser
at http://genome.ucsc.edu/) using the Primer3 software package
(Koressaar and Remm, 2007; Untergasser et al., 2012) available at
http://bioinfo.ut.ee/primer3-0.4.0/primer3/. UBC primers
(SY121212648) were obtained from Sigma-Aldrich (Dorset, UK).
Each qRT-PCR reaction contained 7.5 ml Power SYBR Green PCR
Master Mix (Applied Biosystems, California USA), 0.5 ml of 10 mM
primer mix, 2 ml of a 1:5 dilution of cDNA and nuclease-free water
to a ﬁnal volume of 15 ml. Reactions were performed with the
Stratagene Mx3005P RealTime machine in triplicate. Hot-start Taq
polymerase was heat-activated at 95 "C for 10 min followed by 40
cycles of 15 s at 95 "C and 30 s at 60 "C. Fluorescence was read in
each cycle and a melting curve constructed as the temperature was
increased from 65 "C to 95 "C with continuous ﬂuorescence read-
ings. UBC was used as a control gene to normalize between the
samples and relative expression determined using the delta-delta
Ct method (Livak and Schmittgen, 2001).
2.3. Western blotting
MDA-MB-231-ERbþ, MDA-MB-231-ERbe, MCF-7 and LNCaP
cells were harvested for nuclear extract using the Ne-Per nuclear
extraction kit (Thermo Scientiﬁc Pierce, Rockford IL USA) according
to the manufacturer's instructions. Extracted protein was quanti-
ﬁed using the Direct Detect system (Merrick Millipore, Massachu-
setts USA). Nuclear extracts were prepared with 4X protein sample
loading buffer (LI-COR Biosciences, USA), 10X NuPage sample
reducing agent (Thermoﬁsher Scientiﬁc, Leicestershire, UK) and
water, and 15 mg protein per lane loaded into Bolt 4e12% Bis-Tris
gels (Thermoﬁsher Scientiﬁc, Leicestershire, UK). Gels were run
with MOPS running buffer for 30 min at 60 V followed by 30 min at
120 V. Western transfer was performed using the iBlot system
(Invitrogen, Paisley, UK) according to the manufacturer's
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instructions. Odyssey blocking buffer (LI-COR Biosciences, USA)
was added to membranes for one hour at room temperature. Pri-
mary antibodies (Table 2 and Supplementary Fig. 1) were added at
the following dilutions and incubated overnight at 4 !C:
Novocastra-ER-beta (EMR02-NCL-ER-BETA) (Leica Biosystems,
Newcastle, UK) 1:100, ERb1 PPG5/10 (MAI-81281) (Thermo Scien-
tiﬁc Pierce, Rockford IL USA) 1:100, ERb-antibody H150 (sc8974)
(Santa Cruz Biotechnology, Dallas TX, USA) 1:200, CWK-F12, USA)
(Choi et al., 2001) 1:200, MC10 (Wu et al., 2012) 1:300, GeneTex
ERb 70182 (Irvine, CA, USA) 1:200, ERb 06-629 (Merck Millipore,
Watford, UK), 1:500, Abcam 288 [14C8] (Cambridge, UK) 1:500. The
following were used as loading controls: rabbit anti-beta actin
(ab8227) (Abcam, Cambridge, UK) 1:5000 or mouse anti-beta actin
[AC-15](ab6276) 1:1000 according to the species of the ERb anti-
body. The membranes were washed three times with PBS/0.1%
tween and incubated with secondary antibodies for one hour at
room temperature: Goat anti-mouse (green) 1:5000 with Goat
anti-rabbit (red) 1:20000 or Goat anti-rabbit (green) 1:5000 with
Goat anti-mouse (red) 1:20000 according to the species of the ERb
antibody. Membranes were imaged using the Li-Cor Odyssey ﬂuo-
rescent imaging system (LI-COR Biosciences, USA).
2.4. Immunohistochemistry (IHC)
Formalin-ﬁxed, parafﬁn-embedded MDA-MB-231-ERbe and
MDA-MB-231-ERbþ cell pellets were generated, with ~2# 107 cells
per pellet. ERb expression was induced with 0.5 mg/ml doxycycline
for 24 h. Antigen retrieval was achieved by incubating in citrate-
based retrieval solution for 20 min. Sections were stained using
CWK-F12 ERb antibody, diluted 1:250 in standard Bond diluent
using Leica's Polymer Reﬁne Kit (Catalogue No: DS9800) on the
automated Bond platform (Leica Biosystems Newcastle Ltd, New-
castle UK). Images were captured using Aperio® software (Leica
Biosystems Newcastle Lt, Newcastle UK).
A prostate tissue microarray (TMA) was created from a random
selection of prostate cancers, including a range of different tumor
grades, and benign prostatic tissue (10 cancer, 5 benign in total)
(ethical approval: ProMPT study MREC/01/4/061). The areas to be
sampled from the formalin-ﬁxed and parafﬁn embedded tissue
blocks were marked on the corresponding Haematoxylin and Eosin
stained parafﬁn sections. Each block was assessed to ensure that
there was an adequate amount of tissue for sampling, and cores of
tissue punched from the selected area of the block using 5 mm skin
biopsy punches. Each core was re-embedded into a new recipient
parafﬁn block and its position in the block recorded on a TMAmap.
Cores of pig kidney were used as orientation markers.
The breast TMA was constructed using the Chemicon Advanced
Tissue Arrayer (Merck Millipore, Germany) according to the man-
ufacturer's instructions. This contained 30 benign samples, 56
grade I, 55 grade II and 57 grade III ER alpha positive tumors. An
additional TMA was constructed from 10 invasive carcinomas and
10 non-malignant tissues for optimisation of antibody staining. To
ensure adequate representation of the tissue, core size of 1 mmwas
selected and cores arranged in duplicate with liver and spleen as
orientation cores. The study protocol for tissue collection was
approved by the University of Adelaide Human Research Ethics
Committee (#s H-2005-065).
For the prostate IHC, 3.5 mm sections were cut and mounted
onto charged slides, dried and sealed with parafﬁn. The CWK-F12
ERb antibody was further optimized to the clinical samples and
diluted at 1:200 in diluent consisting of 1% donkey serum, 0.05%
Tween20 in 300 mM TBS to reduce background staining. Antigen
retrieval was achieved by incubating in Tris EDTA for 20 min at
100 !C. Images were captured at 250 # magniﬁcation using Image
Pro-Insight (Media Cybernetics. Rockville, MD. USA).
For the breast IHC, 4 mm sections were cut and adhered to
Superfrost UltraPLUS slides (Thermo-Fisher Scientiﬁc
#1014356190). Slides were dewaxed in xylene followed by 100%
EtOH and then PBS. Endogenous peroxidase was quenched with
0.3% hydrogen peroxide (Ajax Finchem ##7722-84-1). Antigen
retrieval was performed in 10 mM Citric acid buffer (pH 6.0) within
a decloaking chamber (Biocare Medical #DC2012), for 5 min at
120 !C. Slides were blocked in 5% normal goat serum (Sigma-
Aldrich #G9023) in PBS for 30 min at room temperature. CWK-F12
antibody was added at a dilution of 1:100 and incubated overnight
at 4 !C. A second section of TMA tissue that received buffer in the
absence of primary antibody served as a negative control. Sec-
ondary antibody (biotinylated anti-mouse antibody (Dako #E0433)
diluted in PBS with 5% normal goat serumwas added and incubated
for 60min at room temperature. Sections werewashed twice in PBS
followed by addition of HRP-conjugated streptavidin (Dako
#P0397). Tissue was counterstained with haematoxylin and
mounted under DPX mountant (Sigma #06522). Slides were
scanned on a Nanozoomer slide scanner (Hamamatsu #C9600).
2.5. Rapid immunoprecipitation and Mass Spectrometry of
Endogenous Protein (RIME)
RIME experiments were conducted as previously described
(Mohammed et al., 2013). Brieﬂy, MDA-MB-231-ERbþ, MDA-MB-
231-ERbe (2 # 107 cells per condition for antibody evaluation),
LNCaP and MCF-7 cells (4 # 107 cells per condition for cell line
characterization) were grown in 15 cm2 plates to 90% conﬂuency.
Cells were crosslinked with media containing 1% EM grade form-
aldehyde (TEBU biosciences, Peterborough UK) for 8 min and the
formaldehyde quenched with 0.1 M glycine. Cells were washed,
harvested and pelleted in cold PBS. To enrich the nuclear fraction
the cell pellet was suspended in 10 ml of lysis buffer 1 (50 mM
HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5%
NP-40 or Igepal CA-630, and 0.25% Triton X-100) for 10 min at 4 !C.
Cells were pelleted and resuspended in lysis buffer 2 (10 mM Tris-
HCL [pH 8.0], 200 mMNaCl, 1 mM EDTA, and 0.5 mM EGTA) for ﬁve
minutes at 4 !C. Cells were pelleted and resuspended in 300 ml of
lysis buffer 3 (10 mM Tris-HCl [pH 8], 100 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.5% N-lauroylsarcosine)
and sonicated (Diagenode bioruptor. Diagenode, Seraing Belgium)
for 45 min 30 ml of 10% Triton-X was added and the sonicated lysate
centrifuged at 17,000G for 10 min to remove cell debris. The su-
pernatant was incubated with 100 ml of magnetic beads (Dyna-
beads®, Thermo Fisher Scientiﬁc, Waltham MA USA) pre-bound
with antibody.
For evaluation of the 8 ERb antibodies, immunoprecipitations
(IP) were set up each for MDA-MB-231-ERbe and MDA-MB-231-
ERbþ cells using 10 mg of antibody (NCL-ER-BETA, GeneTex
70182, Millipore 06-629, Abcam 288 [14C8], MC10, CWK-F12,
sc8974 and PPG5/10). For characterization of LNCaP and MCF-
7 cells, 20 mg of MC10 ERb antibody was used in each IP. In all cases,
10 mg of E2F1-C20 IP was used as a positive control (Sc-193, Santa
Cruz Biotechnology, Dallas TX, USA) and species-speciﬁc IgG used
to detect non-speciﬁc pull-down (Mouse sc2025 or Rabbit sc2027,
Santa Cruz Biotechnology, Dallas TX, USA). Samples were incubated
Table 1
Sequence of ERbmRNA primers used in qRT-PCR validation of theMDA-MB-
231-ERb cell line. These primer sequences ﬂank a region spanning exons 2
and 3, which is common to wild type ERb and ERb isoforms.
Primer Sequence
ERb e fwd 50 AAAACCGGCGCAAGAGCTG 30
ERb e rev 30 TGCTCGTCGGCACTTCTCTG 50
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overnight at 4 !C. Beads were washed 10 times in 1 ml RIPA buffer
(50mMHEPES pH 7.6,1mM EDTA, 0.7% Na deoxycholate,1% NP-40,
0.5 M LiCL) and twice in 100 mM ammonium hydrogen carbonate
(AMBIC) solution. Dry, frozen beads were submitted for tryptic
digestion of bead-bound protein, and peptides pulled down by IP
identiﬁed by mass-spectrometry (LTQ Velos-Orbitrap MS, Thermo
Fisher Scientiﬁc, Waltham MA USA). Raw MS data ﬁles were pro-
cessed using Proteome Discoverer v.1.3 (Thermo Scientiﬁc). Pro-
cessed ﬁles were searched against the SwissProt human database
using the Mascot search engine version 2.3.0 with a false discovery
rate (FDR) of less than 1%. For each ERb antibody tested, the
resulting list of puriﬁed peptides identiﬁed was ﬁltered against the
corresponding IgG control to remove non-speciﬁc proteins pulled
down. Mean percentage ERb peptide coverage, and mean number
of unique ERb peptides identiﬁed in biological duplicate experi-
ments were calculated.
2.6. Parallel Reaction monitoring (PRM)
Nuclear pellets of MDA-MB-231-ERbþ, MDA-MB-231-ERbe,
LNCaP and MCF-7 cells were prepared using the Panomics nuclear
extraction kit (Affymetrix, CA USA) as per the manufacturer's pro-
vided instructions. Nuclear pellets were lysed in 8 M Urea, 0.1% SDS
in 50 mM TEAB by sonication twice, each for 5 min. After protein
estimation 20 mg of protein was taken for tryptic digestion. 50 mM
of TEAB (pH¼ 8) was added up to a total volume of 100 ml. Cysteines
were reduced in 0.1 mM DTT for 1 h at room temperature and
alkylated in 0.1 mM IAA for 30 min at room temperature in the
dark. Alkylation was quenched by adding 0.1 mM DTT for 15 min.
Trypsin (Promega trypsin (V5111)) was added in a 1:100 trypsin:-
protein ratio for 1 h at room temperature. Another batch of trypsin
(1:100 ratio) was added to have a ﬁnal ratio of 1:50 for incubation
overnight. Samples were acidiﬁed to a ﬁnal concentration of 1%
formic acid (FA) and cleaned over C18 spin columns (Harvard
apparatus C18 Micro SpinColumn™). After elution from the col-
umns samples were lyophilized in a speedvac and resolubilized in
0.1% FA, 5% ACN to a ﬁnal peptide concentration of 1 mg/ml. Samples
were subjected to liquid chromatography-electrospray ionization
in an Orbitrap nano-ESI Q-Exactive mass spectrometer (Thermo
Scientiﬁc), coupled to a nanoLC (Dionex Ultimate 3000 UHPLC).
Samples were trapped on a 100 mm$ 2 cm, C18, 5 mm,100 trapping
column (Acclaim PepMap 100) in mL-pickup injection mode at 4 mL/
min ﬂow rate for 10 min. Samples were loaded on a Rapid Sepa-
ration Liquid Chromatography, 75 mm $ 25 cm nanoViper C18 3 mm
100 column (Acclaim, PepMap) retroﬁtted to an EASY-Spray source
with a ﬂow rate of 300 nL/min (buffer A, HPLC H2O, 0.1% FA; buffer
B, 100% ACN, 0.1% FA; 60-min gradient; 0e5 min: 5% buffer B,
5e45 min: 5 to >56% buffer B, 45.1e50 min: 56% to >95% buffer B,
50.1e60 min, 5% buffer B). Peptides were transferred to the gaseous
phase with positive ion electrospray ionization at 1.8 kV. Precursors
were targeted in a 2Th selectionwindow around them/z of interest.
Precursors were fragmented in high-energy collisional dissociation
mode with normalized collision energy dependent on the target
peptide. The ﬁrst mass analysis was performed at a 70,000 reso-
lution, an automatic gain control target of 3 $ 106, and a maximum
C-trap ﬁll time of 200 ms; MS/MS was performed at 35,000 reso-
lution, an AGC target of 5 $ 104, and a maximum C-trap ﬁll time of
100 ms. Spectra were analyzed using Skyline with manual
validation.
2.7. Statistics
Differences in ERbmRNA levels observed inMDA-MB-231-ERbe
and MDA-MB-231-ERbþ conditions were analyzed using unpaired
t-tests. Differences were considered statistically signiﬁcant at
p % 0.05. Data presented are mean of technical triplicate
experiments ± standard deviation. Analysis was performed in
GraphPad Prism version 6.
3. Results
3.1. ERb antibody validation
Given the confusion in the ERb ﬁeld and the concern associated
with variable and potentially non-speciﬁc reagents, we sought to
extensively validate commonly used ERb antibodies in a systematic
manner that does not rely upon a priori assumptions regarding ERb
expression in cell line models or in tissues. As a control, we
employed a cell line system with doxycycline-inducible expression
of the ERb protein, allowing us to assess antibodies in ERb negative
and matched ERb positive conditions (Fig. 1A). One hundred-fold
induction of ERb mRNA in MDA-MB-231-ERb cells treated with
doxycycline 0.1 mg/ml for 24 h (p¼ 0.01) was conﬁrmed by qRT-PCR
(Fig. 1B).
Western blots of MDA-MB-231-ERbþ and MDA-MB-231-ERbe
cell lysates with 8 different ERb antibodies were performed
(Fig. 1C). Six commonly used antibodies in the literature were
included; PPG5/10 (Asgari and Morakabati, 2011; Carder et al.,
2005; Ciucci et al., 2014; Shaaban et al., 2003; Wimberly et al.,
2014), NCL-ER-BETA (Ellem et al., 2014; Hussain et al., 2012;
McPherson et al., 2007; 2010; Morais-Santos et al., 2015; Oliveira
et al., 2007; Umekita et al., 2006; Yang et al., 2015; Zellweger
et al., 2013), Genetex 70182 (Celhay et al., 2010; Madak-Erdogan
et al., 2013; Mak et al., 2013, Mak et al., 2015, ; Nakajima et al.,
2011), Millipore 06-629 (Bouchal et al., 2011; Chen et al., 2009;
Grubisha et al., 2012), Abcam 288 [14C8] (Abd Elmageed et al.,
2013; Carder et al., 2005; Colciago et al., 2014; Cotrim et al., 2013;
Dey et al., 2012, 2014; Setlur et al., 2008; Shaaban et al., 2003;
Vivar et al., 2010; Yang et al., 2012) and Santa Cruz 8974 (Al-
Bader et al., 2011; Foryst-Ludwig et al., 2008; Han et al., 2015;
Rossi et al., 2011; Zhou et al., 2012) antibodies. The PPG5/10 anti-
body detected a protein band of 77 kDawith no difference between
Table 2
Details of ERb antibodies validated. Application details are as recommended by the manufacturer. IHC, immunohistochemistry; WB, western blot; IF, immunoﬂuorescence;
ChIP, chromatin immunoprecipitation; ELISA, enzyme-linked immunosorbent assay; Flow cyt, ﬂow cytometry; ICC, immunocytochemistry; IP, immunoprecipitation; Wt, wild
type; NTD, N terminal domain; LBD, ligand binding domain.
Antibody Immunogen Host species Class Binding region Application
NCL-ER-BETA Recombinant protein. Wt ERb. C terminus Mouse Monoclonal C terminus IHC, WB
PPG5/10 Synthetic peptide C terminus of wt ERb Mouse Monoclonal C terminus IF, IHC, WB
GeneTex 70182 Amino acids 1-153 of human ERb expressed in E.coli Mouse Monoclonal N terminus IP, WB, ChIP
Millipore 06-629 Amino acids 46-63 of human ERb Rabbit Polyclonal NTD WB, IHC
Santa cruz sc8974 Amino acids 1-150 of human ERb Rabbit Polyclonal N terminus WB, ChIP, IF, ELISA
Abcam 288 [14C8] Recombinant fusion protein. Amino acids 1-153 of human ERb in E.coli Mouse Monoclonal N terminus WB, Flow cyt, IHC, ICC, ChIP
CWK-F12 Recombinant protein. Amino acids 272-285 of human wt ERb Mouse Monoclonal LBD WB, IP, IHC
MC10 Fusion protein. Amino acids 1-140 of human ERb in E.coli Mouse Monoclonal N terminus IHC, IP, WB, IF
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ERbþ or ERbe conditions, suggesting it is recognizing a non-
speciﬁc protein. Similarly, the NCL-ER-BETA antibody detected a
band of ~59 kDa, which is the correct size for ERb however, there
was no difference between ERbþ or ERbe conditions implying that
this band was not ERb. The GeneTex 70182 antibody detected a
band of 59 kDa with differential signal between ERbþ and ERbe
conditions, and a non-speciﬁc band was present at around 65 kDa.
The Millipore 06-629 antibody detected a band of 59 kDa in both
ERbþ and ERbe conditions, however the band was stronger in the
ERbþ condition, suggesting that the antibody could be cross-
reacting with another protein of 59 kDa in addition to detecting
ERb. MC10, CWK-F12, Abcam 288 [14C8] and sc8974 ERb antibodies
all detected protein bands of 59 kDa with differential signal be-
tween ERbþ and ERbe conditions, conﬁrming their speciﬁcity for
ERb by Western blotting. Further conﬁrmation of the speciﬁcity of
CWK-F12 to ERb was demonstrated by IHC of MDA-MB-231-ERbþ
and MDA-MB-231-ERbe cell pellets (Fig. 2), showing differential
nuclear staining between the two conditions. The 8 ERb antibodies
were then assessed by an independent method called RIME, which
uses an antibody-based puriﬁcation followed by mass spectrom-
etry (MS) to identify enriched peptides. We conducted RIME in
MDA-MB-231-ERbe and MDA-MB-231-ERbþ cells using all 8 an-
tibodies. E2F1 antibody was included in parallel as a positive con-
trol since E2F1 is a ubiquitous protein (Fig. 3A) and an IgG was used
as a negative control (Fig. 3C). In MDA-MB-231-ERbe cells, no ERb
peptides were puriﬁed by any of the ERb antibodies, conﬁrming the
ERb negative status of the uninduced MDA-MB-231-ERb cell line
(Fig. 3C). Following ERb induction, RIME revealed diverse coverage
of the ERb protein by the different antibodies. The percent coverage
of the ERb protein following puriﬁcation with each of the ERb an-
tibodies, and the location of the peptide fragments identiﬁed byMS
are shown in Fig. 3B. To provide an indication of the speciﬁcity of
each antibody, we ranked all the proteins puriﬁed by the IP and
identiﬁed by MS according to the number of unique peptides
(conﬁrmed with a false discovery rate (FDR) of <1%). We hypoth-
esized that the higher the ranking of ERb, the greater the speciﬁcity
of the antibody. Hence, if ERb has the greatest number of unique
peptides relative to all other proteins, it is ranked 1st.
NCL-ER-BETA did not purify any ERb peptides (Fig. 3B), which is
consistent with the lack of speciﬁcity identiﬁed from the Western
blot result (Fig.1C). TheMillipore 06-629 antibody positively pulled
down ERb in the test condition, although coverage and ranking
were not as favorable as compared with some of the other anti-
bodies. Interestingly, LACTB, a 60 kDa protein was puriﬁed by
Millipore 06-629 in both ERbþ and ERbe conditions (data not
shown), which may explain the ~60 kDa band identiﬁed from
Western blotting. Whilst the PPG5/10 did not detect ERb by
Western blotting, by RIME it detected ERb with 25% coverage, with
ERb ranking 3rd in the list of identiﬁed peptides, suggesting dif-
ferences in the speciﬁcity of this antibody from one experimental
assay to another. PPG5/10 has been previously validated for IHC in a
doxycycline-inducible U2OS-ERb cell line, developed using the
same plasmids as the MDA-MB-231-ERb cell line (Wu et al., 2012).
The Abcam 288 [14C8] antibody is a very commonly used ERb
antibody (Abd Elmageed et al., 2013; Colciago et al., 2014; Cotrim
et al., 2013; Dey et al., 2012, 2014; Setlur et al., 2008; Shaaban
et al., 2003; Vivar et al., 2010; Yang et al., 2012), which performed
well by Western blotting, and also had the best antibody coverage
by RIME (31.9%). However ERb ranked 20th in the list of identiﬁed
peptides when using Abcam 288 [14C8], suggesting that this anti-
body might also be purifying additional non-speciﬁc proteins. The
MC10 antibody had the second-greatest coverage (28.2%) with ERb
ranking 1st in the list of identiﬁed peptides. In view of this ﬁnding,
along with the positive Western blot result (Fig. 1), the MC10
antibody was carried forward into the RIME experiments for the
cell line characterization. The CWK-F12 antibody had 17.7%
coverage, with ERb ranking 2nd in the list of puriﬁed peptides. As
the CWK-F12 antibody produced very clean results by Western
blotting, IHC and ranked ERb second in the list of puriﬁed proteins,
it was used forWestern blotting in the cell line characterization and
directly compared against the non-speciﬁc NCL-ER-BETA antibody.
The goal was to use independent validated ERb antibodies and
additional independent methods to assess whether the most
commonly studied breast and prostate cancer cell line models ex-
press ERb.
3.2. Characterization of LNCaP and MCF-7 cell lines for ERb
expression
Given the wealth of publications assessing ERb in breast (MCF-
7) and prostate (LNCaP) cancer cell lines (Abd Elmageed et al., 2013;
Al-Bader et al., 2011; Bouchal et al., 2011; Chen et al., 2009; Dey
et al., 2014; Ellem et al., 2014; Fuqua et al., 1999; Hinsche et al.,
2015; Kim et al., 2002; Lau et al., 2000; Mak et al., 2013; Shaaban
et al., 2003; Skliris et al., 2002; Weng et al., 2013; Yang et al., 2012,
2015; Zhou et al., 2012), we sought to investigate the expression of
ERb in these models, using the newly validated ERb antibodies.
Protein lysate and RNA was collected from LNCaP and MCF-7 cells.
Using primers validated in the inducible MDA-MB-231-ERb cell
line, which binds to sequence common towild type (wt) ERb and its
isoforms (Fig. 1B), LNCaP and MCF-7 were shown to express no
detectable levels of ERb mRNA (Fig. 4A). Using the validated CWK-
F12 ERb antibody, ERb protein was undetectable by Western blot-
ting in these cells. By way of contrast, using the NCL-ER-BETA
antibody on the same cell lysates, we detected a protein band of
approximately 59 kDa in all conditions tested, including the MDA-
MB-231-ERbe cell line, conﬁrming the non-speciﬁcity of this
antibody to ERb (Fig. 4B). Importantly, this demonstrates that the
NCL-ER-BETA antibody is not detecting ERb in either LNCaP orMCF-
7 cancer cell line models and is instead identifying a non-speciﬁc
protein of similar molecular weight.
Furthermore, RIME analysis of LNCaP and MCF-7 cells using the
validatedMC10 ERb antibody did not purify any ERb peptides byMS
(Fig. 4C). This result was conﬁrmed by an antibody-independent
approach known as Parallel Reaction Monitoring (PRM), which
demonstrated that no ERb peptides were present in either of these
cell lines (Fig. 4D). As such, our early passage LNCaP and MCF-7 cell
line models are ERb negative and these cancer models should not
be used for the analysis of this protein.
3.3. ERb expression in prostate and breast tissue
Importantly, whilst the LNCaP and MCF-7 cell-line models do
not express ERb, application of the validated CWK-F12 ERb anti-
body to prostate and breast cancer TMAs demonstrated variable
ERb expression in differing cancer grades. In prostate tissue, pre-
vious reports have described an inverse correlation between ERb
expression and increasing Gleason grade of prostate cancer (Asgari
and Morakabati, 2011; Attia and Ederveen, 2012; Dey et al., 2014;
Horvath et al., 2001; Leav et al., 2001; Risbridger et al., 2007),
whereas others have reported an association between increased
ERb expression and higher Gleason grade (Zellweger et al., 2013) or
increased expression of ERb in bone and lymph node metastases
(Bouchal et al., 2011; Zhu et al., 2004). In our prostate TMA
(Fig. 5AeD) we observed high expression of ERb in the basal
epithelium of benign glands, with no expression in Gleason grade 3
cancer. Gleason grade 4 cancer showed weak nuclear staining of
ERb and in areas of Gleason grade 5 cancer, ERb nuclear expression
was of moderate intensity. In breast tissue, previous studies have
shown greatest ERb expression in benign tissue, with a gradual
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decrease in expression associated with increasing cancer grade
(Guo et al., 2014; Omoto et al., 2002). Conversely, a non-statistically
signiﬁcant trend towards higher ERb expression in Grade 3 tumors
has also been reported (Myers et al., 2004). In our breast TMA
(Fig. 5FeI), we observed greatest expression of ERb in benign
epithelium, with a trend towards decreasing ERb expression asso-
ciated with increasing cancer grade.
One potential explanation for the inconsistencies in ERb tissue
expression is the presence of ERb splice-variant isoforms, which are
fully conserved in exons 1e6, but have differing C-terminal do-
mains (Leung et al., 2006). Different antibodies that bind either to
the conserved regions or only to the C-terminal domain of the full-
length ERb protein may therefore give differing results
(Supplementary Fig.1). This may particularly be the case in prostate
cancer, where it has been reported that ERb isoform expression
increases with the development of CRPC (Dey et al., 2012; Leung
et al., 2010). Whilst this is likely to have an impact, our data
suggest that some of the differing conclusions around ERb
expression in primary tissues are a direct result of certain in-
vestigations utilizing non-speciﬁc reagents that lack speciﬁcity for
ERb.
4. Discussion
Despite a large body of published literature, the role of ERb in
cancers of the prostate and breast is not clear. Contradictions be-
tween IHC ﬁndings and antibody-dependent molecular biology
methods have contributed to this uncertainty, particularly the lack
of clear consensus regarding correlation between tissue expression
of ERb and clinico-pathological parameters (Asgari andMorakabati,
2011; Attia and Ederveen, 2012; Bouchal et al., 2011; Dey et al.,
2014; Esslimani-Sahla et al., 2004; Guo et al., 2014; Hieken et al.,
2015; Horvath et al., 2001; Leav et al., 2001; Leygue and Murphy,
2013; Myers et al., 2004; Omoto et al., 2002; Risbridger et al., 2007;
Fig. 1. Validation of ERb antibodies using doxycycline-inducible MDA-MB-231-ERb cells. (A) MDA-MB-231-ERb cells were treated with doxycycline to induce ERb expression.
Untreated cells provided an ERb-negative control. Messenger RNA was extracted for qRT-PCR and protein for Western blotting. MDA-MB-231-ERbþ and MDA-MB-231-ERbe cells
were crosslinked and immunoprecipitated with antibody for RIME. (B) qRT-PCR conﬁrmed 100-fold induction of ERbmRNA in MDA-MB-231-ERbþ cells versus untreated MDA-MB-
231-ERbe cells. Data are mean ± S.D. of technical triplicate experiments. (C) Western blots of MDA-MB-231-ERbþ and MDA-MB-231-ERbe cells with the 8 antibodies undergoing
assessment. The MC10, CWK-F12, Abcam 288[14C8] and sc8974 antibodies detected bands of 59 kDa, with differential signal in the ERbþ versus ERbe conditions, indicating
speciﬁcity to ERb. GeneTex 70182 detected ERb, although there was non-speciﬁc signal at 65 kDa. Millipore 06-629 appears to detect ERb, although there is also a 59 kDa band in the
ERbe condition. Review of the RIME data suggests this may be cross-reactivity with LACTB. NCL-ER-BETA, the most commonly used ERb antibody, gives bands of the correct size for
ERb, but there is no difference between ERbe and ERbþ conditions, conﬁrming that this antibody is not speciﬁc to ERb.
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Roger et al., 2001; Umekita et al., 2006; Zellweger et al., 2013; Zhu
et al., 2004).
Our results have demonstratedmarked variation in the ability of
commonly used commercially available ERb antibodies to accu-
rately detect ERb by Western blotting and protein puriﬁcation-MS
based methods. Most notably, NCL-ER-BETA, a commonly used
antibody (Ellem et al., 2014; Hussain et al., 2012; McPherson et al.,
2007; 2010; Morais-Santos et al., 2015; Oliveira et al., 2007;
Umekita et al., 2006; Yang et al., 2015; Zellweger et al., 2013) did
not detect ERb by any methodological approach. This antibody
consistently yields bands on Western blots of the appropriate size
for ERb (59 kDa) in all tested conditions (Figs. 1C and 3B), but we
have conﬁrmed that this protein band is not ERb through the use of
the MDA-MB-231-ERb inducible cell line system and the RIME
technique. As such, this non-speciﬁc ~59 kDa band is likely to be the
source of much of the controversy and confusion surrounding the
study and characterization of ERb. The PPG5/10 antibody targets
the C-terminus of wt ERb, and as such may be useful for dis-
tinguishing wt ERb from expression of ERb isoforms. PPG5/10
identiﬁed ERb in the MDA-MB-231-ERb cell line by RIME, and has
previously been shown to be ERb-speciﬁc by IHC in both an
inducible cell line model (Wu et al., 2012) and in breast tissue
(Carder et al., 2005). However, in our study this antibody did not
show speciﬁcity byWestern blot analysis (Fig. 1C). In their antibody
validation study, Carder et al. also assessed the Abcam 288[14C8]
antibody and found it to be ERb-speciﬁc for IHC in tissue (Carder
et al., 2005). Whilst our Western blotting data support this asser-
tion (Fig. 1C), our RIME data suggest that this antibody also puriﬁes
additional, non-speciﬁc peptides, and as such should be used with
caution for IP-based methods (Fig. 3B). Taken together, these
ﬁndings reassert the importance of validating antibodies for indi-
vidual experimental approaches, rather than assuming general
applicability across methodological platforms (Baker, 2015;
Bordeaux et al., 2010).
RIME was initially developed as a discovery tool to study the
interacting proteomes of transcription factors in an unbiased
manner (Mohammed et al., 2013). The advantage of using RIME in
antibody validation arises from being able to identify speciﬁc,
named peptides puriﬁed by an antibody, rather than relying on the
presence of a protein band of approximate size on a Western blot.
This is typiﬁed by the NCL-ER-BETA antibody, which gave bands on
Western blot in both ERbe and ERbþ conditions and no ERb pep-
tides identiﬁed by RIME. Taken together, these data conﬁrm that
this antibody is not speciﬁc to ERb. The non-commercially available
ERb antibodies tested (MC10 and CWK-F12) have been previously
validated by other approaches (Choi et al., 2001; Wu et al., 2012)
and our results add further conﬁdence in their speciﬁcity using
multiple independent assays. By comparing the peptide coverage of
each antibody along with the ERb ranking (as a surrogate of spec-
iﬁcity) RIME facilitated an informed decision-making process in
selecting which antibody to carry forward to the cell-line charac-
terization. Our multi-modal approach to cell-line characterization
using both antibody-dependent (Western blotting and RIME) and
antibody-independent (qRT-PCR and PRM) approaches has shown
that low-passage, genotyped LNCaP and MCF-7 cell lines do not
express detectable ERb, despite numerous publications making
conclusions about ERb biology using these cell line models (Abd
Elmageed et al., 2013; Al-Bader et al., 2011; Bouchal et al., 2011;
Chen et al., 2009; Dey et al., 2014; Ellem et al., 2014; Fuqua et al.,
1999; Hinsche et al., 2015; Kim et al., 2002; Lau et al., 2000; Mak
et al., 2013; Weng et al., 2013; Yang et al., 2012, 2015). Whilst we
acknowledge that immortalized cell lines may have variable
expression of certain factors across passage numbers and labora-
tories (Masters, 2000), our data suggest the need for caution in
making this assumption with respect to ERb. Reassuringly, we have
conﬁrmed expression of ERb in prostate and breast tissue using the
validated CWK-F12 antibody. Our IHC study is not intended to be an
exhaustive analysis of ERb expression in prostate and breast tissue,
and we acknowledge the limitations presented by our small sample
size and lack of statistical correlation with clinico-pathological
parameters. We have however, demonstrated that the CWK-F12
ERb antibody is validated for IHC and in principle can be used for
larger scale assessment of ERb expression in tissue.
Epidemiological evidence suggests that estrogen and its re-
ceptors have important roles in the development and progression
of prostate cancer. Japanese men are known to have a very low
incidence of prostate cancer (Ross et al., 1992), and it has been
proposed that their traditional diet, which is high in ERb selective
phytoestrogens may exert a protective role (Andres et al., 2011;
Attia and Ederveen, 2012; Hori et al., 2011; Messina, 2010; Reiter
et al., 2011; Shen et al., 2000; Stettner et al., 2007; Thelen et al.,
2007, Thelen et al., 2005; Wuttke et al., 2002). Further evidence
from studies of ERb knockout mice (bERKO) shows a clear pheno-
type and tumor-suppressive effect of ERb (Ricke et al., 2008).
However, clinical trials of agents seemingly effective in vitro have
demonstrated no clinical beneﬁt of estrogen-selective agents in
prostate cancer (Bergan et al., 1999; Kim et al., 2002). There are
numerous explanations as to why this might be, for example,
expression of ERb in non-epithelial cell types (Gargett et al., 2002;
Pierdominici et al., 2010) modulating the tissue response to these
Fig. 2. IHC validation of CWK-F12 ERb antibody in MDA-MB-231-ERb cell pellets. Nuclear staining is evident in MDA-MB-231-ERbþ cells and absent from the MDA-MB-231-
ERbe control, conﬁrming the speciﬁcity of CWK-F12 to ERb.
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agents, but in light of our ﬁndings we would suggest that use of
poorly validated reagents and inadequately characterized cancer
cell line models is an important contributing factor.
In the presented study, detailed validation of commonly used
ERb antibodies has demonstrated that some of these reagents
either detect ERb in speciﬁc experimental conditions only or lack
any speciﬁcity for ERb across multiple assays. ERb has been inves-
tigated in numerous cancers including prostate, breast, kidney (Yu
et al., 2013), colon (Dey et al., 2013), endometrium (Han et al., 2015),
ovary (Ciucci et al., 2014; Suzuki et al., 2008) bladder (Hsu et al.,
2013) and non-small cell lung cancer (He et al., 2015; Luo et al.,
2015) but in many cases, the ﬁndings are predicated on non-
speciﬁc reagents. As such, a re-evaluation of ERb expression and
biology is needed using reliable, speciﬁc reagents. Our determina-
tion of ERb antibody speciﬁcity will contribute towards clarifying
existing, conﬂicting data on the role of ERb in these diverse cancers
and provide the necessary, validated tools with which to move
forward our understanding of ERb biology.
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Fig. 4. Multimodal characterization of LNCaP and MCF-7 cell lines conﬁrms absence of ERb expression. LNCaP and MCF-7 are cell lines commonly used to study ERb. We
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protein expression in LNCaP and MCF-7 cells. The ERb peptides (peptide 1 is SLEHTLPVNR and peptide 2 is SSITGSECSPAEDSK) identiﬁed in the MDA-MB-231-ERbþ positive control
(red arrows) are absent in the other cell lines. Data shown are representative of 2 independent biological replicates.
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Fig. 5. IHC of prostate and breast tissue with validated CWK-F12 ERb antibody. Demonstration of variable ERb expression in differing grades of prostate (AeD) and breast (FeI)
cancer. In prostate, ERbwas highly expressed in basal and luminal epithelial cells of benign glands (A), whereas there was no nuclear staining in Gleason grade 3 cancer (B). In Grade
4 mucinous tumor (C) and high grade tumor (D) nuclei showed weak to moderate expression of ERb. In breast, ERb expression was greatest in nuclei of benign epithelial cells (F),
which was observed to decrease with increasing grade of cancer (G, H and I e Grade 1, 2 and 3 respectively). The greatest difference in expression was observed between benign (F)
and Grade 3 cancer (I). E and I - no primary antibody negative controls.
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Appendix B
List of abbreviations
1. ADT; Androgen deprivation therapy
2. AF; Activation function
3. AR; Androgen receptor
4. ARE; Androgen response element
5. ArKO; Aromatase knock-out
6. aERKO; ERα knock-out
7. bERKO; ERβ knock-out
8. BCR; Biochemical relapse
9. ChIP; Chromatin immunoprecipitation
10. COX2; Cyclo-oxygenase 2
11. CRPC; Castrate resistant prostate cancer
12. CSS; Cancer specific survival
13. CT; Computed tomography
14. DBD; DNA-binding domain
15. DES; Diethylstilbestrol
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16. DHEA; Dihydroepiandrosterone
17. DHT; Dihydrotestosterone
18. EBRT; External beam radiotherapy
19. ERα; Estrogen receptor alpha
20. ERβ; Estrogen receptor beta
21. ERE; Estrogen response element
22. EMT; Epithelial-mesenchymal transition
23. FDR; False discovery rate
24. GR; Glucocorticoid receptor
25. HN; hormone na¨ıve
26. HPG; Hypothalamo-pituitary-gonadal
27. IHC; Immunohistochemistry
28. IMRT; Intensity modulated radiotherapy
29. IP; Immunoprecipitation
30. LBD; Ligand-binding domain
31. LHRH; Leutinising hormone releasing hormone
32. MR; Mineralocorticolid receptor
33. MRI; Magnetic resonance imaging
34. MS; Mass spectrometry
35. NO; Nitric oxide
36. NTD; N-terminal domain
37. PC; Prostate cancer
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38. PIN; Prostatic intraepithelial neoplasia
39. PR; Progesterone receptor
40. PRM; Parallel reaction monitoring
41. PSA; Prostate specific antigen
42. RIME; Rapid immunoprecipication and mass spectrometry of endogenous
protein
43. RP; Radical prostatectomy
44. SERM; Selective estrogen receptor modulator
45. STAT; Signal transducer and activator of transcription
46. Tet-R; Tetracycline repressor
47. TMA; Tissue microarray
48. TNM; Tumour, nodes, metastasis
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